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Abstract 
 
Plant-produced proteins of pharmaceutical interest are beginning to reach the market, and the 
advantages of transient plant expression systems are gaining increasing recognition. In parallel, 
the use of virus-like particles (VLPs) has become standard in vaccine design. The pEAQ-HT 
vector derived from the cowpea mosaic virus – based CPMV-HT expression system has been 
shown to allow the production of large amounts of recombinant proteins, including VLPs, in 
Nicotiana benthamiana. Moreover, previous work demonstrated that a tandem fusion of the 
core antigen (HBcAg) of hepatitis B virus (HBV) could direct the formation of core-like particles 
(CLPs) in plants.  
The work presented here demonstrated that the tandem core system is better suited for the 
plant-based production of CLPs presenting foreign antigens than SplitCore technology. It was 
shown that tandem core technology allows the plant-based production of CLPs which are 
suitable for the presentation of antigens either via chemical coupling or through antibody-
antigen interactions. Of particular significance was the successful display of single domain 
antibody fragments of camelid origin (nanobodies, or VHH). The resulting “tandibody” 
particles, as they are named here, can bind to their cognate antigen to yield CLPs covered in 
the antigen of interest. Furthermore, it was shown that target antigens can be attached to 
CLPs via a fusion partner, raising the possibility of the development of a universal generic 
antigen-display platform.  
In addition to the transient expression work on HBcAg, lines of stably transformed N. 
benthamiana were created which constitutively expressed human gastric lipase (hGL), an 
enzyme of medical importance. In the future, this approach could be used to create transgenic 
plants constitutively expressing a universal tandibody, thus obviating the need for infiltration. 
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Chapter 1 : General Introduction 
 
This thesis describes the development of a novel technique for the display of antigens of 
interest on the surface of a virus-like particle (VLP) using a plant expression system. The 
following introduction will first introduce the field of plant molecular farming and the use of 
plants to produce proteins of interest. The CPMV-HT plant expression system which was used 
throughout this thesis will be described in detail. The concept of a VLP will be introduced, with 
particular emphasis on the production of VLPs intended for use as vaccines. The hepatitis B 
virus (HBV) core antigen (HBcAg) protein will then be introduced, and the history of HBcAg 
manipulation for antigen-display purposes will be reviewed. Finally, the main objectives and 
hypotheses of the thesis will be presented. 
 
I - Plant molecular farming 
 
Plant molecular farming refers to the science of producing large quantities of a molecule of 
interest in plants, through the use of genetic manipulation. The use of plants as expression 
systems for the production of recombinant proteins has emerged as an attractive alternative 
to systems based on bacteria, yeast, or animal cells. Producing proteins in plants potentially 
has advantages in terms of cost as well as safety, since plant pathogens do not infect 
mammals, and mammalian pathogens do not infect plants, thus reducing contamination risks 
when pharmaceutical proteins are produced (Kusnadi et al., 1997; Lico et al., 2008). Moreover, 
certain plants such as Nicotiana benthamiana can be grown in high density and still produce 
large amounts of biomass in a matter of weeks. There are essentially two approaches to 
producing heterologous proteins in plants – stable transformation (either nuclear or plastid) 
and transient expression. Stable transformation involves the production of true-breeding lines 
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of genetically transformed plants. This approach has advantages in terms of reproducibility 
and potential large-scale production; however it is often very time-consuming and is 
unsuitable for the rapid screening of a wide variety of different constructs (Kusnadi et al., 
1997). Transient expression in plants allows for production of high titres of recombinant 
proteins in a matter of days in what is essentially a batch process (Pogue et al., 2002). 
Furthermore, techniques have been developed for scaling-up production of transiently-
expressed proteins in plants (D'Aoust et al., 2010). 
This introduction, like this thesis, will focus on the production of recombinant proteins, which 
are historically the most widely-produced type of molecule in modern plant molecular farming 
(as opposed to secondary metabolites). The history of this field of science dates back to the 
1970’s, when it was discovered that the gram-negative bacterium Agrobacterium tumefaciens 
contains a special plasmid, named Ti (tumour-inducing), which is capable of directing the 
transfer of part of the plasmid (the transfer DNA, or T-DNA), to the plant cell, and integrating 
the T-DNA into the plant genome (Chilton et al., 1977). This led to different research groups 
replicating this natural process in vitro, by infecting tobacco cells (Marton et al., 1979) or 
protoplasts (Wullems et al., 1981b) with A. tumefaciens and regenerating genetically modified 
shoots from these cells. At the time, the only way to obtain complete plants from such 
modifications was to graft regenerated shoots on to healthy tobacco plant root stock, and this 
allowed the plant to flower, set seed, and produce transgenic offspring (Wullems et al., 
1981a). However, it was quickly shown that disabling the tumour-controlling genes of the Ti 
plasmid allowed plants to be regenerated directly after transformation with A. tumefaciens 
(Greve et al., 1982; Barton et al., 1983). Such mutated varieties of Agrobacterium were called 
“disarmed strains”. Up to this point, plants were only transformed with a native A. tumefaciens 
plasmid, so the introduced transgenes were restricted to bacterial opine synthesis and 
tumour-inducing genes. 
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The leap from research to biotechnology was made in 1983. Heterologous genes were inserted 
into the T-DNA: yeast alcohol dehydrogenase and bacterial neomycin phosphotransferase 
(which confers kanamycin resistance) were transferred to plants alongside the native nopaline 
synthase (nos) gene. While the genes were shown to be present, only nopaline (the product of 
the nos gene) was shown to be produced (Barton et al., 1983). However, it was very quickly 
realised that this could be a promoter issue, so antibiotic resistance genes were placed 
downstream of the nos gene promoter, allowing the expression of antibiotic resistance genes 
in transgenic plants (Herrera-Estrella et al., 1983). Another significant breakthrough came 
when it was discovered that the vir (virulence) genes on the Ti plasmid which direct the 
transfer of the T-DNA into the plant cell and its integration into the plant genome could be 
dissociated from the T-DNA itself. That is to say, the vir genes could be placed on one plasmid 
where it could act as genetic background, while the T-DNA could be placed on a separate small 
plasmid that would be easy to manipulate in Escherichia coli. The T-DNA on this “binary 
vector”, as it became known, could be modified to contain a selection marker (such as a 
kanamycin resistance gene) and a multiple cloning site for insertion of heterologous genes of 
interest (de Framond et al., 1983; Hoekema et al., 1983; Bevan, 1984).  
These binary vectors have been continually improved ever since as a result of new research 
into the T-DNA transfer process. For example, it was discovered that it was more effective to 
place the gene of interest (GOI) near the right border (RB) of the T-DNA, and the selection 
marker near the left border (LB), because the RB is the first to be integrated into the plant 
genome (Wang et al., 1984), and because there can sometimes be incomplete transfer of the 
T-DNA at the LB (Rossi et al., 1996). This ensures that transformants displaying antibiotic 
resistance will also contain the GOI. This paradigm shift in biotechnology did not go unnoticed 
by industry: indeed one of the first binary vectors was created by a team from Monsanto 
(Fraley et al., 1983), who considered that the field was now wide open for any gene, from any 
species, to be expressed in plants. The primary result of this was the rapid development of 
Chapter 1: General Introduction 
 
4 
 
industrial-scale genetic engineering technology for agricultural purposes (Marshall, 2012), but 
at the same time it was also the birth of plant molecular farming. 
The next big development came when leaf-disc transformation was developed: this allowed 
transgenic tobacco plants to be regenerated from calli obtained from transformed leaf discs, 
as opposed to protoplasts, which made the production of transgenics much simpler (Horsch 
and Klee, 1986). At the same time, the field of plant virology merged with the nascent field of 
plant biotechnology when it was shown that inserting tandem copies of the cauliflower mosaic 
virus (CaMV) genome into a T-DNA allowed a viral infection to be initiated on a grown plant via 
Agrobacterium-mediated gene transfer (Grimsley et al., 1986). This technique, called 
“agroinfection”, and later, “agroinoculation”, involved pipetting a small volume of a 
suspension of modified bacteria onto an abraded plant leaf. From there, the bacteria infect the 
plant with the virus, which then spreads systemically. At the same time, genetic components 
of viral origins were being deployed to improve the efficacy of binary vectors. The most 
obvious example is the constitutive 35S promoter from CaMV, which was first introduced as a 
feature of a binary vector by Pietrzak et al. (1986). 
Interestingly, while the developments described above had mostly come from research on 
solanaceous species, and Nicotiana in particular, the next important development came from 
research in Arabidopsis thaliana. Stable transgenic plants could be produced in planta (i.e. 
without the need for tissue culture) with this species ever since the description of 
agrobacterium-mediated transformation of germinating seeds (Feldmann and Marks, 1987), 
but this was not deemed to be a very efficient technique in terms of frequency of 
transformants in the progeny. To improve the transformation efficiency of Arabidopsis and to 
obtain large numbers of transgenic progeny from the original transformant, agroinfiltration 
was invented (Bechtold et al., 1993). This technique, described in detail by the original team in 
a subsequent methods book chapter (Bechtold and Pelletier, 1998), involves submerging an 
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entire Arabidopsis plant in a suspension of Agrobacterium and applying a vacuum, which is 
then gently released to allow the bacteria to infiltrate the intercellular spaces of the plant. 
While this technique was originally aimed at producing transgenic Arabidopsis (and is still 
known as “floral dipping” for this purpose), it soon became adapted to the transient 
production of heterologous proteins such as antibodies in the excised leaves of bean and 
tobacco plants (Kapila et al., 1997; Vaquero et al., 1999). The first example of agroinfiltration 
on leaves of whole plants, however, seems to come from Schob et al. (1997), in a paper aimed 
at studying transgene silencing in tobacco: this is the first description of what is now known as 
syringe-infiltration, an alternative to vacuum infiltration. Bizarrely, the first description of 
vacuum infiltration of whole plants, and not just excised leaves, for transient expression 
purposes, was not published until almost a decade later (Marillonnet et al., 2005), with 
detailed methods described after that (Gleba et al., 2007; Garabagi et al., 2012). Until then, it 
seems transient expression on whole plants was either done by syringe infiltration (which is 
more practical on a very small scale) or agroinfection with replicating viral vectors, as in Liu 
and Lomonossoff (2002). A diagram summarising transient expression via agroinfiltration is 
provided in figure 1.1. 
 
Figure 1.1 Transient expression via agroinfiltration. The gene of interest is cloned into an expression vector and 
propagated in E. coli. After sequence verification it is transformed into A. tumefaciens. These are used to infiltrate 
the intercellular space of N. benthamiana leaves, where the gene is transferred to the plant cells. After 5-9 days the 
agroinfiltrated leaves are harvested for protein extraction and purification.  
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Replicating viral vectors, in which a GOI is integrated in a viral genome, became inherently 
linked to agroinfiltration techniques when it was discovered that combining agrobacterial 
transfection efficiency with viral replication could allow “deconstructed” viral vectors to be 
developed. This involved removing viral genes which were not strictly necessary to the 
production of the recombinant protein, such as those coding for the viral coat protein, and 
positioning different viral functions on separate binary plasmids. Probably the most famous 
example of this is the magnICON system, in which a hybrid tobamovirus genome with 
elements from tobacco mosaic virus (TMV) and turnip vein-clearing virus (TVCV) is split into 
three components which are co-infiltrated into the same plants leaves from a mix of three 
Agrobacterium cultures: the 3’ module contains the gene of interest in place of the sequence 
of the viral coat protein along with the nos terminator, the 5’ module contains the Arabidopsis 
actin 2 (ACT2) promoter along with the tobamovirus polymerase and movement protein genes 
(the latter of which contains a subgenomic promoter), while the recombinase module 
containing the PhiC31 integrase gene (from Streptomyces phage C31) acts to fuse the 3’ and 5’ 
modules together in the nucleus to allow the formation of a complete tobamovirus-based 
replicon (Fig. 1.2). Upon transcription, the RNA is able to replicate, spread from cell to cell 
within the leaf (though not throughout the entire plant), and produce high levels of the protein 
of interest (Marillonnet et al., 2004; Marillonnet et al., 2005). This system has been used to 
produce a wide variety of proteins in plants, including antigens (Webster et al., 2009), 
antibodies (Grohs et al., 2010), and VLPs (Matić et al., 2012).  
Deconstructed viral vectors are now also being used to make stable transgenics, as with the 
INPACT system (Dugdale et al., 2013). This is based on a geminivirus expression system (from 
tobacco yellow dwarf mastrevirus, or TYDV), in which a simplified version of the viral genome 
including the GOI is integrated stably into transgenic plants, in a way that is analogous to 
lysogenic bacteriophages (Fig. 1.2). Upon induction with ethanol, the viral genome is excised 
from the chromosome, circularises, and this newly formed replicon replicates as the GOI is 
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transcribed and translated. Another deconstructed viral vector, named delRNA-2 (Sainsbury et 
al., 2008), is based on the cowpea mosaic virus (CPMV) RNA-2 (Fig. 1.2). The genesis of this 
system, along with its successor, are described in the following section, which details the 
development of a non-replicating system based on cowpea mosaic virus (CPMV), called the 
CPMV-HT system, which gave rise to the pEAQ series of expression vectors, which were used 
throughout this thesis. Part of the following section has already been published in a review 
article (Peyret and Lomonossoff, 2013), available in appendix 2. 
 
Figure 1.2 Simplified diagrams of three different deconstructed viral vector systems. Top: the magnICON 
expression system is a tobamovirus-based deconstructed viral vector composed of three modules. The recombinase 
module fuses the 3’ module containing the GOI to the 5’ module containing the promoter, viral polymerase and 
movement protein. This allows replication, cell-to-cell movement, transcription and translation of the GOI-
containing replicon. Middle: the INPACT expression system is a TYDV-based deconstructed viral vector composed of 
two elements which are stably integrated (as opposed to transiently expressed) into the plant genome. Upon 
induction by ethanol, the regulatory element excises the GOI-containing pre-replisome from the plant genome and 
circularises it to form a functional replisome. This allows replication, transcription and translation in every cell of the 
plant. Bottom: the CPMV delRNA-2 system is based on the bipartite genome of CPMV. In the RNA-2 component, 
everything downstream of the 5’UTR is replaced with the GOI, and this component is replicated thanks to the genes 
present on RNA-1. Transcription and translation take place, with the suppressor of silencing acting to increase 
transcript availability.  
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II - The CPMV-HT system and the pEAQ vectors 
 
CPMV is a bipartite virus in the family Comoviridae, with a genome consisting of separately-
encapsidated RNA-1 (6.0kb) and RNA-2 (3.5kb) molecules, each of which has a single long open 
reading frame encoding a polyprotein.  RNA-1 encodes the viral replication machinery and the 
24K protease, which is responsible for processing the polyproteins encoded by both RNAs at a 
number of specific sites. This activity by 24K includes releasing itself from the RNA-1 
polyprotein (Goldbach and Wellink, 1996). RNA-2, which is entirely dependent on RNA-1 for its 
replication, encodes both viral coat proteins and the viral movement protein. It has been 
shown that most of the RNA-2 polyprotein can be deleted and replaced with a foreign 
sequence without abolishing the ability of the molecule to be replicated by RNA-1 (Rohll et al., 
1993; Cañizares et al., 2006), leading to the development of replication-competent deleted 
RNA-2 (delRNA-2) constructs.  These had advantages over the previous vectors based on full-
length RNA-2 molecules both in terms of biocontainment and the size of insert tolerated. 
However, because of their inability to spread from cell-to-cell and the absence of the small (S) 
coat protein, which acts as the  native suppressor of gene silencing (Liu et al., 2004), these 
delRNA-2 constructs had to be introduced into leaves by agro-infiltration (Liu and 
Lomonossoff, 2002) in the presence of RNA-1 and a heterologous suppressor (Cañizares et al., 
2006). The delRNA-2 approach was successfully used to express a number of proteins 
(Sainsbury et al., 2009a). However, to preserve the ability of delRNA-2 constructs to be 
replicated by RNA-1, it was essential to retain the sequence of the first 512 nucleotides at the 
5’ end of RNA-2, including two in-frame AUGs at positions 161 and 512, as well as the entire 
RNA-2 3’UTR (Rohll et al., 1993). This required the precise in-frame positioning of the 
heterologous sequence between AUG512 and the 3’ UTR which made insertion of 
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heterologous sequences into delRNA-2 constructs a cumbersome two-step process (Sainsbury 
et al., 2009a). 
During these studies, it was noticed that co-inoculation of delRNA-2 constructs with the 
powerful P19 suppressor of gene silencing from tomato bushy stunt virus (TBSV) stabilised the 
mRNA transcribed from the incoming T-DNA to such an extent as to make replication by RNA-1 
unnecessary to achieve high levels of protein expression. Through studies originally intended 
to simplify cloning, it was found that removal of AUG 161 caused a 10-fold increase in yield of 
an inserted GFP gene through increased translational efficiency of the mRNA transcribed from 
the T-DNA (Sainsbury and Lomonossoff, 2008). A further enhancement was obtained when an 
additional out-of-frame upstream AUG at 115 was also removed, despite the fact that 
removing AUG 115 alone decreases translation compared to wild-type. These unexpected 
results indicate that AUG 161 inhibits translation initiation at AUG 512. This may be explained 
by the need to promote replication of RNA-2, a process which requires the activity of RNA-
dependent RNA polymerase on a region of an RNA relatively unoccupied by ribosomes. This 
could also explain the observed effect of removing AUG 115, which initiates an open reading 
frame that extends beyond AUG 161: AUG 115 might allow ribosomes to bypass AUG 161 and 
re-initiate at AUG 512 (Sainsbury and Lomonossoff, 2008). Such regulatory activity provided by 
upstream open reading frames is known to occur in other eukaryotic systems (Meijer and 
Thomas, 2002). 
The new expression system, based on a deleted version of CPMV RNA-2 with a mutated 5’UTR, 
was shown to enhance expression of GFP, DsRed, the Hepatitis B virus core antigen HBcAg, and 
human anti-HIV antibody 2G12 (Sainsbury and Lomonossoff, 2008; Sainsbury et al., 2010). 
Because high level expression is based on enhanced translation rather than replication, the 
system was termed CPMV-hypertrans or CPMV-HT. This early HT expression system, which is 
the direct precursor to the pEAQ vector series, facilitated in planta production of Influenza 
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virus-like particles (VLPs): particles that have the appearance of a virus, but do not contain 
infectious viral genetic material. Influenza hemagglutinin (HA) is highly immunogenic and, 
although it is highly variable, it is a good target for narrow host-range VLP vaccines. Influenza 
HA was produced in N. benthamiana using CPMV-HT and this protein budded from plant-cell 
membranes to form vesicular VLPs (D'Aoust et al., 2009). In fact, CPMV-HT was determined to 
provide higher yields of VLPs than the alfalfa plastocyanin gene-based expression system 
which was previously used. For this reason, CPMV-HT was chosen for industrial-scale 
production of HA VLPs which are currently undergoing clinical trials in a commercial context 
(D'Aoust et al., 2010). 
The pEAQ series of transient expression vectors (Sainsbury et al., 2009b) are designed to make 
use of the CPMV-HT effect to achieve high levels of expression while at the same time facilitate 
the insertion of heterologous sequences between the modified (HT) 5’ UTR and the 3’ UTR. 
They are small binary vectors carrying genes essential for replication of the plasmid in E. coli 
and A. tumefaciens on the backbone, along with a T-DNA region. The 5.2 kilobase backbone of 
all pEAQ plasmids carries the oriV and colE1 origins of replication, the trfA gene required for 
plasmid replication, and the nptIII prokaryotic neomycin phosphotransferase gene which 
confers resistance to kanamycin. The T-DNA region varies between pEAQ plasmids to allow for 
maximum flexibility in cloning and expression, although only the pEAQ-HT vector (published on 
GenBank under accession number GQ497234.1) was used for the work described in this thesis 
(Fig. 1.3). This specific plasmid contains the P19 suppressor of gene silencing and NPTII 
eukaryotic kanamycin resistance gene near the LB of the T-DNA, and a multiple cloning site 
within the CPMV-HT cassette near the RB. The design of all pEAQ vectors, including pEAQ-HT, 
is modular, allowing the insertion of multiple CPMV-HT cassettes on the same T-DNA. This is 
important to maximise the efficiency with which multiple proteins can be expressed within the 
same cell (Montague et al., 2011). Once a gene or genes of interest have been inserted into 
the appropriate pEAQ vector, the plasmid is transformed into A. tumefaciens prior to 
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inoculation into N. benthamiana. The Agrobacterium strain of choice for transfer of pEAQ 
vectors to plants has usually been LBA4404 (Sainsbury et al., 2009b), although strains C58C1, 
EHA105 and the cysteine auxotroph C58::pEHA105/Cys32 have also been used with success 
(Sun et al., 2011; Larsen and Curtis, 2012). While the pEAQ vectors have been used for the 
production of stable transgenic plants, their main use has been for transient expression via 
agroinfiltration of N. benthamiana. 
 
 
Figure 1.3 Plasmid map of the pEAQ-HT expression vector. Essential elements for plasmid replication in E. coli and 
A. tumefaciens are located on the plasmid backbone. In the T-DNA, NPTII provides kanamycin resistance to 
transformed plant cells, and the P19 suppressor of silencing increases the availability of transgene transcript. The 
GOI is inserted in the multiple cloning site (MCS) between the modified CPMV RNA-2 5’UTR bearing the HT 
mutations, and the native CPMV RNA-2 3’UTR. These UTRs are themselves flanked by the CaMV 35S promoter and 
the nos terminator. 
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Though the pEAQ system could be used to produce transgenic suspension cultures (Sun et al., 
2011), it proved impossible to regenerate lines of transgenic N. benthamiana with constructs 
expressing wild-type P19 as this interferes with plant regeneration (Saxena et al., 2011). This 
was addressed through the deployment of a version of the P19 suppressor of gene silencing 
(P19/R43W) that is not developmentally toxic to plants and therefore compatible with the 
production of stable transgenic lines (Saxena et al., 2011). Through a point mutation in the P19 
gene that substitutes arginine 43 with tryptophan, the suppressor activity of P19 is reduced 
and ceases to prevent regeneration of fully-grown N. benthamiana plants from callus after 
transformation with Agrobacterium. It was found that plants transiently expressing P19/R43W 
along with GFP produce half as much recombinant GFP as plants transiently expressing wild-
type P19 and GFP, but this reduced yield still represents a 7-fold increase compared to 
transient expression of GFP in the absence of a suppressor of gene silencing. Because the 
difference between wild-type P19 and P19/R43W is a single nucleotide substitution, the pEAQ-
HT vector can be used to rapidly test a construct transiently, and if yield is considered 
adequate, a straightforward site-directed mutagenesis (SDM) reaction on the same plasmid 
can yield a vector which can itself be tested transiently, but which is also ready for the 
production of transgenic plants. This is advantageous as the production of lines of stably 
transformed plants is far more time-consuming than transient expression. It is thought that the 
R43W mutation preserves P19’s capacity to bind siRNAs (crucial for suppression of silencing), 
but prevents it from binding to microRNAs, which play a role in early plant development. This 
development has allowed pEAQ to be used for the production of high-yielding, fertile, stable, 
homozygous transgenic lines that constitutively produce GFP (Saxena et al., 2011) and human 
gastric lipase (see chapter 7). 
The pEAQ vectors have been used to produce a variety of different proteins through several 
different approaches. Along with the transgenic plants described above, pEAQ has also been 
used to produce recombinant proteins in cell suspension cultures (Sun et al., 2011; Larsen and 
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Curtis, 2012). Moreover, numerous groups have produced active enzymes transiently through 
agroinfiltration of pEAQ vectors. The most relevant for this thesis (see chapter 7) is human 
gastric Lipase (hGL), which was produced through transient expression in N. benthamiana. This 
enzyme, responsible for degradation of lipids in the human stomach, has uses in in vitro 
digestion models as well as a potential medical use for patients suffering from pancreatic 
insufficiency. Previous efforts to produce recombinant hGL, in insect cells or yeast, have 
suffered from very low yields and poor recovery (Crabbe et al., 1996; Canaan et al., 1998). By 
using pEAQ, hGL has been produced at levels of about 0.5 g/kg FWT, representing a maximum 
yield of enzymatic activity of 193 U/g FWT (Vardakou et al., 2012). This corresponds to an 
activity of about 310 U/mg of protein, which is about three-fold lower than native human- 
produced hGL. The reasons for this discrepancy are unknown as of yet, but it is possible that 
the purification process could be further optimised to better preserve enzymatic activity. The 
recombinant hGL from plants shares important characteristics with its native human-produced 
version: it is stable at 40 °C as well as at low pH, it exhibits higher affinity for short-chain lipids 
over long-chain lipids, and crucially, it appears to be resistant to digestion by pepsin, the 
protease present in the stomach. This resistance is thought to be caused by the glycosylation 
of the protein, and although the glycosylation profile is predicted to be different for plant-
produced hGL from native hGL in terms of the glycans used, this does not appear to 
compromise resistance to digestion by pepsin.  
While hGL was produced in plants with a view to use the enzyme as a reagent or even a 
medical therapeutic post-purification, pEAQ has also been used to produce enzymes for 
fundamental research. The expression in N. benthamiana of hexahistidine (His) -tagged 
recombinant OsChia4a, a rice chitinase, allowed research to be carried out on this enzyme’s 
anti-fungal activity as well as on the regulation of the gene coding for this enzyme by the plant 
hormone jasmonic acid (Miyamoto et al., 2012). While this is the only currently published 
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example of the pEAQ system being used to study gene function, it is currently being deployed 
for many such studies worldwide.  
It has also been shown that the pEAQ vectors are well suited to the manipulation of entire 
synthetic pathways through the co-expression of multiple enzymes. The coding sequences for 
two sesquiterpene synthases from Artemisia annua, amorpha-3,11-diene synthase (ADS) and 
epi-cedrol synthase (ECS), were cloned into pEAQ and expressed in N. benthamiana to yields of 
90 and 96 mg/kg FWT respectively (Kanagarajan et al., 2012). Moreover, these two enzymes 
converted the product farnesyl diphosphate into (respectively) amorpha-4,11-diene and epi-
cedrol, which are intermediates in the biosynthetic pathway leading to the production of 
artemisinin, an important antimalarial drug. This indicates that pEAQ allowed relatively high-
level expression of these enzymes and that these function in planta with appropriate product 
specificity. Two enzymes from the monocot crop species Avena sativa (oat) have also been 
expressed in order to study their mode of action (Sainsbury et al., 2012b). The oxidosqualene 
cyclase (OSC) and the cytochrome P450 (CYP450) enzymes were expressed both separately 
and on the same T-DNA in pEAQ vectors, and both were found to be active in planta. The 
product β-Amyrin was produced by OSC, and when both enzymes were co-expressed, a novel 
compound was produced which was later identified as an intermediate in the pathway 
towards avenacin, an important antimicrobial compound produced by Avena species (Geisler 
et al., 2013). This indicates that the pEAQ vectors can be used not only to produce large 
quantities of a particular enzyme, but also to study their modes of action alone or with other 
enzymes involved in the same biosynthetic pathway, as well as potentially allowing metabolic 
engineering: the introduction of entire biosynthetic pathways in plants. 
This is made possible, or at least much easier, by the fact that the pEAQ vectors can carry more 
than one GOI in the T-DNA, which improves co-expression in the same cell as compared to co-
infiltration of different constructs carried by separate Agrobacterium clones (Montague et al., 
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2011). This is done by having multiple CPMV-HT cassettes on the same T-DNA, so each GOI 
benefits from the yield-enhancing effects of the expression system. However, when that is 
undesirable (either because proteins of interest must be present in a specific ratio, or due to 
protein toxicity), one of the GOI on the T-DNA can be down-regulated by removing the HT 
mutation on its 5’UTR, thus leading to efficient co-expression in the same cell, but not at the 
same levels (Thuenemann et al., 2013a). This technique is not only useful for the expression of 
enzymes, but first and foremost for the production of VLPs, the production of which has been 
the main use of the pEAQ vectors so far, and is of particular relevance to this thesis.  
 
III - Virus-like particles (VLPs) 
 
A virus-like particle (VLP) is a viral particle, usually produced in a recombinant system, which is 
devoid of viral genome (Roy and Noad, 2008; Plummer and Manchester, 2010; Kushnir et al., 
2012). Typically, the viral coat protein(s) or surface protein(s) are expressed in a heterologous 
system, and these structural proteins self-assemble into nanoparticles that strongly resemble 
(and sometimes are indistinguishable from) native viral particles. Crucially, the fact that only a 
small portion of the viral genome is used in their production (namely, the gene(s) coding for 
the structural proteins) means that VLPs are entirely non-infectious, making them inherently 
safe to produce, handle, and use as vaccines, without any risk of reversion or recombination 
with wild virus strains (Minor et al., 1986; Martin et al., 2004; Kushnir et al., 2012; Lee et al., 
2012). This is in stark contrast to the currently used non-recombinant vaccines, which require 
cultures of pathogens to be grown before the pathogen itself is inactivated (killed vaccines), 
attenuated (live attenuated vaccines), or broken apart for purification of specific protein 
immunogens (subunit vaccines).  
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The first ever example of a recombinant vaccine is a 22 nm particle formed in the yeast 
Saccharomyces cerevisiae through heterologous expression of HBV surface antigen HBsAg 
(Valenzuela et al., 1982; Hilleman, 1987; McAleer et al., 1992). These VLPs mimicked particles 
derived from the plasma of HBV-infected individuals very closely (Ellis and Gerety, 1989), but 
obtaining abundant quantities of clean material was much simpler when using recombinant 
technology. HBsAg VLPs were developed and ultimately licensed for use as human vaccines 
under the trade names Recombivax®, produced by Merck (Krugman and Davidson, 1987); or 
later Engerix-B®, produced by GlaxoSmithKline (Crovari et al., 1987). It has since become 
obvious that these products represented a revolution in vaccine design due to their efficacy 
and safety (Hilleman, 2011), and other VLP vaccines have since been brought to market, such 
as the two human papillomavirus (HPV) vaccines Gardasil®, made in yeast by Merck (Shank-
Retzlaff et al., 2006); and Cervarix®, made in insect cells by GlaxoSmithKline (Monie et al., 
2008).  
While all recombinant vaccines have the inherent safety profile associated with producing just 
one or a few of a pathogen’s proteins, VLPs are also much more immunogenic than simple 
soluble proteins. This is due to the size, geometry, and content of VLPs (Bachmann and 
Jennings, 2010). Firstly, the size of VLPs (typically between 10 and 100 nm) is ideal for direct 
traffic into the lymphatic system, which contains the highest concentration of B cells. Antigens 
larger than 200 nm can only access the lymphatic system by being transported there by 
antigen-presenting cells (APCs) after phagocytosis, which results in antigen breakdown and 
presentation of antigen fragments on the surface of APCs. Antigens smaller than 200 nm 
however, can access the lymphatic system directly in native form, meaning they reach 
follicular dendritic cells (FDCs) intact, and can be presented on the surface of these in immune 
complexes for recognition by follicular B cells. At this point, the geometry of VLPs becomes a 
critical advantage: the symmetrical, quasi-crystalline structure of VLPs (which is absent in 
soluble protein subunit antigens) acts as a pathogen-associated molecular pattern (PAMP), 
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which allows the VLPs to be very efficiently cross-linked on the surface of B cells by B cell 
receptors (membrane-bound IgGs). This cross-linking allows activation of the B cells, causing a 
germinal centre response: proliferation of B cells.  
At the same time as the VLPs stimulate this B cell response, they also stimulate the T cell 
response. VLPs that penetrate the lymphatic system in a native state can be cross-presented 
on the surface of CD8+ dendritic cells (which are typically only found in the lymphoid organs), 
and this cross-presentation allows cytotoxic T lymphocytes to be activated. Moreover, the 
repetitive geometry of the VLPs favours binding to IgM in the circulatory system through 
multivalent, high-avidity interactions. This allows recruitment of the complement system: C1q 
binds the IgM, which in turn bind C3b, and this opsonisation causes complement-mediated 
phagocytosis by APCs. Once the particle is taken up, it is broken down in the endosomal-
lysosomal compartments, and the resulting peptides are presented on the dendritic cell 
surface on the tips of major histocompatibility complex (MHC) class II molecules, where they 
stimulate CD4+ T helper cells, causing them to activate. Activated T cells and B cells then 
“collaborate”, allowing differentiation of B cells into plasma cells (that produce circulatory 
IgGs) and memory B cells, which are essential to long-lasting immunity. Upon challenge after 
immunisation with a VLP, the memory B cells can quickly differentiate into plasma cells while 
primary B cells are activated and differentiate into new memory B cells (Zabel et al., 2013). The 
nucleic acid which is often encapsidated into VLPs also plays a beneficial role in stimulating an 
immune response. VLPs often encapsidate random host RNA in lieu of the viral genome, and 
this RNA is, in fact, a ligand for toll-like receptors (TLR) 7 and 8. These come into play at the 
point where the VLP is taken up by APCs: TLR 7 and 8 are located on the luminal side of 
endosomes, where they are stimulated by RNA taken up by the endosomal-lysosomal 
pathway, so the immune system recognises endosomal RNA as a sign of infection (Zabel et al., 
2013). These TLR stimulate both the T cell response as well as antibody production. The fact 
that the TLR ligand is encapsidated within the VLP is thought to reduce the risk of side effects 
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from VLP vaccines: only the cells which have taken up the antigen are activated by the TLR 
ligand, which focuses the immune system in a way that cannot happen if the antigen and TLR 
ligand are simply mixed together and taken up by different cells (Bachmann and Jennings, 
2010). 
These advantages permit the use of VLPs directly as vaccines, or as presentation systems for 
heterologous antigens through fusion or conjugation of an antigen on the surface of a VLP. In 
this context, the ability of VLPs to stimulate a strong B cell response was at one point thought 
to be potentially problematic, as it was thought that it might lead to “carrier suppression”: the 
suppression of an efficient T cell response against antigens presented on the surface of a VLP 
when antibodies against the VLP carrier already exist from prior vaccination. This was found to 
be unlikely to be a major issue by Ruedl et al. (2005), who showed that the presence of 
antibodies to a VLP carrier does not significantly affect overall induction of immunity. It is clear 
that VLPs combine three crucial advantages (size, repetitive structure, and RNA encapsidation) 
which make them ideally suited for use as vaccines. This explains why so far, the only 
recombinant vaccines approved by the American Food and Drug Administration (FDA) are VLP 
vaccines: all other recombinant subunit vaccine candidates have so far failed to obtain 
regulatory approval. It is also worth noting that subunit vaccines on the market today typically 
require the use of adjuvants such as aluminium hydroxide (alhydrogel), which can in fact be 
seen as crude ways of making antigen subunits take on a particulate form. Bachmann and 
Jennings (2010) refer to this as the “manufacturer’s dirty little secret”, by analogy with the 
“immunologist’s dirty little secret”, which refers to the use of adjuvants to make innocuous 
proteins immunogenic (Janeway, 1989). Although all commercially available VLP vaccine 
formulations contain adjuvant, there is evidence to suggest that in some cases, an antigen 
fused onto the surface of a VLP is just as protective as the antigen mixed with adjuvant, 
meaning the use of VLPs could be a way to reduce or eliminate the need for adjuvantation 
(Wang et al., 2012). 
Chapter 1: General Introduction 
 
19 
 
The production of VLPs in plants is part of the wider field of molecular “pharming”, or 
producing proteins of pharmaceutical interest in plants. One of the most common types of 
protein produced in this regard is candidate vaccines (the other is probably antibodies). This 
includes subunit vaccine candidates, in which a pathogen-derived protein or protein fragment 
is produced in plants either stably (Haq et al., 1995; Mortimer et al., 2012; Perez 
Aguirreburualde et al., 2013; Gorantala et al., 2014) or transiently (Mortimer et al., 2012; 
Gomez et al., 2013), sometimes linked to a carrier to act as a protein adjuvant. But 
increasingly, candidate vaccine production in plants has focused on the production of VLPs 
(Thuenemann et al., 2013b), for the reasons described above. While the HBsAg VLP vaccines 
were licensed in the mid- 1980’s, the field of plant-produced VLPs was not far behind: HBsAg 
VLPs were the first example of heterologous VLPs produced in plants (Mason et al., 1992). 
These particles were produced in stable transgenic tobacco plants, and their properties are 
very similar to those produced in yeast. Other enveloped virus particles have been produced in 
plants, most notably human immunodeficiency virus (HIV) VLPs, through the co-expression of 
the Gag polyprotein as well as the gp41 cytosolic and transmembrane component (Kessans et 
al., 2013); and influenza A VLPs, through the expression (using the CPMV-HT system) of 
haemagglutinin (HA) transmembrane protein (D'Aoust et al., 2009; D'Aoust et al., 2010). 
Moreover, human papillomavirus (HPV) has been produced in potato tubers (Warzecha et al., 
2003) and in tobacco leaves using pEAQ (Matić et al., 2012).  
Using a similar approach, bovine papillomavirus (BPV) VLPs were also produced in plants (Love 
et al., 2012). More impressive is the production of bluetongue virus (BTV) VLPs using pEAQ, 
which involves the co-expression of four different viral structural proteins in the correct ratios 
in order to obtain large quantities of correctly-assembled VLPs. These proved to be effective at 
protecting sheep from challenge (Thuenemann et al., 2013a). Finally, hepatitis B virus (HBV) 
core antigen (HBcAg) has been produced in plants on numerous occasions (Tsuda et al., 1998; 
Huang et al., 2006; Mechtcheriakova et al., 2006; Thuenemann et al., 2013b), and it has been 
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shown to form VLPs, which in this case are more accurately called core-like particles (CLPs), 
since HBV is an enveloped virus. The production and potential pharmaceutical uses of plant-
produced VLPs have been recently reviewed (Scotti and Rybicki, 2013; Thuenemann et al., 
2013b). Figure 1.4 shows three different types of VLP produced in plants using the pEAQ 
vectors. Note that plant-produced HBcAg (the first image), just like wild-type HBcAg, takes on 
both T=3 and T=4 conformations, although T=4 dominates (Crowther et al., 1994). The most 
relevant type of VLP for the purposes of this thesis is particles used for antigen-display. HBcAg 
in particular has played a large role in this field. 
 
 
Figure 1.4 Electron micrographs of virus-like particles produced in plants using pEAQ. Left: HBcAg CLPs. The arrow 
indicates a T=3 particle, whereas the others are T=4. Middle: BTV VLPs, image courtesy of Eva Thuenemann. Right: 
CPMV VLPs, image courtesy of Alaa Aljabali. Scale bars are 100 nm. 
 
IV - Antigen display 
 
Antigen display refers to the presentation of heterologous antigens on the surface of a VLP. 
The purpose is to enhance the immunogenicity of the antigen by using the carrier VLP to 
present a quasi-crystalline ordered repeat antigen structure to the immune system: the VLP 
moiety acts as both a scaffold and an adjuvant for the antigen of interest (see above and 
Plummer and Manchester, 2011). Because the point of an antigen-carrier VLP is that the VLP 
moiety is incapable of causing an infection in the animal host, infectious plant viruses used for 
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antigen display can be considered antigen-carrier VLPs, even though they are not technically 
VLPs. There are numerous examples of replicating plant viruses used to display immunogenic 
epitopes of animal pathogens for vaccine purposes. Chimaeric CPMV particles displaying a foot 
and mouth disease virus (FMDV) epitope, human rhinovirus epitope, or HIV epitope fused to 
the S coat protein have been produced in cowpea plants, and these particles could stimulate 
an immune response against the target epitope in test animals (Usha et al., 1993; Porta et al., 
1994; McLain et al., 1995). Moreover, this technique also permitted the development of a 
vaccine against mink enteritis virus that provides protective immunity in target animals 
(Dalsgaard et al., 1997). TMV particles have also been used to display heterologous epitopes: a 
leaky stop codon strategy was used to produce chimaeric TMV particles in which the C-
terminus of some of the coat proteins in the rod are fused to epitopes from the malaria 
parasite (Turpen et al., 1995), influenza virus, or HIV (Sugiyama et al., 1995).  
Moreover, engineered antibody fragments called single chain variable fragments (scFv) have 
been displayed on the surface of potato virus X (PVX) by fusion of the heterologous protein to 
the viral coat protein via the FMDV 2A peptide, which causes cleavage of some of the 
polypeptides through a ribosomal stutter mechanism (Smolenska et al., 1998). While this is not 
sensu stricto antigen-presentation, the display of a heterologous protein on the surface of a 
viral particle is technically very similar whether the heterologous protein in question is an 
antigen or an antibody fragment. Moreover, the display of antibody fragments on the surface 
of VLPs is extremely relevant to this thesis. It should therefore be pointed out that while the 
example cited above is the only one, to my knowledge, of antibody display in plants; examples 
of antibody display in other systems are legion: scFv have been displayed on the surface of 
hamster polyomavirus (HaPyV) particles produced in yeast (Pleckaityte et al., 2011); on the 
surface of measles virus particles (Peng et al., 2003) and murine leukaemia virus particles 
(Urban et al., 2005) produced in mammalian cells; and on the surface of baculovirus particles 
produced in insect cells (Kitidee et al., 2010). The display of scFv on the surface of 
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bacteriophage viruses in bacteria is known as “phage display” technology, and it has been used 
for years to identify specific antibodies which bind to an antigen of interest (Smith and 
Petrenko, 1997; Willats, 2002). It is not particularly surprising that scFv display was found to be 
possible in plants, since the production of unfused scFv and other types of antibodies, both 
native and engineered (sometimes called “plantibodies”), have been produced in plants 
numerous times through both stable (Hiatt et al., 1989; Ma et al., 1995; Schouten et al., 1997) 
and transient expression (Vaquero et al., 1999; Monger et al., 2006; Sainsbury et al., 2009b; 
Rosenberg et al., 2013). 
The more classic antigen display, however, involves fusing an antigen or epitope of interest to 
a non-replicating VLP in a heterologous expression system. Early successes with this sort of 
technique showed that the antigenicity of a protein or epitope of interest can be dramatically 
increased by presenting it on the surface of a VLP carrier: one of the earliest experiments 
involved fusing an FMDV epitope to the N-terminus of HBcAg CLPs, which led to the formation 
of chimaeric CLPs which were almost as antigenic as FMDV in animal models (Clarke et al., 
1987). It then became widely accepted as fact that any epitope or antigen fused to a VLP 
carrier would be much more immunogenic than if it were alone, to such an extent that 
numerous groups have actually produced and tested antigens displayed on VLP carriers 
without ever comparing them to the antigen or epitope on its own (Birkett et al., 2002; De 
Filette et al., 2005; Sominskaya et al., 2010; Pastori et al., 2012; Ravin et al., 2012).  
This assumption, however, is not foolproof, as there are some examples of antigens being less 
immunogenic (Arora et al., 2012, 2013), or at least no more immunogenic (Middelberg et al., 
2011; Mazeike et al., 2012) when displayed on the surface of a VLP than when administered 
alone. That having been said, it is true that in general, display on the surface of a VLP clearly 
enhances the immunogenicity of the target antigen or epitope. This normally holds true when 
comparing the chimaeric VLP to the antigen alone (Eriksson et al., 2011; Yin et al., 2011; Wang 
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et al., 2012; Skrastina et al., 2013), the antigen mixed with the native VLP (Jegerlehner et al., 
2002; Denis et al., 2008; Dhanasooraj et al., 2013), or the chimaeric VLP after denaturation 
(Chackerian et al., 1999). This demonstrates that it is the particulate structure on which the 
antigen is displayed that confers the increase in immunogenicity, and not simply the VLP or 
individual capsid protein acting as a standard adjuvant. This shows that antigen display is a 
potentially powerful technique which allows the inherent immunogenicity of a given antigen 
or epitope to be enhanced for vaccine development purposes. The main limitation of this 
technique is the risk of abolishing capsid formation by inserting a foreign sequence which is 
either too long or too complex, and thus interferes with carrier protein folding or capsid 
assembly. For this reason, most of the examples of antigen display, including those cited 
above, tend to be of short linear epitopes. However, one carrier in particular has the potential 
to overcome this limitation: the CLP formed by HBcAg. 
 
V - The HBcAg CLP as an antigen carrier 
 
HBcAg is a 20 kDa protein made up of 183-5 amino acids (depending on the strain of HBV). Its 
secondary structure is rich in α-helices, with the longest ones forming a hairpin structure, with 
the immunodominant c/e1 loop bridging the ascending and descending helices (Fig. 1.5). Two 
HBcAg monomers dimerise spontaneously with the hairpin structure forming the dimer 
interface, and these dimers self-assemble to form either T=3 (90 dimers) or T=4 (120 dimers) 
core-like particles with the hairpin structures forming characteristic protruding spikes on the 
surface of the particle (Crowther et al., 1994; Conway et al., 1998; Wynne et al., 1999). The 
CLP structure in general, and the dimer structure in particular, are very stable. This could be 
explained by disulphide bridges between monomers, with C61 from each monomer forming a 
disulphide bridge between the hairpin helices, and C48 from each monomer sometimes 
forming a bridge at the base of the spike (Zheng et al., 1992; Wynne et al., 1999). These are 
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not strictly necessary for dimer or capsid formation, since Jegerlehner et al. (2002) managed to 
obtain CLPs after having removed all of the cysteine residues from the sequence, suggesting 
that these disulphide bridges probably play more of a stabilising role. The C-terminus is very 
arginine-rich, and truncations at position 176, 149, or 144 are tolerated, as they do not 
interfere with capsid assembly but do drastically reduce nucleic acid encapsidation (Gallina et 
al., 1989; Zheng et al., 1992). 
 
 
Figure 1.5 The structure of HBcAg and the HBcAg CLP. Left: two HBcAg monomers (in blue and red) assembled to 
form a dimer, with the e1 loops exposed. The amino (N) and carboxy (C) termini are indicated with arrows. These 
dimers form the building blocks of the core-like particle (CLP) of HBV (right). Structures were obtained from PDB 
entry 1QGT (Wynne et al., 1999). Images were generated using PyMOL. 
  
HBcAg is known to be inherently immunogenic, thanks to both B-cell and T-cell epitopes 
(Francis et al., 1990; Pumpens and Grens, 2001; Cooper et al., 2005). It is a remarkably tolerant 
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protein in terms of the insertions and fusions that can be made without disrupting protein 
folding or capsid assembly. There have been numerous studies looking into how fusions and 
insertions are tolerated in HBcAg, and they have revealed the advantages and disadvantages of 
inserting sequences at the N-terminus, C-terminus, or the immunodominant e1 loop, located 
at the tip of the spikes which protrude outwards from the surface of the HBcAg CLP. It is now 
possible to draw some general conclusions about the possibilities as well as the limits to such 
modifications, and to devise different strategies to attempt to overcome such limits. Many 
groups have inserted identical sequences at different positions within HBcAg in order to assess 
the feasibility and immunogenicity of such insertions (Schödel et al., 1992; Yon et al., 1992; 
Koletzki et al., 1999; Lachmann et al., 1999; Koletzki et al., 2000). They all conclude that 
insertions in the e1 loop allow for greater yields of chimeric particles as well as better surface 
exposure than N- or C-terminal fusions, regardless of the truncation state of the C-terminus. 
Moreover, e1 insertions reduce the antigenicity of the HBcAg carrier, which is often logs higher 
than the target insert in N- or C-terminal fusions: because the e1 loop is the immunodominant 
region, insertions in this area tend to transfer the inherent antigenicity onto the insert protein 
or peptide (Brown et al., 1991; Chambers et al., 1996; Ulrich et al., 1998; Pumpens and Grens, 
1999). This has been extensively reviewed by Pumpens and Grens (2001), and the use of 
HBcAg as a vaccine platform has more recently been reviewed by Whitacre et al. (2009). 
 
A) N-terminal fusions 
Fusions of 5 to 120 amino acids have been attempted at the N-terminus of HBcAg, but the 
latter prevented the formation of particles in E. coli (Koletzki et al., 1999; Lachmann et al., 
1999). The longest N-terminal fusion which allowed particle formation (in E. coli) was a 63 
amino acid-long epitope corresponding to three M2e peptides from Influenza virus fused 
together (De Filette et al., 2005). It is noteworthy that the surface accessibility of N-terminal 
insertions seems to be sequence-specific rather than size-specific. Indeed, a pentapeptide was 
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found to be exposed on HBcAg particles (Lachmann et al., 1999), whereas a much longer 30 
amino acid-long oligopeptide necessitated the use of a four amino acid – long linker between it 
and HBcAg to provide surface accessibility (Schödel et al., 1992). However, accessibility of the 
insert as determined by in vitro methods such as sandwich ELISA, is not always a perfect 
correlate for antigenicity in vivo. Indeed, an N-terminal 45 amino acid-long Hantavirus epitope 
was found to be less exposed than identical C-terminal or e1 insertions when assayed by ELISA, 
but it stimulated greater production of antibodies in animals than the C-terminal insertion 
(Koletzki et al., 2000). Moreover, the N-terminus was found to be the optimal fusion site 
(better than the e1 loop) in the case of the M2e epitope: fusing 3 copies of M2e (with 
cysteines replaced by alanine or serine) at the N-terminus of HBcAg was found to provide a 
superior immune response in animals than an M2e insertion in the e1 loop (though a single 
copy was still more immunogenic in the e1 loop than at the N-terminus). Adding a copy of M2e 
in the e1 loop to the construct already bearing 3 copies of M2e on the N-terminus did not 
improve immunogenicity, and the particles carrying 2 or 3 copies of M2e at the N-terminus 
elicited higher antibody titres against M2e than against the HBcAg carrier (De Filette et al., 
2005). This is thought to be because the immunogenic potential of the M2e epitope requires 
its N-terminus to be free and exposed, which is not the case when it is inserted into the e1 
loop. These data indicate that N-terminal insertions are normally well tolerated in terms of 
capsid assembly up to about 65 amino acids, and are most often surface exposed. While they 
do not normally provide a stronger immune response than e1 insertions, the N-terminus can 
be the fusion site of choice for epitopes that require a free N-terminus, if multiple repeats of 
the epitope can be used. 
 
B) C-terminal fusions 
The C-terminus of HBcAg has been the subject of multiple experiments, with conflicting results 
on whether C-terminal inserts are surface-exposed on the assembled capsids. The truncation 
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state of the HBcAg C-terminus seems to play a crucial role in deciding whether C-terminal 
inserts are surface exposed: fusions to full-length (183 amino acids) cores or cores truncated 
after position 155 seem to be buried (Yon et al., 1992; Beterams et al., 2000), while fusions to 
cores truncated after position 144 or 149 seem to be exposed (Stahl and Murray, 1989; 
Schödel et al., 1992; Ulrich et al., 1992; Yoshikawa et al., 1993; Grene et al., 1997; Koletzki et 
al., 2000). This seems to hold true unless the insert is particularly small: the pentapeptide 
DPAFR was found to be inaccessible when fused after HBcAg position 149 (Lachmann et al., 
1999). Interestingly, larger (37-55 amino acids) sequences inserted after position 144 seem to 
be surface-exposed regardless of whether they are replacing or preceding the C-terminal 
arginine-rich tail (Borisova et al., 1989). However, the specific sequence of the insert does play 
a role in determining surface accessibility: when fusing HIV-1 Gag epitopes to a Δ144 
truncation, Grene et al. (1997) found that while the 90 amino acid insert was surface-exposed, 
certain regions of it were inaccessible, suggesting that certain sequences will have a tendency 
to be more buried than others. Certainly the most impressive insertion made in the C-terminus 
has been the fusion of the entire 167 amino acid (17 kDa) sequence of a bacterial nuclease 
after HBcAg position 155 (Beterams et al., 2000). This resulted in the formation of capsid 
particles which contained properly folded, functional nuclease packaged within them. This is 
particularly impressive given that such a large insert seems to surpass the length of C-terminal 
fusions that others have tried. For example, Ulrich et al. (1992) found that C-terminal 
insertions of 90 amino acids, but not 100, 189, or 317, allowed particles to form with HBcAg 
truncated after position 144. Similarly, Koletzki et al. (1999) found that 120 amino-acid long 
inserts prevented the formation of particles in Δ144 truncated HBcAg. In a Δ149 truncated 
HBcAg, Yoshikawa et al. (1993) demonstrated that a C-terminal fusion of 37 amino acids of 
Hepatitis C Virus core protein allowed particle formation (but that this epitope was not surface 
accessible), as did 91 amino acids of the same core protein (which was surface accessible). The 
authors attempted to fuse the full 180 amino acids of the HCV core protein, as well as 2, 3, and 
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4 copies thereof, but they failed to prove particle formation with such large inserts. Taken 
together, these data indicate that there is a size limit for C-terminal fusions of about 90-100 
amino acids for unstructured peptides, but that this limit can be extended for globular 
proteins, thus hinting that particle assembly can be limited by spurious interaction between an 
unstructured insert and the HBcAg polypeptide. Furthermore, C-terminal inserts tend to be 
surface-exposed provided that they are long enough and fused upstream of the last 34 amino 
acids of the HBcAg C-terminus. 
 
C) Insertions in the e1 loop 
The e1 loop has been recognised as the insertion site of choice for eliciting a strong immune 
response, and has therefore been the subject of great attention in recent years. It is known 
that small oligopeptide inserts are well tolerated in the e1 loop, and that these tend to yield 
higher quantities of particles than equivalent N- or C-terminal fusions (Schödel et al., 1992; 
Yon et al., 1992; Ulrich et al., 1998; Koletzki et al., 1999; Lachmann et al., 1999; Koletzki et al., 
2000). Moreover such insertions disrupt the immunodominant region of HBcAg, which means 
that they tend to reduce the antigenicity of the HBcAg carrier, particularly if some of the 
HBcAg amino acids in the flexible loop (positions 74-81) around the insertion site are removed. 
The impressive tolerance of the e1 loop for insertions allows much larger sequences, both 
conformational and disordered, to be displayed in this region without abolishing particle 
assembly (although the yield of chimeric particles is often adversely affected to a certain 
extent). In a series of experiments aimed at displaying different long (~25 kDa) epitopes based 
on the polymorphic immunodominant molecule (PIM) protein of the parasite Theileria parva, 
it was determined that the e1 loop of HBcAg could handle such long inserts without impairing 
particle formation, so long as a flexible glycine-rich linker of 15 or 20 amino acids was added 
on either end of the insert; whereas the use of a similar linker of only 9 amino acids failed to 
allow particle assembly (Janssens et al., 2010). The authors speculate that large inserts are 
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likely to be tolerated in the e1 loop so long as linkers of sufficient length allow the necessary 
flexibility for folding, and for the termini of the insert to be relatively close together (10-18 Å 
apart) at the e1 loop. Another group demonstrated that ~190 amino acids corresponding to 
the entire sequence of the OspC protein from Borrelia burgdoferi, with the exception of the 
signal peptide, could be fused into the e1 loop of HBcAg without impairing the folding of either 
HBcAg or OspC (Skamel et al., 2006). Moreover, the resulting particles seemed to be coated 
with OspC proteins that were dimerising with inserts on neighbouring e1 spikes, thus 
demonstrating great flexibility both within and between the e1 spikes on assembled HBcAg 
particles. So far, the largest sequence directly fused into the e1 loop of HBcAg is GFP (Kratz et 
al., 1999). The 238 amino acid –long, 27 kDa protein sequence was inserted in the e1 loop 
(with amino acids P79 and A80 removed) with glycine-rich linkers on either end (9 amino acids 
long). This construct yielded fluorescent fusion protein, some of which assembled into 
fluorescent particles. Cryo-electron microscopy revealed that these particles looked very much 
like native HBcAg capsids, but with an extra dense shell on the surface, corresponding to the 
position of the GFP molecules. In some cases, insertions can cause problems related to 
solubility of chimeric capsids, but these are not necessarily unsurmountable. An 11 kDa 
insertion from Dengue Virus EDIII yielded insoluble particles which had to be denatured to be 
purified from E. coli, but these were capable of being refolded into capsids displaying the insert 
(Arora et al., 2012). This inherent insolubility was not resolved by switching to a yeast 
expression system (Arora et al., 2013). 
It is possible to use more than one insertion site on HBcAg at the same time without abolishing 
capsid formation. Ulrich et al. (1999) inserted 45 amino acids of hantavirus nucleocapsid 
protein in the e1 loop, and a different 44 amino acid –long epitope (from the same protein) at 
the C-terminus, which was truncated after HBcAg position 144. Later, Birkett et al. (2002)  
successfully inserted 20 amino acids from Plasmodium falciparum circumsporozoite protein in 
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the e1 loop, and a different 20 amino acid – long epitope at the C-terminus of a Δ149 
truncation of HBcAg. 
At the time of writing, there have been only two reports of antigen display on HBcAg produced 
in plants. Bandurska et al. (2008) fused the 139 amino acid – long domain-4 epitope of the 
anthrax protective antigen (PA) in the e1 loop and created lines of transgenic tobacco 
containing the sequence. While the fusion protein was expressed and was immunogenic, CLP 
formation was not observed. This contrasts with the findings of Huang et al. (2005), who 
displayed a 21 amino acid – long epitope from FMDV in the e1 loop of HBcAg, also produced in 
transgenic tobacco. This group found that CLPs were formed, and were capable of protecting 
mice from FMDV challenge. 
 
D) Other insertion strategies 
Numerous groups have developed alternatives to straightforward genetic fusions in order to 
develop easier antigen presentation strategies, or to overcome the limits to insertions 
described above. The most common strategy used to force HBcAg capsids to carry large inserts 
at the C-terminus is to produce mosaics: particles containing a mix of modified and unmodified 
HBcAg monomers. Koletzki et al. (1999) used this strategy to fuse 120 amino acids of 
Hantavirus protein at the C-terminus of Δ144 HBcAg: a stop codon read-through mechanism 
was exploited to produce modified and unmodified HBcAg from the same construct. This 
allowed particle formation with this insert, whereas a straightforward C-terminal fusion did 
not. This was seen again by Ulrich et al. (1999), who produced mosaics particles with HBcAg 
Δ144 containing 144 extra amino acids at the C-terminus. This strategy was studied in more 
detail by Kazaks et al. (2002), who found that it permitted the formation of particles with 94, 
114, or 213, but not 433 amino acids fused to the C-terminus of Δ144 HBcAg, even when direct 
fusions failed to allow the formation of such particles (or gave prohibitively low yields). The 
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authors conclude that the mosaic strategy can be of use to incorporate “problematic” (i.e. long 
or hydrophobic) sequences into HBcAg capsids at the C-terminus. The mosaic technique clearly 
provides another tool for the insertion of peptides into the C-terminus of HBcAg, but it should 
be noted that the drawback of this strategy is that particles could contain very few copies of 
the insert, and some particles may not contain any insert at all. 
An alternative strategy for display in the e1 loop is chemical conjugation. It is possible to 
genetically modify HBcAg by inserting a lysine residue in the e1 loop and removing all of the 
cysteines from the sequence. A peptide insert with a cysteine on one terminus can then be 
chemically conjugated to the e1 lysine via its cysteine (Jegerlehner et al., 2002). This allows 
display of peptides to the e1 loop, but it should be noted that the efficiency of conjugation 
decreases as the size of the insert increases. Indeed, a small peptide like the FLAG tag was 
coupled with about 50% efficiency, M2e (23 amino acids) coupling was about 40% efficient, 
and coupling of a 66 amino acid- long epitope from Toxoplasma gondii protein GRA2 was only 
about 30% efficient. The coupling of a 134 amino acid-long PLA2 glycoprotein from bee venom 
was estimated to be even lower. Chemical coupling may therefore be an option if genetic 
fusion is unsuccessful, or if the insert must present a free terminus. 
Another strategy is non-covalent interaction of the insert and the HBcAg carrier through a 
peptide tag that binds to the e1 loop. The natural interaction between HBcAg and HBsAg 
(Dyson and Murray, 1995) was exploited to design an oligopeptide (GSLLGRMKGA) which binds 
the e1 loop of HBcAg (Blokhina et al., 2013). This peptide tag, when fused to M2e, allowed 
display of the epitope on the HBcAg particles. The strength and stability of the interaction 
deserves further study however, as sucrose gradient ultracentrifugation was seen to disrupt 
the interaction between the particles and the tagged epitope. 
Yet another strategy is in situ post-translational cleavage of the insert in the e1 loop (Walker et 
al., 2008). In this case, the insert is designed to contain the cleavage site for tobacco etch virus 
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(TEV) protease at the N-terminus. The modified HBcAg construct is then expressed with the 
protease, which cleaves the insert at its N-terminus without preventing capsid assembly. This 
was shown to allow particle assembly when a straightforward fusion would not, such as in the 
case of the Borrelia burgdoferi protein OspA, a 28 kDa protein, in which the N- and C-termini 
are very far apart. This strategy was simplified to give SplitCore: a strategy whereby the HBcAg 
sequence is split at the e1 loop into two separate open reading frames, placed together as a 
bicistronic operon in an E. coli expression system (Walker et al., 2011). This allows large inserts 
to be fused either at the C-terminus of the upstream (N-terminal) half-monomer, or at the N-
terminus of the downstream (C-terminal) half-monomer. This strategy is discussed in more 
detail in Chapter 3. 
An interesting alternative to the above strategy is the tandem core technology, patented by 
Gehin et al. (2004) after development in E. coli, and tested in plants using the CPMV-HT system 
(Thuenemann, 2010). This involves genetically fusing two HBcAg monomers in order to 
produce the HBcAg dimer as a single polypeptide chain. This allows large insertions to be made 
in only one of the e1 loops in each dimer, thus reducing the risk of steric hindrance with large 
inserts. This technique has been shown to allow the formation of capsid particles with large 
inserts in the e1 loop in both bacteria and plants. Two main types of tandem core constructs 
were produced and tested: the homotandem core construct (CoHo) is composed of two core 
sequences both truncated at position 149, whereas the heterotandem core construct (CoHe) 
has a truncated N-terminal core but a full-length C-terminal core (more details are given in 
Chapter 3). While both expressed and formed particles in both plants and E. coli, it was found 
that CoHe yielded more homogenous CLPs and was more suited to antigen display in plants 
(Thuenemann, 2010). Of particular interest for this thesis is the fact that GFP was successfully 
displayed on the surface of CoHe particles in plants using the pEAQ-HT vector. This is the main 
technique which was used in this thesis to display large correctly-folded inserts on the surface 
of HBcAg CLPs. 
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E) Other antigen carriers and the advantages of HBcAg 
While it is beyond the scope of this introduction to comprehensively review the use of 
nanoparticles for antigen display, the main differences between HBcAg and other commonly 
used carriers can be addressed. As mentioned previously, other viruses have been used for the 
surface display of epitopes. Chimaeric TMV (Sugiyama et al., 1995; Turpen et al., 1995) and 
CPMV (Usha et al., 1993; Porta et al., 1994; McLain et al., 1995; Dalsgaard et al., 1997) have 
both been used, but only with small epitopes (<100 amino acids). PVX, on the other hand, has 
proven to be much more tolerant of larger inserts, provided that the 2A peptide is used to fuse 
the insert protein to the N-terminus of the PVX coat protein. This ensures that a certain 
number of coat proteins are insert-free, which allows the assembly of chimaeric PVX rods 
despite potential steric hindrance caused by large protein inserts. In that sense, this 2A 
strategy is essentially very similar to a mosaic strategy. By using this method, whole proteins 
such as GFP (Cruz et al., 1996), scFV (Smolenska et al., 1998), and the rotavirus VP6 capsid 
protein (O'Brien et al., 2000) have all been displayed on the surface of PVX rods. Small 
epitopes can be fused to the PVX coat protein directly without the need for 2A, as was 
demonstrated by Marusic et al. (2001), who displayed a 6 amino acid – long epitope from the 
conserved region of HIV surface glycoprotein gp41 on the surface of chimaeric PVX rods. 
HBcAg can accommodate larger inserts than CPMV, and unlike PVX does not necessarily 
require a mosaic strategy to display large folded proteins. 
As mentioned above, animal viruses have also been used to display proteins of interest. 
Murine polyomavirus VLPs have been used to display a Streptococcus peptide epitope 
(Middelberg et al., 2011) as well as the entire 34 kDa human prostate specific antigen (Eriksson 
et al., 2011). VLPs from the related hamster polyomavirus has also been used to display a 9 
amino acid - long model epitope from lymphocytic choriomeningitis virus (Mazeike et al., 
2012), as well as an entire scFv-Fc fusion which retained antigen-binding activity when 
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displayed on the surface of the VLPs (Pleckaityte et al., 2011). While this is reminiscent of 
HBcAg in terms of the size and complexity of inserts, polyomavirus VLPs require the co-
expression of at least two capsid proteins (in the latter example, the insert was fused to VP2 
and co-expressed with VP1). Protein display on HBcAg does not require the co-expression of 
other structural proteins, which is an advantage as the stoichiometry of different capsid 
proteins can sometimes be a barrier to efficient VLP production (Thuenemann et al., 2013a). 
Other viruses have been used to display short epitopes, including bovine papillomavirus 
(Chackerian et al., 1999), papaya mosaic virus (Denis et al., 2008), and the AP205 
bacteriophage (Pastori et al., 2012), but the display of full-length proteins is not normally 
possible in such systems. As noted above, many different viruses have been used to display 
scFv, but most of those viruses are not typically used for antigen display stricto sensu. This 
underlines the fact that the display of a protein on the surface of a viral particle depends not 
only on the viral particle, but also on the nature of the protein being used as an insert. Non-
viral nanoparticles have also been used: apoferritin is a ubiquitous protein complex which 
forms symmetrical nanoparticles reminiscent of VLPs. Apoferritin has been used to display 
short epitopes (Han et al., 2014) as well as the 65 kDa ectodomain of influenza virus HA, which 
formed physiologically and immunologically relevant trimers on the surface of the apoferritin 
nanoparticle (Kanekiyo et al., 2013). 
Ultimately, HBcAg is not the only candidate for the display of heterologous proteins, and in 
some cases it may not be the best candidate. But it does generally have advantages over other 
carriers. A single protein forms the stable capsid, and there are three possible insertion sites 
within HBcAg including the immunodominant e1 loop which tends to boost the antigenicity of 
the insert. This e1 loop can accommodate large inserts, although GFP appears to be the limit in 
terms of size and complexity that the e1 loop can handle in the context of native HBcAg. The 
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use of different bionanoparticles for antigen display has been reviewed by Lee and Wang 
(2006). 
 
 
VI - Aims of this thesis 
 
The primary aim of this thesis is to develop plant-produced HBcAg CLPs as carriers for any 
antigen of interest. Specifically, the goal is to produce a generic antigen presentation system, 
which would easily allow any antigen to be presented on the surface of an HBcAg CLP. In order 
to do this, both the SplitCore and tandem core technologies mentioned above were tested to 
determine which might be most suitable for chimaeric CLP production in plants. Once it was 
determined that tandem core technology was better suited, two different generic antigen 
display systems were developed: the first, very simple in design, is intended to allow antigen 
display on a CLP via post-purification chemical conjugation. The second system, which is more 
complex in nature and formed the bulk of the project, investigated the possibility of displaying 
an antibody fragment (scFv or camelid nanobody) on the surface of the CLPs. This would allow 
the non-covalent binding of an antigen of interest to the chimaeric CLP via the antibody 
fragment. The hypothesis on which this system is founded is that all antibody fragments of a 
particular type (scFv or camelid nanobody) will behave in the same way when fused onto the 
surface of the tandem core particle. Thus, if a system could be developed whereby an antigen 
could be displayed on the surface of a CLP through the interaction with an antibody fragment 
expressed in HBcAg, it should be straightforward to switch the antibody moiety to create a CLP 
that will capture and display a completely different antigen.   
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Chapter 2 : Materials and Methods   
 
I - DNA constructs 
 
Numerous DNA constructs were ordered for synthesis from GeneArt (Life Technologies) in 
order to quickly obtain reliable, high-quality material for subsequent cloning and gene 
expression. Details of the specific sequences synthesised are given in the relevant chapter. 
 
II - DNA isolation/purification 
 
DNA was isolated from bacteria by using the QIAprep Spin MiniPrep Kit (Qiagen), from PCR 
reactions by using the QIAquick PCR purification kit (Qiagen), and from agarsose gels by using 
the QIAquick Gel Extraction kit (Qiagen). Purified DNA was stored at -20°C. 
 
III - Restriction digests 
 
Restriction enzymes were obtained from New England Biolabs (NEB), Roche or Invitrogen. 
Restriction digests were carried out in the appropriate buffer as recommended by NEB. 
 
IV - Ligation 
 
Ligation of DNA fragments was carried out using either Quick Ligase (NEB) or T4 Ligase (NEB) as 
per manufacturer’s instructions. When ligations were of an insert into a plasmid, the individual 
fragments were quantified using a NanoDrop spectrophotometer and a 3:1 insert:plasmid 
molar ratio was used. 
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V - Media 
 
Solution Composition 
ELISA BUFFERS  
ELISA Block Buffer 5 % (w/v) dry milk, 0.05 % (v/v) Tween-20, in PBS 
ELISA sample buffer 1 % (w/v) dry milk, 0.05 % (v/v) Tween-20, in PBS 
Wash buffer (ELISA) 0.05 % (v/v) Tween-20, in PBS 
ELISA detection reagent 
50 mM NaHPO4; 25 mM citric acid; 3,3’,5,5’–
Tetramethylbenzidine (TMB) tablet (Sigma-Aldrich)  
ELISA stop solution 1 M H2SO4 
EXTRACTION BUFFERS  
AmBic 20 mM ammonium bicarbonate, pH 8.5 
HBexB1 
10 mM Tris-HCl pH 8.4; 120 mM NaCl; 1 mM EDTA; 0.75 % 
(w/v) sodium deoxycholate; 1 mM DTT; Complete 
Protease Inhibitor Cocktail tablet (Roche) 
P 
0.1 M sodium phosphate, pH 7.5; Complete Protease 
Inhibitor Cocktail tablet (Roche) 
P+ 
20 mM sodium phosphate, pH 7.0; 1 mM EDTA; 5 mM 
DTT; 0.1 % (v/v) Triton X-100; Complete Protease Inhibitor 
Cocktail tablet (Roche) 
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IQUR 
20 mM Tris-HCl pH 8.0; 1 mM EDTA; 5% isopropanol (v/v); 
5 mM DTT; 0.1 % Triton X-100; Complete Protease 
Inhibitor Cocktail tablet (Roche) 
AngeliTris 
100 mM Tris pH 9.0; 100 mM NaCl; 1 mM EDTA; 0.75 % 
(w/v) sodium deoxycholate; Complete Protease Inhibitor 
Cocktail tablet (Roche) 
AngeliBor 
100 mM boric acid pH 10; 100 mM NaCl; 1 mM EDTA;   
0.75 % (w/v) sodium deoxycholate; Complete Protease 
Inhibitor Cocktail tablet (Roche) 
GROWTH MEDIA  
Luria Bertani broth (LB) 
10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl adjusted to 
pH 7.0 
L-agar as LB, with 1.5 % (w/v) Lab M agar added 
SOC (Life technologies) 
2 % (w/v) tryptone, 0.5 % (w/v) yeast extract, 10 mM NaCl, 
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM 
glucose. 
WESTERN BLOT BUFFERS  
Western Blot Transfer 
buffer 
3.03 g/l Tris-HCl, 14.4 g/l glycine, 20 % (v/v) methanol 
Western blot block 
buffer 
5 % (w/v) dry milk, 0.1 % (v/v) Tween-20, in PBS 
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Wash buffer (western) 0.1 % (v/v) Tween-20, in PBS 
Western blot detection 
solution 
1.25 mM luminol; 200 mM paracoumaric acid; 27 mM 
H2O2; 100 mM Tris-HCl pH 8.5 
OTHER  
MMA 
10 mM MES, pH 5.6; 10 mM MgCl2; 100 µM 
acetosyringone 
Phosphate-buffered 
saline (PBS) 
150 mM NaCl; 2 mM NaH2PO4; 15 mM Na2HPO4; pH 7.2 
Protein loading buffer 
(2X) 
900 µl 4x LDS sample buffer (Invitrogen), 300 µl β-
mercaptoethanol 
TBE 10.8 g/l Tris-HCl, 5.5 g/l Boric, 2 mM EDTA 
 
 
VI - Polymerase Chain Reaction (PCR) 
 
Amplification of DNA to be used for subsequent cloning was carried out using Phusion high-
fidelity polymerase (Roche) and the supplied buffer using the following protocol. Details of the 
primers used can be found in Appendix 1. 
Recipe 50  µl  Cycles   
5X HF buffer  10 µl  98°C  30  sec 
10 mM dNTPs  1.25 µl  98°C 10  sec 
DNA template 1 µl  70°C 20  sec 
30 X 
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10 µM forward primer 2.5 µl  72°C 20 sec/kb 
10 µM reverse primer 2.5 µl  72°C 5 min 
Phusion polymerase 0.5 µl     
dH2O 32.25 µl     
 
Amplification of DNA to be used only for agarose gel electrophoresis analysis only was carried 
out using GoTaq Green Master Mix (Promega) using the following protocol. For colony PCR 
(always carried out using the C1 and C3 primers), the DNA template was replaced with a small 
amount of bacteria picked off an agar plate with a sterile toothpick. 
Recipe 20  µl  Cycles   
2X Go Taq Green MM  10 µl  95°C  5  min 
DNA template 1 µl  95°C 1  min 
10 µM forward primer 0.5 µl  58°C 45  sec 
10 µM reverse primer 0.5 µl  72°C 1 min/kb 
dH2O 8 µl  72°C 5 min 
 
 
VII - Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used to analyse PCR reactions, or to analyse and purify 
restriction fragments. Gels contained 0.8- 1.2 % (w/v) agarose dissolved in TBE. The marker 
ladder used was HyperLadder I (Bioline). 
 
 
31 X 
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VIII - DNA sequencing 
 
Sequencing reactions were either carried out entirely by Eurofins Genomics; or prepared as 
“ready reactions” using BigDye Terminator v3.1 (Applied Biosystems) according to 
manufacturer’s instructions, the sequences were then analysed by either Eurofins Genomics 
(i54 Business Park, Valiant Way, Wolverhampton, WV9 5GB, UK) or Genome Enterprise Ltd. 
(The Genome Analysis Centre, Norwich Research Park, Norwich, NR4 7UH, UK). 
 
IX - Bacterial strains, growth and storage conditions 
 
Escherichia coli strain TOP10 (Life Technologies) and Agrobacterium tumefaciens strain 
LBA4404 (Hoekema et al., 1983) were used throughout. E. coli containing a pMA plasmid with 
the appropriate insert obtained from GeneArt (Life Technologies) were grown at 37 °C using LB 
broth or L-agar supplemented with carbenicillin (100 µg/ml) for plasmid selection. E. coli 
containing a pEAQ plasmid were grown using the same conditions, but 50 µg/ml kanamycin 
was used for plasmid selection instead of carbenicillin. A. tumefaciens containing a pEAQ 
plasmid were grown at 28 °C using LB broth or L-agar supplemented with kanamycin (50 
µg/ml) for plasmid selection plus 50 µg/ml rifampicin to select for A. tumefaciens LBA4404. 
Once a clone of E. coli or A. tumefaciens had been identified as positive for the desired plasmid 
by colony PCR and sequence analysis, a glycerol stock was prepared: the clone was grown in 
liquid culture and an aliquot of stationary phase culture was supplemented with glycerol (final 
concentration 25 % [v/v]), snap-frozen in liquid nitrogen, then stored at -80°C.   
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X - Transformation of competent bacterial cells 
 
Purchased E. coli TOP10 chemically competent cells were transformed as per manufacturer’s 
instructions. Briefly, aliquots of cells mixed with 10-50 ng of plasmid DNA were heat-shocked 
at 41°C for 30 seconds then allowed to recover in SOC for one hour at 37°C before being plated 
on agar plates containing the appropriate antibiotic. A. tumefaciens LBA4404 
electrocompetent cells were made in the laboratory. These were transformed by mixing 50 µl 
of competent cell aliquots with 10-50 ng of plasmid DNA, then electroporating at 2,500 V. The 
cells were allowed to recover in SOC for one hour at 28 °C before being plated on agar 
containing appropriate antibiotics. 
 
XI - Plasmids used 
 
The pMA plasmids are small simple plasmids used by GeneArt (Life Technologies) to facilitate 
the propagation and transportation of synthetic gene constructs. They carry a resistance gene 
to ampicillin, and were selected for in bacterial cultures with carbenicillin. The pEAQ-HT 
plasmid is a binary vector tailored to allow high-yielding overexpression of recombinant 
proteins in plants (Sainsbury et al., 2009b). It contains a CPMV-HT cassette composed of a 35S 
promoter, Nos terminator, and Cowpea Mosaic Virus RNA-2 5’ and 3’ untranslated regions 
(UTRs), with two point mutations in the 5’ UTR which increases translational efficiency. This is 
the vector which was used to express the proteins discussed in this thesis. The pFSC5 and 
pFSC6 plasmids are small plasmids used to insert two genes of interest (one in each plasmid) 
each within its own CPMV-HT cassette: both contain a CPMV-HT cassette with a multiple 
cloning site for ORF insertion, and the CPMV-HT cassette is flanked by the restriction sites PacI 
and SbfI for pFSC5, and SbfI and AscI for pFSC6 (Sainsbury et al., 2012a). These restriction sites 
can be used to integrate both cassettes into a single pEAQ-HT vector using the PacI and AscI 
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restriction sites, with the shared SbfI site allowing the two cassettes to form a single DNA 
fragment. 
 
XII - Agroinfiltration 
 
For transient expression of recombinant proteins, liquid cultures of A. tumefaciens were 
prepared. For bacteria taken from glycerol stocks, the primary culture was subcultured, and 
this subculture was used for agroinfiltration. Agroinfiltration was carried out using a similar 
method to that described in (Thuenemann et al., 2013a). Briefly, the cultures were centrifuged 
at 1,100 x g for 20 min, then resuspended in MMA buffer to an OD600 of 0.4 unless otherwise 
stated. A syringe was used to infiltrate the suspension into the extracellular space of N. 
benthamiana leaves (Schob et al., 1997). Typically, for small-scale experiments designed to test 
expression of a recombinant protein, two leaves from each of three plants were infiltrated in 
order to minimise variability of expression levels. 
 
XIII - Plant growth conditions 
 
N. benthamiana plants were grown in glasshouses maintained at 25°C and watered daily. 
Supplemental lighting was provided to maintain 16 hours of daylight in the winter months 
(October – April, inclusive). Plants were agroinfiltrated 3 weeks after pricking out. 
 
XIV - Small-scale protein extraction 
 
Small-scale extractions were used to test expression and accumulation of recombinant 
proteins. Agroinfiltrated leaf tissue was harvested 7 days post-infiltration (dpi), and a cork-
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borer (size number 7) was used to sample six leaf discs (corresponding to 90 mg of fresh-
weight leaf tissue, or FWT) from infiltrated areas of the leaves. These were placed in a 2 ml 
screw-cap microcentrifuge tube with a ¼-inch ceramic bead (MP Biomedicals) and 270 µl of 
the appropriate extraction buffer (buffer P, unless otherwise stated). The leaf tissue was then 
homogenised using a FastPrep homogeniser (MP Biomedicals) at speed setting 5.0 for 40 
seconds, or on an Omni Bead Ruptor 24 homogenizer (Camlab) at speed setting 4 for 30 
seconds. The samples were then centrifuged at 16,000 g for 10 minutes, and the supernatant 
(soluble protein extract) was separated from the pellet (insoluble protein extract). 
 
XV - Large-scale protein extraction 
 
Large-scale protein extractions were used to obtain recombinant protein for experiments. 
Agroinfiltrated leaf tissue was harvested 6 or 7 dpi, and the infiltrated areas of the leaves were 
excised with a razor blade. The infiltrated leaf tissue was weighed and homogenised in a 
Waring blender with 3 x volume of the appropriate extraction buffer (P, unless otherwise 
stated). The crude extracts were filtered over one layer of Miracloth (Calbiochem) and the 
filtrates were clarified by centrifugation at 9,000-15,000 x g for 10-15 min (depending on 
volume and turbidity of the filtrate) at 4°C. The clarified extracts were then filtered over a 0.45 
µm syringe filter (Sartorius). After this, the extracts were either purified by sucrose cushion 
(for core-like particles), or by affinity chromatography (for His-tagged proteins). 
 
XVI - Sucrose cushions 
 
The extracts were underlain with sucrose solutions prepared in the corresponding extraction 
buffer (usually 2 ml 25 % [w/v], then 0.5 ml 70 % [w/v] sucrose solutions) in UltraClear 14X89 
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mm ultracentrifuge tunes (Beckman Coulter) and centrifuged at 273,800 x g in a TH641 
ultracentrifuge swing-out rotor (Sorvall) for 2 h 30 min at 4°C. For even larger-scale, a SureSpin 
630/36 ultracentrifuge swing-out rotor (Sorvall) was used: in this case, 5 ml 25 % (w/v) sucrose 
and 1 ml 70 % (w/v) solutions were used in UltraClear 25X89 mm ultracentrifuge tubes. These 
were centrifuged at 167,000 x g for 2 h 30 min at 4 °C. Fractions were then collected by 
piercing the bottom of the ultracentrifuge tube with a needle and collecting the material as it 
dripped out. 
XVII - His-tag affinity chromatography 
 
The extracts were loaded onto a HisTrap FF crude pre-packed nickel column (GE Healthcare) 
using a peristaltic pump (Watson-Marlow Ltd.) as per the manufacturer’s instructions. 
 
XVIII - Photography 
 
Photography was used to document fluorescence of GFP-containing leaves and leaf extracts as 
visualised under ultraviolet light. Excitation of GFP was achieved using several Blak-Ray (Ultra-
Violet Product Ltd) lamps, and all photographs were taken by Mr. Andrew Davis.  
 
XIX - Polyacrylamide gel electrophoresis 
 
SDS-PAGE was carried out using NuPAGE Bis-Tris pre-cast gels, containing either 12 % (w/v)  or 
4-12 % (w/v gradient) acrylamide. Electrophoresis was carried out in NuPAGE MOPS buffer at 
200 V for 50 minutes. All samples were boiled in protein loading buffer for 20-30 minutes 
before being loaded onto the gels. The protein marker ladder used was SeeBlue Plus 2 (Life 
Technologies). After electrophoresis, gels were either transferred to nitrocellulose membrane 
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for western blotting (see below), or stained with InstantBlue (Expedeon) for at least one hour 
before being destained in water for at least 16 hours. When necessary, protein bands of 
interest from stained gels were identified by Mass Spectrometry by Dr. Gerhard Saalbach (John 
Innes Centre Proteomics facility). 
 
XX - Western blotting 
 
After electrophoresis, gels were transferred to membrane by wet transfer in western blot 
transfer buffer to Amersham Hybond-ECL nitrocellulose membranes (GE Healthcare), and 
membranes were blocked in western blot block buffer either overnight at 8°C or for one hour 
at room temperature. The membranes were then blotted with the appropriate antibody (see 
below) in block buffer for one hour at room temperature, then washed three times in wash 
buffer for 15 minutes, then blotted with the appropriate horseradish peroxidase – conjugated 
antibody secondary antibody (if applicable, see below) before washing again. After a final wash 
in PBS, protein was detected using the western lot detection solution, and the 
chemiluminescent signal was detected either on Amersham Hyperfilm ECL (GE Healthcare), or 
digitally on an ImageQuant LAS 500 (GE Healthcare). For protein quantification, western blots 
were carried out with multiple standards of known concentrations, and the ImageQuant LAS 
500 (GE Healthcare) was used to quantify the protein based on signal in the bands. 
 
XXI - Enzyme-linked immunosorbent assay (ELISA) 
 
ELISA was used to study binding of tandibody particles to their target antigens. Tandibody 
particles in PBS (50 µl per well) were used to coat the wells of a F96 Maxisorp 96-well plate 
(Nunc) overnight at 8 °C. For positive controls, a commercially obtained antibody against the 
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target antigen was coated at the same concentration and volume as the tandibodies (unless 
otherwise stated). The wells were then blocked in blocking buffer for 2 h at 37°C. After 
washing 3 times in 200 µl wash buffer, the target antigen in sample buffer was added to the 
wells at varying concentrations obtained via a dilution series, and the plate was incubated for 2 
h at 37 °C. The GFP used was N-terminal His-tagged GFP (Millipore), the gp120 was 
recombinant HIV-1 IIIB gp120 produced in Baculovirus (CFAR NIBSC EVA607), and the p24 was 
recombinant p24 from HIV-1 HxB2 produced in Pichia pastoris (CFAR NIBSC ARP678). After 
washing again, the detection antibody (specific to the target antigen and conjugated to HRP) in 
sample buffer was added to the wells and the plate was incubated for 2 h at 37°C. After 
washing, 50 µl of detection solution was added to each well and then stopped with 50 µl of 
stop solution. The OD450 of the wells was read on a POLARstar Omega plate reader (BMG 
Labtech), and the average signal from control wells (octuplicate wells with PBS added instead 
of the antigen) was subtracted from the average signal from experimental wells 
(quadruplicates for each treatment) in order to obtain an average signal net of background. 
A) Antibodies used in western blots and ELISA 
 
Name Target Species HRP Use Supplier 
10E11 HBcAg mouse no Western blot Abcam 
Anti-His His-tag mouse no Western blot Qiagen 
Anti-mouse Mouse IgG goat yes Western blot Life Technologies 
Ab53840 gp120 goat yes ELISA and western blot Abcam 
Ab6673 GFP goat no ELISA Abcam 
A10260 GFP rabbit yes ELISA and western blot Life Technologies 
Ab53841 p24 goat no ELISA Abcam 
Ab20365 p24 goat yes ELISA and western blot Abcam 
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XXII - Dialysis 
 
The dialysis material used for low volumes of CLPs was float-a-lyzer dialysis devices with either 
100 or 1,000 kDa molecular weight cut-off (MWCO) with either 2 ml or 5 ml chamber volumes. 
For larger volumes or lower molecular weight proteins, SnakeSkin dialysis tubing with 10 kDa 
MWCO was used as per manufacturer’s instructions. Buffer exchanges were carried out in 
either 3 l or 5 l buckets, with at least one buffer change over at least 16 hours, depending on 
the volume of the samples.  
 
XXIII - Protein concentration 
 
Protein preparations were dialysed against AmBic and concentrated by vacuum evaporation 
using a SpeedVac (Savant). 
 
XXIV - Size-exclusion chromatography (SEC) 
 
CLP preparations requiring higher purity than could be obtained from sucrose cushions, and 
syringe filtrations, and clarification centrifugation were purified by gel-filtration size-exclusion 
chromatography. Samples in PBS were purified on a FPLC column (Pharmacia) containing 
Sephacryl S-500 medium (GE Healthcare) with the help of an ÄKTA FPLC system (Amersham 
Biosciences). 
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XXV - Nycodenz gradient 
 
The t-KD extract, after large-scale extraction, protein concentration, and dialysis against PBS, 
was underlain with nycodenz AG (Axis-Shield PoC, Oslo, Norway) solutions prepared in PBS (2 
ml each of 10, 20, 30, 40, 50, and 60 %. Nycodenz solutions) in UltraClear 14X89 mm 
ultracentrifuge tunes (Beckman Coulter) and centrifuged at 273,800 x g in a TH641 
ultracentrifuge swing-out rotor (Sorvall) for 20 h at 4 °C. Fractions were then collected by 
piercing the bottom of the ultracentrifuge tube with a needle and collecting the material as it 
dripped out. 
 
XXVI - Apoplastic wash 
 
In order to extract proteins located in the intercellular space (apoplast) of N. benthamiana 
leaves, apoplastic washes were carried out. These consist of infiltrating the P extraction buffer 
into the intercellular space of agroinfiltrated leaves at 7 dpi, then wrapping those leaves in 
muslin cloth and trapping the package at the top of a 50 ml centrifuge tube with the lid, before 
centrifugation at 2, 000 x g for 5 minutes. The buffer, along with any soluble proteins in the 
apoplast, is forced out of the leaf tissue and is collected at the bottom of the centrifuge tube. 
XXVII - Transmission electron microscopy (TEM) 
 
TEM was used to confirm that plant tissue expressing a construct contained CLPs, as well as to 
observe homogeneity and morphology of CLPs. Samples (typically in AmBic) were adsorbed 
onto copper-palladium grids composed of a plastic-covered hexagon mesh, washed by 
dripping 5-8 drops of sterile distilled water over the sample on the grid, then staining with 2 % 
(w/v) uranyl acetate for 1 minute. Particles were then imaged using a FEI Tecnai 20 TEM with a 
bottom-mounted digital camera. 
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XXVIII - Cryo-electron microscopy (cryo-EM) 
 
All cryo-EM was carried out at the Division of Structural Biology (University of Oxford, Oxford, 
UK). Dr. Robert Gilbert provided guidance and supervision for the data collection, and carried 
out the data analysis. Concentrated size-exclusion chromatography fractions of τ-GFP bound to 
GFP were dialysed against 20 mM Tris-HCl (pH 8.5) and an aliquot was placed on a holey 
carbon grid and vitrified by flash-freezing. Images of the particles were obtained on a Tecnai 
F30 microscope at 200 kV and 80,000 x magnification and a range of defocus values from -2 to 
-5 µm on a Falcon 2K CCD camera. After manual selection of 2,385 particles from the obtained 
images using EMAN software (Ludtke et al., 1999), particles were corrected for contract 
transfer function and classified in two dimensions before being reconstructed in 3D using 
RELION software (Scheres, 2012). The initial 3D model was generated with IMAGIC software 
from seven RELION-derived class averages (van Heel et al., 1996). Using this, a reconstruction 
at a resolution of 25 Å was created. 
 
XXVIV - Software 
 
• Vector NTI Advance 11.5 (Invitrogen) was used for vector design, in silico cloning 
strategies, sequence analyses and alignments, as well as predictions of protein 
sequences, sizes and attributes.  
• The BLAST function of the National Center for Biotechnology Information website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used both for nucleotide and protein 
sequence alignments. 
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• The GenBank database of the National Center for Biotechnology Information 
website (http://www.ncbi.nlm.nih.gov/genbank/) was used to find sequences of 
interest. 
• Predicted crystallographic structures were constructed by Dr. Ellis O’Neill using 
Swiss-Prot (ExPASy) and imaged using the PyMOL software (DeLano Scientific). 
• Microsoft Office software suite was used for analysing data and making figures. 
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Chapter 3 : Evaluation of tandem core and SplitCore technologies 
for the expression of chimaeric HBcAg particles in plants 
 
I - Introduction 
 
As discussed in chapter 1, there is a limit to the size of sequence that can be displayed in the 
e1 loop of HBcAg: the longer the epitope, the lower the yield of chimeric CLP is likely to be, 
and whole folded proteins are difficult to display with success. GFP was successfully displayed 
on HBc (Kratz et al., 1999), but this was an ideal candidate: GFP forms a tight easily-folding 
barrel structure with N- and C-termini close together, so inserting this sequence in the e1 loop 
flanked by long (9 amino acid) flexible linkers on either side allowed the particles to form with 
GFP displayed on the outside. The reported yield of this chimaeric CLP was between 10 and 20 
mg per litre of E. coli culture, and the authors do not specify the yield that is normally obtained 
for unmodified HBcAg produced in E. coli. For slightly more complicated inserts (either larger 
proteins or proteins with distant N- and C- termini), insertion in the e1 loop becomes more 
complicated, if not impossible.  
To overcome the size limit of the proteins which can be displayed in the e1 loop, two methods 
stand out. The first, called SplitCore, involves splitting the HBcAg sequence into two separate 
open reading frames (ORFs) by inserting a stop codon in the e1 loop after P79, and a start 
codon before A80 (Walker et al., 2011)). This technique proved successful in a bacterial 
expression system in which both half-cores (called CoreN and CoreC) were produced from a 
bicistronic operon with a ribosomal binding site (RBS) between the two ORFs. This allowed 
whole proteins (GFP, Borrelia burgdorferi protein OspA, and Plasmodium falciparum 
circumsporozoite protein CSP) to be displayed on the surface of HBc by fusing them either to 
the C-terminus of CoreN, or the N-terminus of CoreC, which reduces steric constraints on the 
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insert because in either case, one of the termini has free movement, not being fused to the 
rest of the HBcAg protein (Fig. 3.1).  
 
Figure 3.1 The SplitCore system as used in E. coli. The native HBcAg sequence (a) is split at the tip of the e1 loop by 
adding a stop codon after position P79, followed by a ribosome binding site (RBS), and a start codon before position 
A80 (b). This allows the upstream CoreN and the downstream CoreC to be produced as two separate polypeptide 
chains but as part of the same bicistronic operon. Sequences of interest can be inserted either at the C-terminus of 
CoreN or at the N-terminus of CoreC without preventing both half-cores from forming a complete core. This can 
then go on to form complete capsids of T=3 or T=4 conformation. Figure reprinted from Walker et al., 2011. 
 
The other technique to overcome limits to e1 insertions is called tandem core (Gehin et al., 
2004), and this involved fusing two HBcAg sequences together in order to produce the HBcAg 
dimer as a single polypeptide chain. This allows only one of the e1 loops in a dimer to be 
modified with an insert, thus eliminating steric hindrance of protein inserts on neighbouring e1 
loops on the same dimer. This is thought to aid dimer formation which is critical for particle 
assembly. While the SplitCore system has only been tested in bacteria, the tandem core 
system has been successfully used in both bacteria and plants (Thuenemann, 2010). In this 
work, two different types of tandem core were studied. The first was the homo-tandem core 
CoHo, which is composed of a truncated N-terminal core (at amino acid position 149) fused to 
another similarly truncated C-terminal core. The second was the hetero-tandem core CoHe, 
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where the N-terminal core is truncated but the C-terminal core contains the full-length 
arginine-rich C-terminus (Fig. 3.2).  
It was demonstrated that both types of tandem core constructs could be produced in plants 
using the CPMV-HT expression system, although CoHe gave better results in terms of CLP 
quality and homogeneity. Moreover, it was found that CoHe could be modified by inserting the 
sequence for GFP in the e1 loop of the C-terminal core, thus leading to the formation in planta 
of tandem core CLPs displaying GFP on the surface. This could be achieved with either very 
short (2 aa) or long (9 aa) linkers, whereas monomeric HBcAg is known to require long linkers 
to display GFP (Kratz et al., 1999). However, it must be acknowledged that plant-produced 
CoHe with GFP displayed on the surface (CoHe-GFP) was largely insoluble, and a special buffer 
containing sodium deoxycholate (HBexB1, see Chapter 2) had to be used to obtain enough 
soluble CLPs for analysis to take place (Thuenemann, 2010). Moreover, the CoHe construct was 
in fact optimised for use in E. coli with bacterial expression vectors, because it was developed 
for use in a bacterial expression system. This meant that sequence manipulation and cloning of 
CoHe-based constructs was suboptimal in the pEAQ-HT vector used for expression in plants. 
The pre-existing CoHe-based vectors therefore needed to be modified in order to create 
comparable SplitCore and tandem core constructs, both designed to display GFP on the 
surface of assembled CLPs.  
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Figure 3.2 The tandem core system as used in E. coli and N. benthamiana. a) Two HBcAg sequences are fused end-
to-end via a flexible glycine-serine linker (GGS) to form a tandem core. The upstream N-terminal core is truncated at 
position 149, whereas the downstream C-terminal core is either full-length (hetero-tandem core) or similarly 
truncated (homo-tandem core). The truncated C-terminus corresponds to the arginine-rich nucleic acid binding 
domain. b) Predicted structure of the hetero-tandem core protein (t-EL, see figure 3.3) used in this thesis: two 
HBcAg monomers (blue and red) are fused by a linker (yellow) to form a single polypeptide chain, with multiple 
cloning sites inserted in both e1 loops (green) to facilitate insertions by genetic fusion. The amino and carboxy 
termini are indicated in the top view image. The structure prediction is courtesy of Dr. Ellis O’Neil, and the image 
was generated using PyMOL. 
 
II - Design of constructs 
 
The CoHe construct was redesigned with the goal of simplifying its use in pEAQ-HT. 
Simultaneously, constructs were designed to evaluate the SplitCore strategy in plants. The goal 
was to create comparable systems to determine which was best suited for the production of 
an HBcAg-derived antigen display system in plants. In order to do this, a modified version of 
CoHe (named t-EL, for tandem HBcAg Empty Loop) was designed which contained unique 
restriction sites and polylinkers in strategic regions to allow easy cloning and modifications of 
both e1 loops in pEAQ-HT (construct diagrams are provided in figure 3.3). This basic sequence 
was the basis for a SplitCore construct aimed at testing the SplitCore system in plants. This 
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construct, named sCore-EL (for Split Core Empty Loop), is analogous to that described in 
Walker et al. (2011), except that it is meant to be used as two different gene cassettes instead 
of a bicistronic operon. GFP-carrying versions of both t-EL and sCore-EL were also created 
which contained a solubility-optimised GFP sequence in the e1 loop. For the tandem core 
construct, the sequence is in the C-terminal e1 loop (and this construct is named t-sGFP). For 
the SplitCore construct, the GFP sequence is split to create a split GFP system similar to that 
used in Walker et al. (2011), in which the sequence for GFP is split between the two half cores 
so that fluorescence only occurs if the two parts of GFP come together; this only occurs if the 
two halves come together. This construct, named sCore-sGFP, was intended to provide 
evidence for particle assembly simply by analysing fluorescence of the infiltrated leaves. These 
constructs were designed so that future work could be based on either tandem core or 
SplitCore, depending on which gave the best results in the plant expression system. 
In addition, a monomeric version of HBcAg was designed that could be readily compared to 
the t-EL construct. This construct, named m-EL (for monomeric HBcAg Empty Loop), is identical 
in sequence to the C-terminal core of t-EL. This allows comparison between monomeric and 
tandem constructs modified for use in pEAQ-HT, as well as comparisons with the original 
tandem and monomeric constructs used in previous work (Thuenemann, 2010). Because basic 
sequences were ordered for synthesis from GeneArt (Life Technologies), care was taken to 
order sequences from which other constructs could be easily derived. This means that the 
initial sequence which was ordered and from which others are derived is a tandem core 
construct containing the sequence of an anti-phOx single chain variable fragment (scFv) in the 
C-terminal e1 loop (t-α-phOx, described in Chapter 4). Details are given in the following 
section, and construct diagrams, along with predicted protein structures of selected 
constructs, are shown in figure 3.3. 
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Figure 3.3 Diagrams of constructs and protein structures. a) Maps of the constructs t-EL (empty loop tandem core), 
t-sGFP (tandem core with sGFP sequence in the C-terminal e1 loop), m-EL (a monomeric HBcAg construct based on 
the C-terminal core of t-EL); and SplitCore-EL (composed of CoreN and Core-C), and sCore-sGFP (composed of 
CoreN-sGFP1-10 and CoreC-sGFP11). All SplitCore constructs are based on t-EL with and without split sGFP). b) 
Structure predictions of an m-EL dimer (left, C-termini are labelled), t-EL (middle, blue represents the N-terminus 
and red the C-terminus), and t-sGFP (right, blue represents the N-terminus and red the C-terminus. The first and last 
amino acids of sGFP are represented as sticks and indicated with arrows). Structure predictions are courtesy of Dr. 
Ellis O’Neil, images were generated using PyMOL. 
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A) Cloning 
i) t-EL sequence 
The features of the t-α-phOx construct described in Chapter 4 allowed the creation of different 
constructs from this sequence:  t-EL (tandem core, empty loops) was made by digesting pEAQ-
HT- t-α-phOx with AvrII and religating.  
ii) t-sGFP sequence 
The sequence for sGFP was based on eGFP used by Thuenemann (2010), with point mutations 
S30R, F99S, E111V, I128T, Y145F, M153T, V163A, K166T, I167V, I171V, S205T, and A206V  to 
improve solubility and folding as described by (Cabantous et al., 2005; Pedelacq et al., 2006). 
This sequence was ordered from GeneArt (Life Technologies) without a stop codon and with 5’ 
SalI and 3’ AseI restriction sites. This construct was cloned into pEAQ-HT-t-EL using the SalI and 
AseI restriction. 
iii) m-EL sequence 
The m-EL construct (monomeric core with empty e1 loop) is based on a monomeric HBcAg 
construct containing the anti-phOx scFv sequence in e1 loop (see Chapter 4). The m-EL 
construct was made by digesting pEAQ-HT-m-α-phOx with AvrII and religating. 
iv) sCore-sGFP sequences 
The concept of split cores was obtained from Walker et al. (2011). The authors demonstrated 
particle formation and insert display with a split GFP experiment: The N-terminal 10 sheets of 
GFP (named sGFP1-10) were fused to the C-terminus of CoreN (to give CoreN-sGFP1-10), and 
the 11th sheet (named sGFP11) was fused to the N-terminus of CoreC (to give CoreC-sGFP11). 
This construct was made for use in plants using CoreN and CoreC sequences based on t-EL, and 
the GFP sequence was sGFP described above. The HBcAg amino acid E77 was replaced with 
the polylinker GG-XmaI-G-AvrII-GSGGGG to link sGFP1-10 to CoreN, and sGFP11 was linked to 
CoreC using the polylinker GGGGGGSGG-AvrII-GIN. An AvrII restriction site was added at the 
Chapter 3: Evaluation of tandem core and SplitCore technologies 
 
59 
 
end of the sGFP1-10 sequence immediately before the stop codon, and another was added at 
the start of the sGFP11 sequence immediately after the start codon. CoreN-sGFP1-10 and 
CoreC-sGFP11 were cloned into entry plasmids pFSC5 and pFSC6 respectively. PacI and SbfI 
were then used to digest pFSC5 while AscI and SbfI were used to digest pFSC6, and PacI and 
AscI were used to digest pEAQ-HT. A triple ligation then allowed the insertion of the two 
constructs, each now in a separate CPMV-HT cassette, into pEAQ, to give pEAQ-HT-sCore-sGFP. 
This single plasmid contains both genes coding for CoreN-sGFP1-10 and CoreC-sGFP11 on the 
same T-DNA.  
v) sCore-EL 
The pFSC5 and pFSC6 plasmids containing CoreN-sGFP1-10 and CoreC-sGFP11 respectively 
were digested with AvrII in order to remove the split GFP components. The resulting 
constructs, with no insert in the e1 loop, were then cloned into pEAQ-HT as described above to 
give pEAQ-HT-sCore-EL. 
 
III - Comparing tandem core and SplitCore constructs 
 
The tandem core constructs t-EL and t-sGFP, the SplitCore constructs sCore-EL and sCore-sGFP, 
and the monomeric m-EL control were expressed transiently in Nicotiana benthamiana and 
fluorescence of GFP-bearing constructs was inspected under ultraviolet light (Fig. 3.4). Firstly, 
the results show that t-sGFP fluoresces at least as much as CoHe-GFP. This demonstrates that 
the modifications made to the GFP sequence did not abolish fluorescence, and these 
modifications, along with those made to the tandem HBcAg sequence, clearly did not abolish 
expression. Secondly, it is clear that t-sGFP is more intensely fluorescent than sCore-sGFP. This 
suggests that either there is more protein accumulated in t-sGFP – expressing leaves, or that 
sCore-sGFP is inefficient at particle formation. It should be noted that while fluorescence from 
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the tandem constructs is associated with whole sGFP, fluorescence from sCore-sGFP is 
associated with split sGFP, and it is possible that sGFP is less fluorescent when split. 
  
Figure 3.4 Comparing SplitCore and tandem core technologies for GFP display. Photographs of leaves expressing 
different constructs viewed under UV light. The caption indicates which protein(s) is being expressed by the leaf. EV: 
empty vector control. There is clearly more fluorescence (and therefore more correctly-folded GFP) in leaves 
expressing tandem constructs (right) than the SplitCore split GFP construct (bottom left). All photographs were 
taken 7 dpi, courtesy of Mr. Andrew Davis. 
 
In order to compare these different constructs in more depth, small-scale protein extractions 
were carried out and equal volumes for each construct of the insoluble (resuspended pellet) 
and soluble (supernatant) fractions were analysed by western blot with the anti-HBcAg 10E11 
antibody (Fig. 3.5). It should be noted that since 10E11 recognises the N-terminus of HBcAg, it 
is not expected to detect CoreC of the SplitCore constructs. 
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Figure 3.5 Western blots of supernatant and pellet fractions of plant extracts after expression of different 
construct. After a small-scale extraction, the equal volumes of supernatant fractions (left) and resuspended pellet 
fractions (right) were loaded onto SDS-PAGE gels for western blot analysis with the anti-HBcAg 10E11 monoclonal 
antibody. Monomeric constructs are expected to be about 20 kDa, while tandem core constructs are expected to be 
about 40 kDa, and tandem core constructs with GFP inserted in the C-terminal e1 loop are expected to be about 67 
kDa. Exact sizes can be found in figure 3.3. 
 
The results show that the SplitCore constructs did not seem to be as highly expressed. For 
plants infiltrated with sCore-EL, the CoreN-EL protein, with an expected size of about 9 kDa, 
was not detected either in the pellet or the supernatant fraction. Because of the nature of the 
antibody used in this western blot, we would not expect to detect CoreC. When the SplitCore 
system is combined with a split GFP, there is detectable accumulation of CoreN-sGFP1-10 
(which is expected to a 34 kDa protein). Because the sCore-sGFP – expressing leaf tissue 
fluoresces, one explanation for this could be that SplitCore proteins are unstable, but the split 
GFP works to stabilise them by favouring the association of CoreN with CoreC. The empty 
vector control in the next lane shows no signal, which is to be expected. The 19 kDa 
monomeric wild-type HBcAg truncated at position 176 (Δ176), which has been expressed in 
plants before (Meshcheriakova et al., 2008; Thuenemann, 2010) is expressed and mostly 
soluble. The 22.5 kDa m-EL construct, despite being extremely similar, does not accumulate at 
the same levels. There are three main differences between these two constructs. The first 
difference is the length: m-EL contains the full-length C-terminus of HBcAg, while Δ176 is 
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truncated at position 176. The second difference is the state of the e1 loop: in m-EL, the e1 
loop contains a polylinker allowing easy insertion of sequences. The third main difference is 
that m-EL, as a distant relative of CoHe, is codon optimised for use in E. coli, whereas Δ176 
retains the native HBV codon usage. Any of these differences, or a combination of them, could 
be the cause of the difference in yield.  
CoHe (expected to be about 40 kDa) is seen to be expressed, though it does not seem to 
accumulate to the same levels as the 41.8 kDa t-EL (which was estimated to accumulate to 
200-500 µg/g of fresh weight tissue, or FWT). This suggests that the modifications intended to 
simplify cloning in pEAQ-HT actually improved expression or accumulation of the protein in 
plants. The difference between t-sGFP and CoHe-GFP points to a similar improvement in yield: 
t-sGFP seems to be more abundant and more soluble than CoHe-GFP, which is consistent with 
the differences in fluorescence intensity shown in figure 3.4. The insolubility of CoHe-GFP seen 
here is in agreement with the findings of Thuenemann (2010), who developed the more 
complex HbexB1 extraction buffer to improve solubility of CoHe-GFP. The simpler P buffer was 
used for this experiment, which reveals superior yield and solubility of t-sGFP compared to 
CoHe-GFP. This is probably due to both the superiority of the t-EL moiety as well as the 
modifications made to the GFP sequence. Interestingly, the sGFP insert is inserted in the e1 
loop of t-EL without any flexible linkers added on either side, relying only on the inherent 
flexibility of the N- and C-termini of GFP and of the e1 loop. This is thought to be impossible 
with monomeric HBcAg, in which long extra-long flexible linkers are thought to be necessary 
(Kratz et al., 1999; Janssens et al., 2010). Moreover, it is clear from these western blots that t-
sGFP is not significantly degraded: the majority of the signal for this construct appears in the 
67.8 kDa band, although there does seem to be some degradation product in the insoluble 
fraction. It is also noteworthy that higher molecular weight specific bands were seen for CoHe, 
CoHe-GFP, t-EL and t-sGFP. These are diagnostic of tandem core proteins, and were seen in 
every western blot for every plant-expressed tandem core construct described in this thesis, 
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despite the fact that samples were prepared by boiling in LDS and β-mercaptoethanol before 
loading on the SDS-PAGE gel. Taken together, these data clearly indicate that tandem core 
technology is better suited to chimeric CLP production in plants than SplitCore technology. 
Future work was therefore carried out using the tandem core system. 
Once it had been established that m-EL, t-EL and t-sGFP are expressed in plants, it was 
necessary to demonstrate that they form CLPs. In order to do this, large scale extraction was 
carried out with a final partial purification step involving ultracentrifugation over a sucrose 
cushion (see Chapter 2). These partially purified fractions were then analysed by transmission 
electron microscopy (TEM, figure 3.6). This showed that all three constructs were capable of 
directing the formation of particles in plants. These particles had the distinctive appearance of 
CLPs, indicating that the modifications carried out to the basic HBcAg sequences, as well as 
insertion of GFP, did not abolish assembly. As with native wild-type HBcAg, the majority of 
CLPs were T=4, although some T=3 particles were observed. Moreover, the sucrose cushion 
interface fraction for t-sGFP fluoresced under UV light, indicating that the GFP is not cleaved 
from the CLP. An attempt to partially purify sCore-sGFP in a similar manner is described in 
chapter 4, and did not result in the detection of CLPs. 
 
 
Figure 3.6 Electron micrographs of plant-produced CLPs expressed using different constructs. The caption 
indicates the construct used to produce the CLPs. Left: monomeric m-EL, middle: tandem core t-EL , right: tandem 
core with sGFP inserted in the C-terminal e1 loop. Arrows indicate T=3 particles, scale bars are 100 nm. 
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IV - Discussion 
 
The data presented here describe a continuation of the work carried out by Thuenemann 
(2010). That work described the transfer of tandem core technology from a bacterial 
expression system to a plant expression system. It concluded that plants are a suitable host for 
tandem core technology, and that a heterotandem construct is more suitable for antigen 
display than a homotandem construct. The work described in this chapter built upon this 
previous work by attempting to make the constructs more compatible with the pEAQ-HT 
expression system, and the whole tandem core concept was compared to the more recent 
SplitCore system (Walker et al., 2011). The results show that optimising the tandem core 
construct for use in pEAQ-HT actually improves the yield of protein obtained. This could be due 
to the polylinkers added in the e1 loops: these contain short glycine-rich sequences which may 
improve the solubility (and therefore stability) of the whole complex, thereby increasing the 
amount of material accumulated in plant leaves. Interestingly, the monomeric m-EL did not 
accumulate as much as t-EL, which suggests that the modifications made to the sequence only 
improve yield in a tandem construct. This is logical in the sense that the “ideal” monomeric 
HBcAg sequence is probably the native sequence, which has evolved to be stable and 
produced at high titres. Modifying the sequence to make a tandem core construct essentially 
creates a new protein, which might not be optimal in terms of stability or capsid assembly 
unless a few extra modifications are carried out. It is possible that such modifications are, 
serendipitously, the ones that I implemented during optimisation for use in pEAQ-HT. 
Moreover, modifying the sequence of GFP to improve its solubility as well as its suitability for 
split GFP experiments (Cabantous et al., 2005; Pedelacq et al., 2006; Walker et al., 2011) 
clearly improved the yield of GFP-displaying tandem core compared to the previously used 
version of GFP. This demonstrates the importance of the insert sequence for yield and 
solubility of the whole chimeric CLP. The new, modified constructs were not only expressed in 
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plants, but also directed the production of chimeric CLPs which look indistinguishable from 
wild-type HBcAg CLPs in TEM analysis. This proves that the modifications made to the original 
sequence did not abolish capsid assembly, thus demonstrating the incredible flexibility of 
HBcAg as a biotechnological and research tool. 
These data leave unanswered the question about the role of E. coli codon-optimisation in 
terms of recombinant protein yield in a plant expression system. It is possible that plant 
codon-optimisation would result in higher yields of chimeric CLPs, but this was not attempted. 
There are examples of codon-optimisation actually reducing yields of recombinant protein 
(Maclean et al., 2007), so it was considered safer to continue working with E. coli – optimised 
sequences, since these yield enough material for the necessary work to be carried out. 
However plant codon-optimisation would be an interesting follow-up to the data presented in 
this thesis. 
The SplitCore system was tested in plants and did not seem to be as suited to the plant 
expression system as it was to E. coli (Walker et al., 2011). Indeed, expression could only be 
detected when split GFP was deployed, suggesting that CoreN and CoreC are rapidly degraded 
in plants unless they are brought together to form a complete HBcAg, which appears to be 
very inefficient unless the split GFP acts like a chaperone to bring the two segments together. 
This, in turn, means it is unlikely that inserting another protein would lead to higher yield than 
sCore-EL. By contrast, in E. coli, the use of split GFP was not necessary to obtain high 
expression of SplitCore CLPs (Walker et al., 2011). While it is true that the conclusion about 
plant-produced SplitCore is based on a single set of experiments experiment, the result 
obtained does not bode well for display of other proteins of interest using SplitCore in plants, 
since insert proteins cannot always be split and assembled as readily as sGFP. It is also true 
that the results presented in figures 3.4 and 3.5, which show the comparison between tandem 
core and SplitCore technologies, involve the GFP being split in the SplitCore system but not in 
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the tandem core system. Had time allowed, it would have been useful to carry out this 
experiment with whole (non-split) GFP in either CoreN or CoreC.  
The important difference between the plant and bacterial SplitCores is that in E. coli, a 
bicistronic operon was used, whereas in the plant-based system deployed here, the two halves 
of the protein were translated from different mRNAs, albeit transcribed from the same T-DNA. 
This difference may reduce the relative efficiency with which the two halves interact in the 
plant system. It may be possible to develop a bicistronic approach analogous to that used in E. 
coli by using an internal ribosome binding site (IRES) which is functional in plants, such as those 
present in the genomes of the crucifer-infecting tobamovirus (Dorokhov et al., 2002) or the 
Rhopalosiphum padi virus (Groppelli et al., 2007). However, even if this could be done, it would 
probably be inefficient at producing equimolar amounts of the CoreN and CoreC moieties. An 
alternative could be to use a picornavirus 2A self-cleaving peptide, which could be used to link 
CoreN and CoreC on the same ORF, and have them separate upon translation through a 
ribosome stutter mechanism (Minskaia et al., 2013; Minskaia and Ryan, 2013).  
Moreover, it is conceivable that tandem core technology might be combined with SplitCore 
technology, in an attempt to develop a system that combines the advantages of each. In such a 
hypothetical system, a tandem core construct could include an insert (such as GFP) in the C-
terminal e1 loop flanked on either its N-terminal or C-terminal end by a 2A or 2A-like 
sequence. In this scenario, a single transcript would direct the production of a polypeptide 
chain which would be cleaved during translation at the 2A site. One terminus of the insert 
(depending on the position of the 2A sequence) would be free and untethered to the rest of 
the tandem core molecule, which may favour folding. However, it is also possible that splitting 
the tandem in this way may simply prevent the structural dimer from folding properly. None of 
these approaches were investigated because the demonstration that the tandem core 
technology was suitable for plant-based expression of CLPs obviated the need to optimise 
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SplitCore. However, the optimisations described above would be a worthy follow-up to the 
experiments presented in this thesis. In conclusion, the experiments described in this chapter 
showed that t-EL was a suitable construct on which to base future work on the display of 
protein inserts.  
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Chapter 4 : Two strategies for a generic protein presentation 
system 
 
I - Introduction 
 
The work described in the previous chapter demonstrated that the new tandem core 
construct, t-EL, is a good candidate to act as a scaffold for antigen display on the surface of a 
CLP. The ultimate goal of the work described in this thesis was to develop a generic antigen 
scaffold system based on HBc. A generic system would involve post-translational attachment 
of the antigen to the CLP scaffold, so that the same scaffold (or very similar ones) could be 
produced regardless of the antigen to be fixed onto its surface. Such a system might already 
exist, thanks to a system allowing non-covalent linking of proteins of interest to the e1 loop of 
HBcAg: this is through the use of a peptide tag, GSLLGRMKGA, which specifically binds the e1 
loop of HBcAg and can be fused to a protein of interest (Blokhina et al., 2013). However, 
binding of a peptide of interest (Influenza M2e) to CLPs via this tag is undone during sucrose 
cushion purification. This suggests that binding with this tag is likely to be relatively weak, 
which means that it is worth developing alternative systems. Two techniques applicable to the 
tandem core system fit these criteria: antibody–antigen interaction, and chemical conjugation.  
In the first scenario, a version of HBc would be designed which would contain an antibody 
fragment, such as a single chain variable fragment (scFv), in the e1 loop (Fig. 4.1a). Such an 
antibody fragment would have specificity to an antigen of interest, and the antigen could then 
be used to coat the particle post-translationally.  An advantage of such a system would be that 
the antigen would be presented in the same orientation at each position around the CLP, since 
the antibody would always bind to the same epitope. Moreover, the specificity of an antibody-
antigen interaction means that the attachment of the antigen to the CLP could be carried out 
after purification, during purification, or even in situ in the expression system if both elements 
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are co-expressed. The disadvantages are that the antigen would not be covalently linked to the 
particle surface, and switching from one antigen to another would require changing the 
antibody fragment. This means that this system would only be generic insofar as we consider 
all scFv to be identical in terms of surface properties for the purposes of expression, capsid 
assembly, extraction and purification. This point could be addressed by using a scFv against a 
common tag that could be readily added to any antigen of interest, although this would 
require modifying the antigen.  
In the second scenario, a version of HBc would be designed which would readily allow 
chemical conjugation of any antigen onto the e1 loops. This would be done by inserting a 
lysine-rich linker in the e1 loop which would allow antigens of interest to be covalently linked 
to the loop through bioconjugation (Fig. 4.1b). Lysine residues are commonly used for 
bioconjugation because the primary amine is amenable to a wide variety of different 
bioconjugation methods. For example, Pastori et al. (2012) used the bifunctional cross-linker 
succinimidyl-6-(β-maleimidopropionamido)-hexanoate (SMPH) to cross-link C-terminal 
cysteine residues of target epitopes to surface lysines of the carrier viral particle (in this case, 
bacteriophage AP205). Moreover, bioconjugation is not limited to proteins. Indeed, 
carbohydrates can be bioconjugated onto lysine residues via reductive amination: the vicinal 
diol of a sugar can be oxidised to two aldehydes which react with the primary amine of the 
lysine residue, thus forming an imine group. This imine group, which covalently links the lysine 
and the sugar, is unstable, but can then be stabilised by reduction to a secondary amine. The 
advantages of this display method are that conjugated antigens would be covalently bound to 
the CLP surface, and a single conjugation-ready construct would be a suitable scaffold for 
essentially any antigen with easily-addressable surface residues, making it truly generic in this 
sense. The potential disadvantages are that it would be difficult to guarantee the homogeneity 
of a sample of conjugated CLPs, both in terms of the number of antigens presented on a single 
particle, and in terms of the conformation of each conjugated antigen molecule: indeed, 
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depending on the conjugation method, the antigen may be  attached to the CLP via one of 
many possible surface-exposed addressable chemical groups, so for most antigens there could 
be a plethora of different ways in which the molecule could be presented on the surface of the 
CLP. This could have negative effects on the antigenicity of the conjugated antigen: it is 
thought that antigens displayed on nanoparticles or virus-like particles (VLPs) have increased 
antigenicity because they are presented in a regular, quasi-crystalline array. Moreover, a 
practical consideration is that chemical conjugation is a non-specific process, which means that 
the conjugation reaction would need to take place with extremely pure CLP and antigen in 
order to avoid conjugating contaminants onto the surface of the particles. 
 
 
Figure 4.1 Two strategies for a generic antigen presentation system. a) A single-chain antibody (scFv, in purple) is 
fused to the C-terminal e1 loop (black) of a tandem core construct. When the cognate antigen (green) is placed in 
contact with the chimaeric core protein, the antigen binds the core through an antibody-antigen reaction. b) A 
lysine-rich peptide (red) is fused to the C-terminal e1 loop (black) of a tandem core construct. When an antigen of 
interest (green) with addressable surface residues (blue line) is placed in contact with the modified core protein, the 
antigen can be covalently linked to the core through a variety of bioconjugation techniques. 
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II - Design of constructs 
 
In order to test both scenarios, two different constructs based on t-EL were designed (see 
below and chapter 3). The first, named t-α-phOx, contains an insert in the C-terminal e1 loop 
composed of the anti-phOx scFv flanked on either side by a glycine-rich 15 amino acid – long 
linker. This scFv specifically binds to the small organic hapten phenyl-oxazolone, or phOx, and 
has been used numerous times over many years. The anti-phOx scFv (or α-phOx) is described 
by Marks et al. (1992), and has since been displayed on the surface of bacteriophages (Hayashi 
et al., 1995); secreted by insect cells using a baculovirus expression system (Kretzschmar et al., 
1996); expressed in the bacterial periplasm (Schmiedl et al., 2000); displayed on the surface of 
Bacillus thuringiensis (Bt) spores (Du et al., 2005); and displayed on the surface of mammalian 
cells (Chesnut et al., 1996). In fact, a cell transfection kit based on phOx – mediated capture of 
α-phOx – displaying cells called Capture-Tec pHook-3 System was commercially produced by 
Invitrogen (now Life Technologies). This included the use of phOx-coated magnetic beads to 
capture cells displaying functional α-phOx. Moreover, protocols exist for “phoxylation” of 
proteins, notably bovine serum albumin (BSA), in order to assay recombinant α-phOx function 
(Chesnut et al., 1996; Schmiedl et al., 2000; Du et al., 2005). Crucially, the sequence of α-phOx 
was submitted to GenBank by Hayashi et al. (1995), where it is publicly available (accession 
number X82190.1). All of these factors made α-phOx an ideal candidate to provide proof of 
concept for the display of scFv on the surface of HBc. The second construct, named t-KD, was 
designed to allow chemical conjugation and contains an insert in the C-terminal e1 loop 
composed of six lysine residues flanked on either side by three aspartate residues (a “KD” 
linker) in order to balance the overall charge. This should allow antigens to be linked directly to 
the e1 loop by chemical conjugation. In order to determine whether tandem core technology 
was specifically useful for these two scenarios, monomeric equivalents of both t-α-phOx and t-
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KD, named m-α-phOx and m-KD respectively, were also produced based on the m-EL construct 
(see chapter 3). Diagrams of the different constructs are shown in figure 4.2, and details of the 
cloning are given below. 
 
 
Figure 4.2 Diagrams of construct. Maps of the constructs t-α-phOx (tandem core with anti-phOx scFv in the C-
terminal e1 loop), m-α-phOx (monomeric core with anti-phOx scFv in the e1 loop), t-KD (tandem core with a lysine-
rich peptide in the C-terminal e1 loop), and m-KD (monomeric core with a lysine-rich peptide in the e1 loop). The 
key is the same as in figure 3.3a.  
 
 
A) Cloning 
i) t-α-phOx and t-α-phOx-OPT sequences 
In order to maximise the use of a single sequence ordered for synthesis from GeneArt (Life 
Technologies), the t-α-phOx construct (tandem core with anti-phOx scFv sequence in C-
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terminal e1 loop) was designed with features enabling the easy cloning of t-EL, m-EL, and m-α-
phOx from this one sequence. The sequence of tandem HBcAg used in this work was based on 
CoHe7e used by Thuenemann (2010). This is itself based on the full-length 185 amino acid 
sequence capsid protein sequence published Ono et al. (1983), available on GenBank 
(UniProtKB/Swiss-Prot: P03149.1). Like CoHe7e, t-α-phOx is codon-optimised for E. coli, the N-
terminal core is truncated at position 149, a linker was used to link the N- and C-terminal 
cores, and the C-terminal core contains the full-length arginine-rich C-terminus. To simplify 
cloning and use in the pEAQ-HT plasmid, and to derive the aforementioned constructs from 
this one, a few modifications were implemented. In the N-terminal core e1 loop, the polylinker 
XmaI-Ala-Gly-Gly-Ser-Ser-Gly-MfeI was inserted between E77 and D78. In the C-terminal e1 
loop, amino acid E77 was replaced with the polylinker SalI-Ala-Gly-Gly-Gly-AvrII-Gly-Gly-Ser-
Gly-AseI, with the anti-phOx scFv sequence (Hayashi et al., 1995), with silent mutations to 
remove unwanted restriction sites, inserted in the AvrII site. Between the N-terminal and C-
terminal cores, the peptide linker (GGS(SGG)6TGT) was used, which is very similar to that used 
in CoHe7e, but it contains an AgeI-like restriction site at the C-terminus (Thr-Gly: ACTGGT), 
which differs from an authentic AgeI restriction site (ACCGGT) by a single nucleotide. This is 
followed by the ACA codon (Thr) just before the starting methionine of the C-terminal core. A 
Kozak consensus sequence (AACAATG) was used upstream of the start codon after the AgeI 
restriction site, and an XhoI site was added after the stop codon. This construct was ordered 
for synthesis from GeneArt (Life Technologies) and cloned into pEAQ-HT with the AgeI and 
XhoI restriction sites. In later experiments, the anti-phOx scFv sequence was ordered for 
synthesis again with codon use optimised for Nicotiana benthamiana and cloned into t-EL 
using the SalI and AseI restriction sites: this construct was named t-α-phOx-OPT.  
ii) m-α-phOx sequence 
The m-α-phOx construct (monomeric core with anti-phOx scFv sequence in the e1 loop) was 
made by amplifying the C-terminal core of t-α-phOx with an upstream primer containing the 
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authentic AgeI site instead of the AgeI-like site, thus creating a monomeric construct with an 
upstream AgeI site followed by a favourable Kozak context. This construct was inserted into 
pEAQ-HT using AgeI and XhoI. 
iii) t-KD sequence 
The sequence for t-KD (tandem core with GDDDKKKKKKDDDG peptide insertion in C-terminal 
e1 loop) was prepared from t-EL (see chapter 3) and a set of oligonucleotides containing the 
KD sequence. Partially overlapping 5’-phosphorylated oligonucleotides coding for the above 
peptide with 5’ SalI and 3’ AseI restriction site overhangs were ligated into pEAQ-HT-t-EL which 
had been digested with SalI and AseI. 
iv) m-KD sequence 
The m-KD sequence (monomeric core with with GDDDKKKKKKDDDG peptide insertion in e1 
loop) was prepared from m-EL (see chapter 3) in the same way as t-KD (see above). 
 
III - Properties of t-α-phOx 
 
To test expression of t-α-phOx and m-α-phOx, the constructs were individually agroinfiltrated 
into N. benthamiana leaves and small scale extractions were carried out in parallel with leaves 
infiltrated with m-EL, CoHe and t-EL (see chapter 3) in order to compare the expression levels 
of empty-loop and scFv-bearing constructs. The soluble (supernatant) and insoluble 
(resuspended pellet) fractions were assayed by western blotting (Fig. 4.3). 
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Figure 4.3 Western blots of supernatant and pellet fractions of plant extracts after expression of different 
constructs. After a small-scale extraction, the equal volumes of soluble fractions (left) and resuspended pellet 
fractions (right) were loaded onto SDS-PAGE gels for western blot analysis with the anti-HBcAg 10E11 monoclonal 
antibody. Monomeric constructs are expected to be about 20 kDa (47 kDa with the anti-phOx scFv inserted in the 
e1 loop), while tandem core constructs are expected to be about 40 kDa, (67 kDa with the anti-phOx scFv inserted 
in the C-terminal e1 loop). Exact sizes can be found in figure 4.2. These are the same western blots as shown in 
figure 3.5. 
 
This western blot shows that there is expression of soluble m-EL (22.5 kDa) and t-EL (41.8 kDa, 
this is in fact the same western blot as shown in Chapter 3), with CoHe (40 kDa) accumulating 
at lower levels. However, there is no sign of expression from either t-α-phOx (with an expected 
size of about 69 kDa) or m-α-phOx (with an expected size of about 50 kDa). This disappointing 
result seemed worthy of further investigation since tandem cores with properly-folded, 27 kDa 
GFP displayed on the surface could be produced (see chapter 3). Another experiment was 
therefore set up in which leaf tissue infiltrated with t-α-phOx underwent a large-scale 
extraction with HBexB1 buffer (which yields cleaner extracts than P buffer) followed by a 
sucrose step gradient with increasing concentrations of sucrose (20, 30, 40, 50, and 60 % 
sucrose). Crucially, aliquots were taken at every step in the process in order, and these were all 
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analysed on the same anti-HBcAg western blot in order to determine if any material was 
produced, and how it behaved during the extraction process and sucrose step gradient (Fig. 
4.4). No further work was carried out on m-α-phOx. 
 
 
Figure 4.4 Western blot of the fractions obtained at each step of extraction and purification of t-α-phOx. TP: total 
protein extract. CF: crude filtrate. 1S: supernatant from the first clarification centrifugation step. 1P: pellet from the 
first clarification centrifugation step. 2S: supernatant from the second clarification centrifugation step. 2P: pellet 
from the second clarification centrifugation step. The following step gradient fractions were collected after 
ultracentrifugation: Sn: supernatant of the sucrose step gradient. 20: 20% sucrose fraction. 30: 30% sucrose 
fraction. 40: 40% sucrose fraction. 50: 50% sucrose fraction. 60: 60% sucrose fraction. The primary antibody used 
was the anti-HBcAg 10E11 monoclonal antibody, and t-α-phOx has a predicted mass of 69.5 kDa.  
 
This result shows reveals that soluble t-α-phOx is difficult to detect. Indeed, nothing was 
detected in the total protein extract (TP, leaves just after blending in buffer), the crude filtrate 
(CF, just after filtration of the total protein extract over miracloth), or the supernatant of the 
first clarification spin (1S, just after centrifugation of the crude filtrate). There was, however, 
signal in the fraction corresponding to the pellet of the first clarification spin (1P), indicating 
that although t-α-phOx is expressed, it is mostly insoluble. There are also higher molecular 
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weight bands, which, as mentioned in chapter 3, are diagnostic of all tandem core – based 
constructs. This could correspond to stable multimers of tandem cores, or (at least in some 
cases), improperly folded aggregates. Moreover a band around 39 kDa in size was reproducibly 
seen in insoluble t-α-phOx (which is expected to be 69 kDa in size). While this could be a sign 
of degradation of the protein, a band of similar size was sometimes seen in western blots of 
plant extracts, even when these came from plants agroinfiltrated with an empty vector control 
(see below and chapter 6). The soluble fraction of the extract (1S) was centrifuged a second 
time and although t-α-phOx was not detected in either the supernatant or the pellet, this 
second soluble fraction (2S) was used to load the sucrose step gradient. After 
ultracentrifugation, t-α-phOx could be detected in the sucrose fractions, particularly the 30% 
sucrose fraction, this time with much less non-specific antibody binding (or degradation) being 
observed. Whatever that 39 kDa band is, it does not seem to be incorporated into the soluble 
particulate matter formed by t-α-phOx. It should be pointed out that the 30% sucrose fraction 
(along with the 40% fraction) is typically where t-EL particles were seen to sediment in similar 
experiments. While it does show that soluble t-α-phOx is forming particulate material, it is not 
proof that this particulate material is definitely CLPs. Moreover, the fact that t-α-phOx is 
detectable in the sucrose fractions but not the 2S fraction indicates that t-α-phOx is only 
readily detectable when it has been concentrated to a certain degree: the material detected in 
the pellet is essentially a very concentrated form of the insoluble proteins present in the crude 
filtrate, and the sucrose fractions are concentrated forms of the particulate matter present in 
the second soluble fraction (2S). This reveals that t-α-phOx is expressed at low levels in plants, 
and that the vast majority of the material is insoluble. The fraction which is soluble migrates 
down a sucrose step gradient, which indicates that it is particulate, but it does not seem to 
settle in one specific part of the gradient, indicating that the particulate matter is 
heterogeneous. It is possible to detect t-α-phOx in the more dilute fractions by significantly 
increasing the exposure time during ECL detection (data not shown). 
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These results suggested that it would be possible to further characterise t-α-phOx if enough 
material could be produced and purified. Thus, plant tissue agroinfiltrated with t-α-phOx was 
extracted in either HBexB1 or P buffer and concentrated over sucrose cushions or step 
gradients and any particles present in the fractions were then visualised by TEM: in these cases 
no CLPs were ever observed, despite multiple attempts. Another experiment was therefore set 
up to try to produce a purer, more concentrated sample of t-α-phOx. As controls, and for 
comparison, m-EL, t-EL, CoHe, m-α-phOx, and sCore-sGFP (see chapter 3) were also used in 
this experiment. Leaf material expressing the different constructs was used for large-scale 
extractions (see chapter 2) followed by a sucrose step gradient. The sucrose fractions in which 
particles were expected, or hoped, to be found (20%-60% for t-α-phOx and 30%-60% for m-α-
phOx) were pooled, diluted with water, and concentrated further on YM-100 Microcon 
centrifugal filter devices (Millipore) as per manufacturer’s instructions. These filter units 
allowed the removal of sucrose from the samples while concentrating them. Importantly, the 
molecular weight cut-off (MWCO) of these filter units is 100 kDa, so unassembled monomers 
of any construct would be expected to be removed from the sample. The concentrates thus 
obtained were analysed by anti-HBcAg western blot (Fig. 4.5).  
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Figure 4.5 Western blot of different protein extracts after concentration. Large-scale extractions were carried out 
followed by a sucrose gradient, and further concentration with a Microcon centrifugal filter device. While m-EL 
(22.5 kDa), t-EL (41.8 KDa) and CoHe (41 kDa) are readily detected; m-α-phOx (50.1 kDa), CoreN-sGFP1-10 (34 kDa, 
the detectable moiety of sCore-sGFP) and t-α-phOx (69.5 kDa) are not. The primary antibody used was the anti-
HBcAg 10E11 monoclonal antibody. 
 
Again, the characteristic ladder pattern involving higher molecular weight structures was seen, 
this time with the monomeric core as well as the tandem core constructs. In fact the ladder 
pattern seen with m-EL makes it very clear that this does correspond to multimers, as the well-
defined bands are clearly one (~20 kDa), two (~40 kDa) and three (~60 kDa) times the size of 
m-EL. This is less clear with tandem core constructs: since they are so large to begin with, 
multimers are always in the less-well defined higher molecular weight area of the gel. The 
presence of these bands revealed that while m-EL, t-EL and CoHe could be concentrated using 
the method described above, m-α-phOx, t-α-phOx, and sCore-sGFP were not detected. This 
could be because these proteins do not assemble into structures larger than 100 kDa (and 
were therefore lost during filtration), or because higher order structures like particles are 
present in such small amounts to begin with that they were not sufficiently concentrated, and 
any signal that there might be from these constructs is drowned out by the much stronger 
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signal from the other, positive samples. It is also theoretically possible that particulate matter 
pelleted through the gradient, but if that were the case one might expect to detect something 
in the 60% sucrose fraction (the bottom fraction), which was included in the pooling and 
concentration.  
In any case, this is not conclusive proof that t-α-phOx does not form CLPs, although it clearly 
shows the struggle that might be necessary to obtain enough material to have a chance of 
observing such particles if they do in fact exist. It would in theory be possible to conclusively 
exclude the possibility that t-α-phOx forms CLPs, if large amounts of soluble t-α-phOx were 
readily detected, but never penetrated low-concentration sucrose layers during a sucrose 
cushion or gradient. The problem here is that low yield of soluble protein makes detection in 
any fraction difficult. Moreover, this low yield makes it unlikely that enough material could 
ever be produced for further work. 
Attempts at optimising extraction and concentration of t-α-phOx were carried out with the 
assistance of an undergraduate student (Angelika Jaroschek). Among these experiments were 
attempts at developing a polyethylene glycol (PEG) precipitation protocol (which had not been 
attempted for other CLPs) for concentrating t-α-phOx from crude plant extract prior to sucrose 
gradient analysis. An initial concentration step such as this could be used to increase the 
amount of starting leaf material that could be used for purification. These experiments never 
resulted in any demonstrable improvement in obtaining concentrated soluble t-α-phOx. 
Another approach was an attempt to produce mosaics in order to reduce the number of scFv 
molecules on each assembled CLP: to this end, plants were co-infiltrated with t-α-phOx and 
either t-EL or m-EL in various ratios. The hope was that capsid formation might be rescued if 
only some of the spikes contain the scFv insert. Thus, plants were co-infiltrated with mixes of 
Agrobacterium suspensions consisting of t-α-phOx and either t-EL or m-EL in ratios of 10:1, 1:1, 
or 1:10. After small-scale extractions in either AngeliTris buffer or AngeliBor buffer 
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(respectively tris and borate – based buffers which had been previously determined by 
Angelika to be no worse than HBexB1 for the extraction of t-α-phOx from plant tissue), the 
soluble fractions were analysed by anti-HBcAg western blot (Fig. 4.6). In theory, if particle 
formation could be rescued by the mosaic method, more t-α-phOx should be seen here than in 
previous experiments: it is likely that in previous experiments, t-α-phOx was not forming 
particles and was therefore largely degraded in the plant, which explains why so little of it was 
ever detectable. If mosaics are a success, however, then t-α-phOx should be detectable in 
amounts comparable to t-EL.  
 
 
Figure 4.6 Western blots of plant extract soluble fractions after expression of mosaic HBcAg constructs. In order 
to rescue particle formation with t-α-phOx (69.5 kDa), Agrobacteria carrying either t-EL (41.8 kDa) or m-EL (22.5 
kDa) constructs were co-infiltrated with Agrobacteria carrying t-α-phOx (right on each blot). The relative ratios of 
the bacteria carrying the different constructs are shown: 1:10, 1:1, or 10:1. The controls (left of each blot) are 
similarly-treated soluble fractions of plants expressing only t-EL, t-α-phOx, m-EL or the empty vector control (EV). All 
lanes represent soluble fractions obtained after small-scale extractions carried out using either AngeliTris (left) or 
AngeliBor (right) extraction buffers.  
 
It is important to note the apparently non-specific bands which are present in all samples, 
including the empty vector negative control (EV): a 39 kDa band is visible in all samples for 
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both sets of extractions, and two larger bands above 64 kDa are also visible in all samples from 
AngeliTris buffer extractions. This means that the bands visible in t-α-phOx extractions cannot 
be considered to be specific. For both extraction buffers, and for both m-EL and t-EL, there is 
no visible influence from the presence of t-α-phOx.  The co-infiltrations with t-EL or m-EL show 
bands of approximately 40 and 20 kDa, respectively, which correspond to these constructs and 
not t-α-phOx. The amount of material in the co-infiltrations correlates to the amount of t-EL or 
m-EL used, and the presence of Agrobacteria directing the expression of t-α-phOx seems to 
have no effect. For both extraction buffers, and for both m-EL and t-EL, there is no visible 
influence from the presence of t-α-phOx: mosaics could not be formed with t-α-phOx. This 
experiment was repeated with the same buffers used for extraction as well as HBexB1, and the 
ultimate result was identical. A final attempt at increasing the yield of t-α-phOx consisted of 
using a codon-optimised sequence of the anti-phOx scFv and using this new sequence to 
create a new tandem core construct with the scFv in the e1 loop. This construct, named t-α-
phOx-OPT (see section II.A.i above), failed to improve accumulation of the t-α-phOx protein in 
plants, and failed to direct the production of detectable CLPs. 
 
IV - Properties of t-KD 
 
In order to test expression of t-KD and m-KD, small scale extractions were carried out on plants 
infiltrated with three different Agrobacterium clones (transformed with the same sequence-
verified plasmid) for each construct. The extractions were carried out in both P and HBexB1 
extraction buffers. A western blot of the soluble fraction was then carried out to assay 
expression of the proteins (Fig. 4.7).  The results clearly show that while t-KD (with an expected 
size of about 42 kDa) is expressed in plants and can be extracted using either buffer, m-KD 
(with an expected size of about 22 kDa) either does not accumulate in leaf tissue or cannot be 
extracted in either buffer. A possible explanation for this is that the lysine-rich linker abolishes 
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HBcAg dimer formation if it is present in both e1 loops of a dimer, possibly through repulsion 
caused by the charged residues inserted in the e1 loop. If dimer formation is abolished, then 
capsid assembly is impossible, so the m-KD monomers would likely be degraded.  
 
 
Figure 4.7 Detection of m-KD or t-KD in soluble plant extracts following agroinfiltration with different 
Agrobacterium clones. PCR-positive Agrobacterium clones (identified by numbers) carrying monomeric m-KD (23.3 
kDa) or tandem t-KD (42.6 kDa) constructs were used to agroinfiltrate N. benthamiana. Small-scale extractions were 
performed in either P (left) or HBexB1 (right) extraction buffers, and the soluble fractions were analysed by western 
blot using the anti-HBcAg 10E11 monoclonal antibody. While soluble protein was detected for the tandem 
construct, this was not the case for the monomeric construct. 
 
Once expression of t-KD had been established, it was necessary to demonstrate particle 
formation. Because both P and HBexB1 buffers seemed suitable for extracting t-KD, parallel 
large-scale extractions were set up in both buffers before partial purification over sucrose 
cushions. The samples were then observed by TEM in order to confirm the presence of CLPs 
(Fig. 4.8). Particles were indeed observed in samples from both extractions, but those 
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originally extracted in P buffer seemed much more homogeneous and less aggregated than 
those extracted in HBexB1. Further purification of t-KD CLPs extracted in P buffer by size-
exclusion chromatography (SEC) increased the quality of the images that could be obtained by 
TEM. 
 
 
Figure 4.8 Electron micrographs of t-KD CLPs purified in different ways. Left, t-KD CLPs purified by sucrose cushion 
after extraction in HBexB1 buffer. Middle, t-KD CLPs purified by sucrose cushion after extraction in P buffer. Right, t-
KD CLPs purified by sucrose cushion and size-exclusion chromatography after extraction in P buffer. All scale bars, 
100 nm. 
 
This success allowed large amounts of leaf material to be used to express t-KD CLPs, which 
could then be purified and handed over to collaborators in the Prof. Rob Field group (John 
Innes Centre), and Dr. Nicole Steinmetz (Case Western University, USA), for chemical 
conjugation and immunogenicity studies. Dr. Matthew Donaldson, of the Prof. Field group, 
conjugated fluorescein isothiocyanate (FITC) onto the surface of t-KD CLPs, which revealed that 
chemical conjugation on these particles could be done. Attempts to use t-KD to display 
antigens from a bacterial pathogen of the Burkholderia genus for vaccine development 
purposes are ongoing. In order to ensure a supply of highly purified particles for future studies, 
a protocol for the large scale purification of t-KD particles was developed. In this, particles 
were initially partially purified from plant extract via sucrose cushion (large-scale extraction), 
and the resulting extracts were dialysed against AmBic buffer, concentrated further via 
vacuum evaporation (see chapter 2), and then loaded onto a Nycodenz density gradient. After 
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ultracentrifugation, the gradient was fractionated and the fractions were assayed by western 
blot for presence of HBcAg (Fig. 4.9a). The two fractions with the strongest signal (5 and 6 in 
figure 4.9a) were pooled, dialysed against PBS, then diluted tenfold in distilled water and 
visualised by TEM (Fig. 4.9b). The numerous particles were homogenous in morphology and 
resembled native HBcAg particles with visible surface spikes and a majority of T=4 CLPs, 
although a few particles were seen to be misshapen and/or broken. The sample overall 
seemed very clean, indicating that the Nycodenz gradient is a suitable purification technique 
for t-KD. 
 
 
Figure 4.9 t-KD CLPs can be purified by Nycodenz gradient. Top: western blot of the different fractions of the 
Nycodenz gradient on which t-KD (42.6 kDa) was purified. The antibody used was anti-HBcAg 10E11 monoclonal 
antibody. Bottom: electron micrograph of t-KD CLPs purified by Nycodenz gradient (fractions 5 and 6 on western 
blot above). Arrows indicate T=3 particles. Scale bar, 100 nm. 
Chapter 4: Two strategies for a generic protein presentation system 
 
86 
 
 
V - Discussion 
 
The results presented in this chapter reveal the possibilities, as well as the limitations, that 
come with tandem core technology. The t-α-phOx construct directed very low accumulation 
levels of protein, most of which was insoluble, and none of which could be shown to form 
CLPs. All attempts at improving solubility, concentration, and purity were unsuccessful. The 
creation of mosaics is sometimes used to rescue particle formation with chimeric CLPs that 
contain large or complex inserts. This has been carried out successfully with HBcAg CLPs, 
although in those cases it was used to improve particle formation of HBcAg with an insert 
fused to the C-terminus, and not the e1 loop (Koletzki et al., 1999; Beterams et al., 2000; 
Koletzki et al., 2000). In this instance, this approach could not rescue accumulation of t-α-phOx 
or the formation of particles. It seems unlikely that the protein would be expressed at very low 
levels: the HBcAg portion of t-α-phOx is identical in sequence to t-EL, which accumulates at 
much higher levels, and codon-optimisation of the anti-phOx scFv failed to improve 
accumulation of t-α-phOx. This strongly suggests that the low level of protein accumulation is 
caused by rapid turn-over by the plant protein degradation machinery. This in turn suggests 
that t-α-phOx misfolds, a hypothesis which is supported by the failure to improve t-α-phOx 
accumulation through the creation of mosaics. If t-α-phOx were capable of folding properly, 
but could not form particles due to steric constraints, then co-infiltration with t-EL or m-EL 
should have rescued particle formation, and therefore caused an increase in t-α-phOx 
accumulation.  
Taken together, these results indicate that t-α-phOx probably cannot fold properly, and most 
of the material is degraded in the plant. Because of this, attempts at improving accumulation 
are largely futile, because the amino acid sequence of t-α-phOx is not conducive to proper 
protein folding. This is unlikely to be because of the size of the scFv: it is almost identical in size 
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to GFP, which can easily be incorporated in the tandem core construct. The more likely 
explanation is the structure of the scFv. These proteins contain two domains, corresponding to 
the Light (L) and Heavy (H) chain variable regions of IgG antibodies (Ahmad et al., 2012). This 
means that the scFv would need to fold into two distinct domains when fused to the tandem 
core construct despite having both the N- and C-termini anchored to the HBcAg moiety. 
Moreover, these termini are actually at opposite ends to the scFv, which presents further 
conformational issues for the presentation of this protein on the surface of a tandem core 
construct, despite the long linkers used. It seems likely, therefore, that the tandem core 
system does not provide sufficient flexibility for the scFv to fold into two distinct domains. This 
improper folding could lead to spurious interactions between scFv residues and HBcAg 
residues, thus interfering with the correct folding of the rest of the tandem core molecule, a 
phenomenon that has been hypothesised before with unfolded inserts (Janssens et al., 2010). 
The result would be a misfolded protein that might well be targeted for degradation.  
There was considerably more success, however, with t-KD. This construct led to production of 
CLPs with similar yields to t-EL and t-sGFP (see chapter 3, about 200-500 µg/g of fresh weight 
leaf tissue). This is perhaps not surprising given the small size of the insert, and the fact that 
the charge of the six lysine residues was balanced by six aspartate residues. What is perhaps 
more surprising is that this insert prevented accumulation of a monomeric HBcAg construct, 
m-KD, since much larger inserts (both folded and unfolded) have been inserted in the e1 loop 
of monomeric HBcAg. It could be that the charged residues in the e1 loop of one monomer 
interfered with those on another, thus preventing dimer formation, and therefore particle 
assembly. It could also be that the KD linker interacted with the rest of the HBcAg sequence 
during secondary structure formation, leading to improper folding of the entire protein. It 
might be possible to determine which of these two hypotheses is correct by using the mosaic 
system as was done with t-α-phOx, though this was not attempted given the success obtained 
with the tandem core construct. In any case, the logical conclusion to be drawn is that the 
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amino acid composition of the insert can play a key role in determining whether it will be 
successfully displayed in monomeric HBcAg CLPs. Moreover, this experiment has provided 
evidence that the tandem core system can allow protein accumulation and particle formation 
when a monomeric core approach fails.  
This chapter describes an example of a case (with t-KD) where tandem core technology clearly 
has an advantage over the use of monomeric core. However, it also provides an example of 
the limitations of tandem core technology (with t-α-phOx) for the presentation of proteins 
with multiple domains. This has helped to guide subsequent work and will no doubt serve to 
guide research into applications of tandem core technology in the future.  
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Chapter 5 : Introducing the tandibody: a tandem core CLP 
displaying a functional nanobody on its surface 
 
I - Introduction 
 
Due to the failure to obtain CLPs with a single-chain antibody (scFv), an alternative strategy 
was developed in which the scFv sequence was replaced with that of a single-domain 
antibody: a camelid-derived heavy chain variable fragment of a heavy chain antibody (VHH, or 
nanobody). These synthetic antibody fragments are small (13-15 kDa), have high affinity for 
their cognate antigens, can function inside the cell, and are composed of only a single domain 
(Muyldermans and Lauwereys, 1999). They have been expressed heterologously in numerous 
systems and used for research and biotechnological purposes for many years (Riechmann and 
Muyldermans, 1999; Jobling et al., 2003; Dolk et al., 2005; Maass et al., 2007; Teh and 
Kavanagh, 2010). The hypothesis was that a nanobody, being composed of only one domain, 
would be more likely to fold properly when fused into the C-terminal e1 loop of tandem 
HBcAg. However, just like an scFv, the N- and C-termini of VHH are exposed at opposite ends 
of the protein, so it seemed that long linkers (15 amino acids on either end) would be 
necessary to allow proper folding of the insert. Moreover, success with VHH insertion using 
this strategy would give further insight into why insertion of an scFv was unsuccessful. Figure 
5.1, originally from Harmsen and De Haard (2007), shows how the structure of a nanobody 
compares to that of an scFv. 
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Figure 5.1 The nanobody, a single-domain antibody fragment obtained from a camelid heavy-chain IgG. 
Conventional single-chain scFv are two-domain constructs obtained from the fusion of the variable regions of the 
heavy and light chains from standard mammalian IgGs (a). Nanobodies, or VHH, are similar constructs obtained 
from the variable region of the heavy-chain from heavy chain IgGs of camelids (b). Nanobodies are therefore not 
only single-chain, but also single-domain antibody fragments. Image reprinted with permission from Harmsen and 
De Haard, 2007. 
 
II - Presentation of a GFP-specific nanobody  
 
The first nanobody used as proof of principle was the well-characterised 12 kDa “Enhancer” 
nanobody, originally from dromedary (Kirchhofer et al., 2010). This nanobody has sub-
nanomolar affinity for green fluorescent protein (GFP), and the amino acid sequence for it is 
publicly available on GenBank (PDB: 3K1K_C). The DNA sequence for this nanobody was 
ordered for synthesis from GeneArt, (Life Technologies) with stop codon removed, codon 
usage optimised for N. benthamiana, and long linkers (GGGGS)3 on either side between the 
SalI and AseI restriction sites. This sequence was inserted into pEAQ-HT-t-EL between the SalI 
and AseI restriction sites so as to insert it into the C-terminal e1 loop of t-EL (see chapter 3). 
The new construct, pEAQ-HT-τ-GFP, is intended to direct the production of a tandem HBcAg 
protein displaying the anti-GFP nanobody: this fusion protein was named “anti-GFP tandibody” 
(abbreviated to τ-GFP), with the word “tandibody” being a contraction of “tandem core HBcAg 
displaying a nanobody” (Fig. 5.2).  
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Figure 5.2 Diagram of construct and protein structures. Top: construct map for τ-GFP, the tandem core construct 
with the anti-GFP Enhancer nanobody inserted in the C-terminal e1 loop. The key is the same as in figure 3.3a. 
Bottom: structure predictions of t-EL (left) and τ-GFP (right), courtesy of Dr. Ellis O’Neil. The N-termini are in blue, 
and the C-termini in red. Arrows indicate the first and last amino acid of the anti-GFP VHH, which are represented in 
stick form. Images were generated using PyMOL. 
 
As a control, the same VHH sequence was also inserted into the c/e1 loop of the monomeric 
construct, pEAQ-m-EL (see chapter 3) to give pEAQ-µ-GFP. The two constructs, together with a 
pEAQ-HT empty vector control were separately infiltrated into N. benthamiana leaves. Small 
scale extractions in P buffer were prepared 7 days post-infiltration (dpi) and the soluble 
fractions were subjected to western blot analysis using anti-HBcAg monoclonal antibody 10E11 
(Fig. 5.3a). The results showed the accumulation of HBcAg-specific material of the expected 
size (55 kDa) in leaves infiltrated with pEAQ-τ-GFP (3rd lane), while no protein corresponding to 
the expected size (37 kDa) could be detected in extracts from leaves infiltrated with pEAQ-µ-
GFP (4th lane). All samples, including those from leaves infiltrated with the empty vector, 
pEAQ-HT, showed a cross-reactive band of unknown origin at approximately 39 kDa, as was 
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seen in some of the other western blots in which this antibody was used (see chapter 4). These 
results demonstrated that a tandem construct, as opposed to a monomeric one, is required for 
the efficient display of VHH sequences. It should be noted, however, that when produced on 
its own, most of the τ-GFP is insoluble. 
As a preliminary assay of whether the expressed τ-GFP retained the ability of the nanobody to 
bind GFP, a co-infiltration experiment was carried out, in which Agrobacterium cultures 
carrying pEAQ-HT containing the sequence for either GFP or τ-GFP were co-infiltrated. These 
leaves were treated as above but the insoluble protein fraction (pellet) was also analysed by 
western blot (Fig. 5.3b). This revealed that when produced on its own, τ-GFP is mainly 
insoluble, but when τ-GFP and GFP are co-infiltrated, most of the τ-GFP can be found in the 
soluble fraction. This suggests that the presence of GFP in planta increases the solubility of τ-
GFP. This strongly hints that τ-GFP binds to GFP, and the entire complex is more soluble than τ-
GFP on its own.  
 
 
Figure 5.3 τ-GFP is expressed in plants, and its solubility is enhanced by the co-expression of GFP. a) Western blot 
of soluble (supernatant) plant extracts expressing different constructs. EV: empty vector control; τ-GFP: tandem 
core construct with anti-GFP nanobody inserted in the C-terminal e1 loop (55.8 kDa); µ-GFP: monomeric core 
construct with anti-GFP nanobody inserted in the e1 loop (36.5 kDa). b) Western blot of supernatant (left) and 
resuspended pellet (right) fractions of plant extract expressing τ-GFP alone or co-expressed with GFP. 
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Sucrose cushion and transmission electron microscopy (TEM) was used to determine whether 
τ-GFP forms particles when expressed in plants and to confirm whether the presence of GFP 
affects the method of purification. Large-scale extractions (see chapter 2) were carried out 
with leaves infiltrated with pEAQ-τ-GFP alone or co-infiltrated with pEAQ-HT-GFP were 
homogenised and the clarified lysates were loaded on to sucrose cushions consisting of two 
layers of sucrose (25 % and 70 %). Particulate matter of the size of assembled HBcAg particles 
was expected to produce a band at the interface between the two sucrose layers: intense 
fluorescence was seen at this interface for the tubes containing the co-expressed material of 
both GFP and τ-GFP. This interface was collected (for both sets of samples) and any particles 
within it further purified by size exclusion chromatography. The fractions from this were 
analysed by western blot and positive fractions were pooled, concentrated by vacuum 
evaporation (see chapter 2), and examined by TEM. This revealed CLPs in both samples (with 
and without GFP), which look extremely similar to wild-type or tandem HBcAg, but with an 
apparent thin layer on the surface in addition to, and partially obscuring, the characteristic 
spikes (Fig. 5.4). This gives them a morphology which I term “knobbly”, as opposed to the wild-
type “spiky” morphology. It is more difficult to distinguish T=3 particles from T=4 particles 
when the CLPs are knobbly, but there do appear to be a small minority of T=3 particles visible 
in the second image (arrows), which is typical of HBcAg. As the images show, more particles 
were obtained from the co-infiltration than from the infiltration of τ-GFP on its own, thus 
further reinforcing the previous data which suggested that the presence of GFP increases the 
solubility of the particles, leading to higher recovered yield. It is estimated that about 5-20 µg 
of τ-GFP can be obtained per gram of fresh weight leaf tissue [FWT] without GFP, and about 
100-500 µg/g FWT with GFP. 
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Figure 5.4 Electron micrographs of τ-GFP CLPs obtained from expression alone or with GFP. Left: τ-GFP CLPs 
obtained from leaves agroinfiltrated with τ-GFP alone. Right: τ-GFP CLPs obtained from leaves that were co-
infiltrated with τ-GFP and GFP. Higher yields of CLPs were obtained from co-expression. Both sets of particles 
present “knobbly” morphology, whereby the characteristic spikes of wild-type HBcAg CLPs are less clearly defined 
and apparently obscured. This seems to be particularly true of the particles obtained from co-infiltration. The 
arrows indicate T=3 particles, both scale bars are 100 nm. 
 
 
To further examine the ability of τ-GFP particles to bind GFP, a similar sucrose cushion 
experiment was carried out, this time with more controls and no co-infiltrations. Plant tissue 
expressing the τ-GFP (or t-EL) particles was mixed with plant tissue expressing GFP (or empty-
vector control), and the leaves were homogenised together before the rest of the large-scale 
extraction and sucrose cushion were carried out as described in chapter 2 (see figure 5.5).  
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Figure 5.5 Experimental set-up to examine binding of τ-GFP to GFP. Leaves were separately agroinfiltrated with 
bacteria containing constructs coding for either GFP or τ-GFP. At 7 dpi, the leaves were mixed and homogenised 
together as part of a large-scale extraction followed by a sucrose cushion. 
 
After ultracentrifugation of material containing both GFP and τ-GFP – expressing plant extract, 
the fluorescence was found to have migrated at the bottom of the sucrose cushion, co-
localising with the τ-GFP particles (Fig. 5.6a). When GFP-containing plant extract was run on an 
identical sucrose cushion on its own or with t-EL-containing plant extract, the fluorescence was 
found to remain in the supernatant, indicating that it is not large enough to migrate into the 
sucrose layers. The co-localisation of GFP with τ-GFP in the sucrose layers was demonstrated 
by western blot analysis of the different fractions of the sucrose gradients using either anti-
HBcAg or anti-GFP antibodies (Fig. 5.6b). This showed that while tandem HBcAg (with or 
without the anti-GFP nanobody) always migrates to the bottom of the cushion GFP mostly 
stays in the supernatant unless it is in the presence of τ-GFP. This indicates that the τ-GFP 
particles interact with GFP in such a way as to confer the properties of a virus-like particle. This 
strongly suggests that GFP binds to the nanobody moiety of assembled τ-GFP particles. 
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Figure 5.6 τ-GFP CLPs bind to GFP in a sucrose cushion. Plant leaves expressing different constructs were mixed as 
shown in figure 5.5. After large-scale extraction, sucrose cushions were loaded with the different plant extracts, and 
these cushions were photographed under UV light after ultracentrifugation (a). While plant extract containing only 
t-EL or τ-GFP do not show fluorescence, plant extracts containing GFP alone or with t-EL show fluorescence in the 
supernatant, above the sucrose layers. When plant extract containing GFP is mixed with extract containing τ-GFP, 
the fluorescence is located at the bottom of the sucrose cushion, indicating that τ-GFP CLPs have dragged GFP down 
through the sucrose. (b) Duplicate anti-HBcAg (top) and anti-GFP (bottom) western blots of the different fractions of 
the sucrose cushions above. GFP (27 kDa) is mostly confined to the supernatant when alone or mixed with t-EL (41.8 
kDa), but it co-localises with τ-GFP (55.8 kDa) at the bottom of the sucrose cushion. S: supernatant, Top: top of the 
sucrose cushion, Mid: interface between the 25% and 70% sucrose fractions, Bott: bottom of the sucrose cushion.  
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The importance of the extraction buffer was tested in an attempt to increase recovered yield 
of particles. Leaf tissue co-infiltrated with pEAQ-HT-τ-GFP and pEAQ-HT-GFP were split into 
four groups and each group was homogenised in one of the following buffers: P buffer (0.1 M 
sodium phosphate, pH 7); P+ (20 mM sodium phosphate, pH 7, 1 mM EDTA, 5 mM DTT, 0.1% 
w/v Triton X-100); IQUR (20 mM Tris-HCl, pH 8, 1 mM EDTA, 5% isopropanol, 5 mM DTT, 0.1% 
w/v Triton X-100); or HBexB1 (10 mM Tris-HCl pH 8, 120 mM NaCl, 1mM EDTA,1 mM DTT,  
0.75% w/v sodium deoxycholate). All buffers were also supplemented with protease inhibitor 
(Roche). The lysates were clarified and filtered over 0.45 µm syringe filters before being loaded 
onto sucrose cushions. Observation of the ultracentrifuge tubes under UV light after 
ultracentrifugation revealed that in all four cases, GFP sedimented in the sucrose layers; 
although the standard extraction buffer and P+ caused the GFP (and therefore presumably the 
τ-GFP) to be in a relatively distinct band at the interface between the two sucrose layers, as 
opposed to HBexB1 and IQUR buffers (Fig. 5.7a). It was also clear that the standard extraction 
buffer and HBexB1 had clean interfaces, unlike P+ and IQUR buffers, which gave rise to thick 
green contamination at the interface region. The fluorescent interfaces were collected and, 
after dialysis and further concentration and clarification, visualised by TEM (Fig. 5.7b). While 
no structurally sound particles were seen in the IQUR-extracted sample, numerous particles 
were seen from standard and P+ extractions, and fewer particles were seen in the HBexB1-
extracted sample. This is particularly interesting given that extractions of τ-GFP alone (without 
GFP) in HBexB1 was also attempted but no particles were seen with TEM. It could be that the 
increased solubility of the particles in the presence of GFP means that there are simply more 
particles which are more likely to be seen as compared to τ-GFP on its own. However, it could 
also indicate that the presence of GFP makes the particles more resistant to the HBexB1 buffer 
by altering the surface properties of the particles. 
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Figure 5.7 P buffer is the best buffer to extract τ-GFP CLPs that have been co-expressed with GFP. a) UV-imaged 
sucrose cushions of plant extracts from leaves co-infiltrated with τ-GFP and GFP, extracted in four different 
extraction buffers. The extract obtained with buffer P yields the least diffuse fluorescent band with the lowest 
amount of dark green contaminating plant material. b) The fluorescent fractions from the cushions were visualised 
by TEM. CLPs with knobbly phenotype were seen in fractions obtained from material extracted in P, P+, and HBexB1 
buffers, but not IQUR buffer. Scale bars, 100 nm. 
   
More detailed analysis of the binding of GFP to τ-GFP required purified preparations of the two 
components: GFP was obtained commercially (Millipore), while τ-GFP was produced in plant 
tissue on its own via a large-scale extraction followed by sucrose cushion purification. Because 
of solubility issues associated with producing τ-GFP without GFP, it was time-consuming to 
obtain sufficient τ-GFP to carry out the next experiment: analysing the binding of τ-GFP 
particles to GFP through a modified sandwich ELISA (Fig. 5.8a). Briefly, wells of a 96-well plate 
were coated with the τ-GFP particles (purified by sucrose cushion and syringe-filtration as 
described in chapter 2), and different amounts of GFP were added to these wells after 
blocking, before GFP was detected by a commercially available anti-GFP polyclonal antibody 
conjugated to horseradish peroxidase (HRP). As a negative control, wells were coated with the 
same amount of a different (but identically purified) tandibody particle, which displays a 
nanobody against HIV-1 surface glycoprotein gp120 (τ-gp120, see Chapter 6). The positive 
control was a commercially available anti-GFP polyclonal antibody different to that used for 
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detection and already conjugated to horseradish peroxidase (HRP). The negative and positive 
controls were treated identically to the experimental wells, with the sole exception of the 
protein used to coat the wells. Upon detection of HRP activity, it was found that the signal 
from wells coated with τ-GFP was very similar to the signal from wells coated with anti-GFP 
IgG, with signal decreasing concomitantly with the decreasing amount of GFP used (Fig. 5.8b). 
In contrast to this, the negative control showed no signal above background, indicating that 
the interaction between τ-GFP and GFP is caused specifically by the anti-GFP nanobody 
moiety. 
 
Figure 5.8 τ-GFP CLPs bind to GFP in an ELISA. Partially-purified τ-GFP CLPs (circular particles on the left) were used 
to coat the wells of a 96-well plate in order to act like anti-GFP antibodies in a sandwich ELISA (a). Pure GFP (red 
diamonds) was added at a range of concentrations to the wells and the GFP was detected with a polyclonal anti-GFP 
IgG conjugated to HRP (orange). As a positive control, a commercially obtained polyclonal anti-GFP IgG different to 
that used for detection was used (green, on the right) as part of a standard sandwich ELISA. As a negative control, a 
similarly-purified tandibody bearing a nanobody against HIV-1 gp120 (τ-gp120, see chapter 6) was used in the same 
amounts as τ-GFP. b) Absorbance measurements indicated the amount of GFP present in each well. Treatments 
were carried out in quadruplicates and average readings were subtracted from background to give net signal. While 
the τ-gp120 CLPs did not bind GFP, τ-GFP CLPs bound GFP in a similar fashion to the anti-GFP IgG. Error bars 
represent standard error. 
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In an attempt to quantify the strength of binding of τ-GFP to GFP, Surface Plasmon Resonance 
(SPR) was used. In this case, commercially purchased His-tagged GFP (Millipore, the same as 
was used in the ELISA experiment) was fixed onto a Ni-NTA SPR chip, and purified tandibody 
particles (either τ-GFP or τ-gp120 control) at identical concentrations were flowed over the 
GFP, and the interaction between the two was measured using a Biacore T200. The first SPR 
experiment was a simple binding test, to check for any interaction between τ-GFP or τ-gp120 
and GFP (Fig. 5.9a). It revealed that while τ-gp120 did not interact with GFP, τ-GFP interacted 
strongly. It further indicated that there was very little dissociation of τ-GFP from GFP, or that 
this dissociation is very slow: this is reflected in a slow decrease in response units (RU) over 
time after the end of tandibody injection, which is normally indicative of dissociation between 
the two molecules. However, this apparent dissociation is paralleled by the decrease in RU of 
τ-gp120, which decreases to negative values (with 0 being the start of the flow of tandibody), 
indicating that this apparent dissociation in both cases is in fact dissociation of his-tagged GFP 
from the chip, as opposed to dissociation of the tandibody from the GFP. In this light, it is very 
clear that τ-GFP does not significantly dissociate from GFP during the period measured.  
The second SPR experiment was a single-cycle kinetics experiment, in which increasing 
amounts of τ-GFP were flowed over the GFP in order to reach saturation, thus allowing the 
quantification of affinity of τ-GFP for GFP (Fig. 5.9b). The result was a calculated KD of 0.175 
nM, which is, in fact, lower than the published KD of the Enhancer nanobody, which is given as 
0.59 nM (Kirchhofer et al., 2010). However, it should be noted that dissociation of GFP from 
the chip would skew the calculation of the dissociation constant in the SPR experiment. 
Moreover, this calculation is dependent on the concentrations of GFP and of the tandibodies, 
so the KD is only as reliable as the quantification of the tandibodies used in the experiment. 
Because the tandibodies were quantified using western blots, and because the tandibodies 
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always show a diffuse ladder pattern on SDS-PAGE gels, the quantification of tandibodies is 
more of an estimate than an exact measurement. However, the relative quantification 
between the two tandibodies should be fairly accurate. So while the exact KD is difficult to 
measure accurately, the difference seen between τ-GFP and τ-gp120 should be representative. 
 
 
Figure 5.9 τ-GFP CLPs bind to GFP during surface plasmon resonance. Commercially obtained His-tagged GFP was 
bound to the surface of a Ni-NTA SPR chip, and partially purified τ-GFP CLPs were flowed over the GFP. Binding 
resulted in detection of Response Units. a) In a simple binding test, τ-GFP (green line) was seen to bind to GFP 
during tandibody injection (time between red lines) and to stay bound afterwards, while τ-gp120 (orange line) 
injected at the same concentration did not bind to GFP. b) A single-cycle kinetics binding experiment involved 
flowing increasing concentrations (indicated in red) of τ-GFP over the surface-bound GFP until saturation was 
reached. This allowed the quantification of τ-GFP affinity for GFP, which was calculated to be 0.175 nM.  
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The τ-GFP tandibody bound to GFP was also used for preliminary cryo-electron microscopy 
(cryo-EM). Plant material co-expressing τ-GFP and GFP was purified by sucrose cushion and 
size-exclusion chromatography, and the purified particles were flash-frozen in vitreous ice on a 
TEM grid for image collection. Visualisation of the particles confirmed the results seen with 
negative-stain TEM: the τ-GFP particles are intact, proving that the insertion of a nanobody 
sequenced has not abolished capsid assembly. The data obtained from cryo-EM image 
collection was analysed in collaboration with Dr. Robert Gilbert (University of Oxford) and class 
averages were obtained to generate a 25 Å reconstruction of the particles (Fig. 5.10). At this 
resolution, the map is more of a schematic of average electron density within the particles. 
 The particle reconstruction clearly contains spikes reminiscent of those of a standard HBcAg 
CLP, but long projections of extra density are formed on the outside of these particles. These 
projections are too few to each correspond to a nanobody-GFP complex on a single spike, 
since there should be one per spike, and therefore as many projections as there are spikes. 
What is most likely is that these projections are average positions of averaged densities of 
numerous nanobody-GFP complexes from a few different spikes. This is logical when one 
considers the length of the linkers used to fuse the anti-GFP nanobody to the spikes of the 
tandem core. The long linkers were intended to provide the nanobody with flexibility, and this 
flexibility probably means that the nanobody-GFP complex is not in a fixed orientation on the 
surface of the particle with respect to its tandem core partner. This makes structure 
reconstruction complicated, since it relies on average electron densities to determine 
molecular conformation and positioning. When the GFP-τ-GFP reconstruction is overlain on 
the preliminary map obtained for CoHe (hetero-tandem core with no insert in the e1 loop), the 
spikes from both maps overlay, indicating that the basic tandem core particles are similar in 
structure, but the GFP-τ-GFP projections are not present on the CoHe map, which indicates 
that these are extra density on the exterior of the CLP which is not present in CoHe, thus 
reinforcing the likelihood that these projections correspond to the nanobody-GFP complex. 
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Figure 5.10 Cryo-electron microscopy of τ-GFP CLPs bound to GFP. 2,385 CLPs of τ-GFP bound to GFP were imaged 
and analysed with the assistance of Dr. Robert Gilbert. a) Class averages of these CLPs. b) This allowed the 
generation of a 3D reconstruction (resolution estimated at 25 Å) coloured by distance from the centre of the 
particle (red to blue). The map is shown viewed down a 5-fold axis with the bacterially-produced CoHe 
reconstruction on which the construct was based fitted within (grey surface). The projecting spikes represent 
electron density corresponding to the bound nanobody and GFP, but these do not occupy every position expected, 
instead appearing as an average of the density present, with the highest intensity at the 2-fold and 5-fold axes. The 
location of these masses may be due to the icosahedral symmetry imposed on the reconstruction. This may indicate 
that these projections are flexible and are not displayed in a fixed orientation on each spike. 
    
III - Discussion 
 
Nanobodies (or VHH) have been expressed in several expression systems including bacteria for 
phage display (Dolk et al., 2005; Maass et al., 2007; Beekwilder et al., 2008), and plants for 
VHH overexpression (Ismaili et al., 2007; Winichayakul et al., 2009; Teh and Kavanagh, 2010). 
They have found uses in fundamental antibody research (van der Linden et al., 1999; Desmyter 
et al., 2001; Muyldermans et al., 2001) as well as applied biotechnology (Jobling et al., 2003). 
When attempts to display a scFv on the surface of a tandem core CLP proved unsuccessful (see 
the previous chapter), presentation of a nanobody was tried as an alternative, in the hope that 
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the simpler structure would allow proper protein folding and CLP assembly. This proved to be 
highly successful -where scFv failed, VHH prevailed! The GFP-binding Enhancer nanobody 
(Kirchhofer et al., 2010) proved to be an excellent tool for demonstrating that nanobodies 
displayed on the surface of HBcAg retain their binding activity. It was demonstrated that τ-GFP 
can be expressed in plants both with and without GFP, although co-expression with GFP 
increased the solubility of the particles, resulting in much higher yields of recovered protein. 
The particulate nature of τ-GFP with and without GFP was demonstrated with TEM as well as 
cryo-EM, making this the first report of an antibody fragment successfully displayed on HBcAg 
CLPs in any expression system, and the first time an antibody fragment of any kind has been 
displayed on a spherical virus capsid in a plant expression system. The only other example of 
antibody fragments being displayed on the surface of a virus particle in plants is the display of 
scFv on the surface of the filamentous PVX (Smolenska et al., 1998). 
The binding of GFP to τ-GFP could be readily demonstrated using a simple sucrose cushion 
experiment, and further analysed by ELISA and SPR. All of these techniques gave concordant 
results which indicate that τ-GFP CLPs bind GFP with very high affinity. This demonstrates that 
the fusion of a nanobody to tandem HBcAg does not have an adverse effect on the affinity of 
the nanobody for its target antigen. Moreover, these results show that a protein with the N- 
and C-termini on opposite ends can be successfully inserted in the e1 loop of HBcAg provided 
that a tandem construct is used: the fact that the monomeric µ-GFP construct failed to yield 
any detectable material demonstrates that tandem core technology can overcome the limits to 
insertions in the HBcAg e1 loop found with monomeric constructs. Furthermore, the data 
presented here offer some insight into why the attempted display of the anti-phOX scFv failed 
(see chapter 4). The anti-GFP nanobody also has N- and C-termini exposed on opposite ends of 
the protein, and yet 15 amino acid – long linkers on either side were sufficient to allow proper 
folding of the insert and the HBcAg scaffold, so it seems unlikely that this was the limiting 
factor in display of the anti-phOx scFv. The only other differences between the scFv and the 
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VHH are the size and the number of domains. Because the scFv is the same size as GFP, which 
could be displayed on the surface of a tandem core CLP (see chapter 3), the most likely limiting 
factor for particle formation with t-α-phOx is the number of domains on the insert. This seems 
to be the crucial difference between a nanobody and an scFv which determines whether the 
insert will allow particle formation in a tandem core construct. 
The successful tandibody proof of concept paved the way for the next set of experiments: 
using the same methodology to create tandibodies with binding affinity for medically relevant 
antigens. Using GenBank as a source of available nanobody sequences, two nanobodies were 
chosen for the next sets of experiments: one against HIV-1 surface glycoprotein gp120, and the 
other against HIV-1 capsid protein p24. The results of these experiments are presented in the 
following chapter. 
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Chapter 6 : Adapting tandibody technology to display antigens of 
medical relevance 
 
I - Introduction 
 
Success with the anti-GFP tandibody opened up the possibility of displaying nanobodies on the 
surface of tandem HBcAg which recognise medically relevant antigens. A search on GenBank 
revealed the sequences for two nanobodies which recognise HIV proteins.  
The first, known as A12, is described in Forsman et al. (2008) and Strokappe et al. (2012). It is a 
llama-derived nanobody specific to HIV-1 IIIB surface glycoprotein extracellular region gp120. 
HIV gp120 is part of the gp160 protein (coded for by the ENV gene), which during post-
translational processing is split into gp120 (the surface-exposed glycoprotein) and gp41, which 
contains the transmembrane and cytoplasmic domains, along with the fusion peptide and 
heptad repeats which are involved in trimerisation of the gp160 complex on the surface of the 
viral envelope (Chakrabarti et al., 2002). The A12 nanobody has been determined to bind to 
gp120 with a KD of 0.1 nM. There were two reasons for choosing this nanobody to test the 
tandibody system: the sequence of the A12 nanobody is available on GenBank (PBD: 3R0M_A), 
and this nanobody was discovered by panning llama serum against an easily available antigen, 
recombinant gp120 from HIV-1 IIIB, obtained from CFAR, NIBSC (catalogue number EVA607). 
This meant that I could test binding of this nanobody with an antigen that is known to interact 
strongly, without introducing extraneous variables such as sequence variability in gp120 
between different HIV-1 subtypes. Along with these technical considerations, I considered that 
it would be interesting to test the tandibody concept with a glycoprotein antigen. Indeed, the 
tandibody technique, because it is based on non-covalent binding of a scaffold to an antigen of 
interest, would, in theory, be very useful for displaying surface antigens of enveloped viruses. 
For these proteins to fold properly, they normally need to be trafficked through the eukaryotic 
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secretory pathway, which could make it difficult for them to fold properly if fused directly to 
the e1 loop of HBcAg or tandem HBcAg. Post-translational non-covalent linking of the antigen 
to the CLP scaffold has the advantage of allowing the production of each component 
separately in their respective optimal cellular compartment.  
The second nanobody that was chosen was an alpaca-derived nanobody which binds to HIV-1 
capsid protein p24 (GenBank PDB: 2XT1_B). Unlike the anti-GFP and anti-gp120 nanobodies, 
this nanobody is not described in the literature, but there is evidence that it binds to p24: the 
RCSB Protein Data Bank file linked to the GenBank sequence is, in fact, the crystal structure of 
this nanobody (produced in E. coli) in complex with the C-terminus of HIV-1 p24 (also produced 
in E. coli). It seems unlikely that such a structure could have been obtained if the nanobody did 
not bind to this antigen. An advantage of using this nanobody in the tandibody system is that, 
like gp120, the p24 protein is available to purchase as a reagent from the NIBSC (CFAR 
repository reference ARP678). Moreover, there was evidence that recombinant p24 could be 
produced in plants: HIV-1 p24 was produced transiently in N. benthamiana using a TMV-based 
vector, and the resulting p24 proved to be antigenic in animal studies (Pérez-Filgueira et al., 
2004). This anti-p24 nanobody was therefore selected for study in the tandibody system 
alongside the anti-gp120 nanobody. 
II - Design of constructs 
 
A) τ-gp120 
The anti-gp120 nanobody sequence known as A12 (Forsman et al., 2008) was obtained from 
GenBank (PBD: 3R0M_A) and synthesised by GeneArt (Life Technologies) with the stop codon 
removed, codon usage optimised for N. benthamiana, and long linkers (GGGGS)3 on either side 
between SalI and AseI restriction sites. Between the nanobody sequence and the linkers, an 
AvrII site (on the N-terminal side, corresponding to amino acids Pro-Arg) and a SbfI restriction 
site (on the C-terminus, corresponding to amino acids Pro-Ala) were added. This construct was 
Chapter 6: Adapting tandibody technology to display antigens of medical relevance 
 
108 
 
inserted into pEAQ-HT-t-EL between the SalI and AseI restriction sites to give pEAQ-HT-τ-gp120 
(Fig. 6.1). 
 
B) gp120 
A gp120 construct was prepared for co-expression alongside τ-gp120. The sequence for gp120 
(from HIV-1 IIIB) was acquired from NIBSC, and it was found to be identical to a GenBank 
sequence (UniProtKB/Swiss-Prot: P03377.1). For expression in plants, a 6XHis tag was added at 
the C-terminus, and the N-terminal 30 amino acids were replaced with the Arabidopsis basic 
chitinase signal peptide (Samac et al., 1990), which had previously been used by Sainsbury et 
al. (2008) as a strong secretion signal for recombinant protein production in plants. The native 
secretion signal was not used because it has been reported that it does not yield optimal 
secretion of gp120 in heterologous systems (Golden et al., 1998). This modified gp120 
sequence was codon optimised for N. benthamiana and ordered for synthesis. The sequence 
(including the 6XHis tag) was cloned into pEAQ-HT using the AgeI and XhoI restriction sites to 
give pEAQ-HT-gp120. 
 
C) τ-p24 
The anti-p24 nanobody sequence was obtained from GenBank (GenBank PDB: 2XT1_B) and 
ordered for synthesis with stop codon removed, codon usage optimised for N. benthamiana, 
and restriction sites AvrII and SbfI on the 5’ and 3’ ends respectively. This construct was 
inserted into pEAQ-HT- τ-gp120 between the AvrII and SbfI restriction sites to give pEAQ-HT-τ-
p24 (Fig. 6.1). 
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D) p24 
A p24 construct was also prepared for co-expression alongside τ-p24. The sequence for HIV-1 
p24 was obtained from GenBank entry 2XT1_A, which is part of the same entry as τ-p24: this 
entry describes the complex of τ-p24 binding to the C-terminus of p24, so the sequences of 
both are given. However, because this entry only provides the sequence for the C-terminus of 
p24, the N-terminal part of p24 was obtained from GenBank entry AAB50258.1, which is the 
sequence of the entire gag polyprotein of HIV-1. So the p24 sequence to be used was taken 
from accession number AAB50258.1 (from position P149 to Y277) and completed with the 
sequence from accession number 2XT1_A (from position S1 to L86). This complete p24 
sequence was codon-optimised for expression in N. benthamiana and ordered for synthesis. 
This sequence was cloned into the pEAQ-HT vector using the AgeI and XhoI restriction sites to 
give pEAQ-HT-p24, and with the AgeI and XhoI sites to give the C-terminally 6XHis-tagged 
version of p24, pEAQ-HT-p24His. 
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Figure 6.1 Diagram of constructs and protein structures. a) Construct maps for the τ-gp120 and τ-p24 tandibodies. 
The key is the same is in figure 3.3a. b) Structure predictions of t-EL (top left) and τ-GFP (top right), τ-gp120 (bottom 
left), and τ-p24 (bottom right), courtesy of Dr. Ellis O’Neil. The N-termini are in blue, the C-termini are in red. Arrows 
indicate the first and last amino acid of the VHH moieties, which are represented in stick form. Images were 
generated using PyMOL. 
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III - Expression and characterisation of τ-gp120 and gp120 
 
The pEAQ-HT-τ-gp120 construct was expressed in N. benthamiana alongside two controls, 
pEAQ-HT-EV (empty vector), and pEAQ-HT-τ-GFP; and small-scale extractions were subjected 
to western blot analysis using the 10E11 anti-HBcAg monoclonal antibody in order to assay the 
accumulation of recombinant protein in the soluble fractions (Fig. 6.2a). A band of about 57 
kDa was seen in the plant extract expressing pEAQ-HT-τ-gp120, which corresponds to the 
expected size of τ-gp120. A band of a slightly smaller size (and stronger intensity) was seen in 
the extract expressing pEAQ-HT-τ-GFP, which corresponds to τ-GFP (with an expected size of 
55.8 kDa – see figure 5.2). No specific band was seen in the lane corresponding to the empty 
vector control, although the non-specific 39 kDa band described in previous chapters was seen 
in all three lanes (see chapters 4 and 5). This western blot revealed that τ-gp120 is expressed, 
although not quite to the same levels as τ-GFP. This is consistent with all experiments carried 
out with parallel extractions of τ-GFP and τ-gp120: recovered yields of τ-GFP were always at 
least double those of τ-gp120.  
The results shown in the previous chapter indicated that most of the τ-GFP which is expressed 
in N. benthamiana is insoluble unless GFP is co-expressed alongside it. To test whether this 
also holds for τ-gp120, pEAQ-HT-gp120, was created and its expression was tested in N. 
benthamiana with both a small-scale extraction and an apoplastic wash followed by an anti-
HBcAg western blot (Fig. 6.2b). As its name suggests, gp120 is expected to run on an SDS-PAGE 
gel at around 120 kDa, although this is mostly due to its glycosylation: the protein itself is only 
57.5 kDa. Western blot analysis revealed a very diffuse pattern of plant-produced gp120, with 
diffuse major bands running at 70 and 140 kDa, which suggests that the protein is glycosylated, 
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albeit not in the same manner as native gp120 produced in human cells. However, 
recombinant gp120 could not be extracted from an apoplastic wash, suggesting that it is either 
blocked at some stage of the secretory pathway, or that it is bound to the plant cell surface in 
some way.  
As the gp120 construct was designed to include a C-terminal 6XHis tag, extracts from leaves 
agroinfiltrated with pEAQ-HT-gp120 were prepared 7 dpi and used for His-tag affinity 
chromatography. The fractions collected from the chromatography were analysed by an anti-
His western blot (Fig. 6.2c). A similar pattern of bands was seen as with the previous 
experiment (Fig. 6.2b), but most of the signal came from the flow-through fraction (i.e. the 
extract that did not bind to the column) and the wash fraction (i.e. the extract that bound 
poorly to the column): relatively little gp120 was recovered in the elution fractions. Thus, the 
recombinant gp120 seemed to interact poorly with the nickel column, despite the fact that the 
His-tag was still present on the protein (the western blot was carried out with an anti-His 
antibody). This suggests that the His-tag is not properly exposed on the surface of the protein.  
Finally, a co-expression experiment was carried out with gp120 and τ-gp120, alongside the co-
expression of GFP and τ-GFP (see chapter 5). After small-scale extractions, anti-HBcAg western 
blots of the soluble (supernatant) and insoluble (resuspended pellet) fractions were carried out 
(Fig. 6.2d – this is in fact the same western blot as shown in figure 5.3). In both cases, bands of 
the appropriate sizes were seen in the insoluble fractions. However, only the GFP + τ-GFP co-
expression resulted in detectable amounts of tandibody in the soluble fractions. The 
conclusion from this experiment is that co-expression of gp120 with τ-gp120 was not found to 
increase solubility or recovered yield of τ-gp120 in the way that GFP did with τ-GFP (see 
chapter 5). Further experiments showed that yields of τ-gp120 reach about 2-5 µg/g FWT.  
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Figure 6.2 τ-gp120 and gp120 can be expressed in plants. a) Anti-HBcAg western blot of plant extract soluble 
fractions expressing τ-gp120, the empty vector control (EV), or τ-GFP. b) Anti-gp120 western blot of apoplastic wash 
(left) and total soluble protein (right) from leaves expressing τ-gp120 or the empty vector control (EV). The 200 ng 
of gp120 used as an internal control is commercially obtained gp120 produced in insect cells, which explains the size 
difference due to glycosylation. c) Anti-His western blot of the different fractions of his-tag affinity purification of 
plant-produced gp120. d) Western blot of supernatant (left) and resuspended pellet (right) fractions of plant extract 
expressing τ-GFP or τ-gp120 alone or co-expressed with its cognate antigen. This is the same blot as shown in figure 
5.3. 
 
To investigate whether τ-gp120 was able to form CLPs, a large-scale extract of leaf material 
was partially purified on a sucrose cushion and the interface fraction (between the 25% and 
70% sucrose layers) was analysed by TEM. This revealed that τ-gp120 does indeed form 
particles, and that these particles can be produced and extracted from plant material in much 
the same way as τ-GFP (Fig. 6.3). As with τ-GFP CLPs (see chapter 5), the surface spikes of 
HBcAg are not clearly defined, and a minority of these particles adopt T=3 conformation 
(arrows). Moreover, it was found that these particles are stable in PBS for at least 6 months at 
4°C (Fig. 6.3). 
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Figure 6.3 plant-produced τ-gp120 forms stable CLPs. Left: τ-gp120 CLPs produced alone in plants. Right: τ-gp120 
CLPs after storage for 6 months at 4°C. Arrows indicate T=3 particles, scale bars are 100 nm. 
 
The observation that co-expression of τ-gp120 with gp120 does not improve solubility or yield 
of τ-gp120 is not conclusive evidence of lack of binding. To determine whether τ-gp120 can 
bind gp120 in vitro, further tests were carried out. The first test was a sucrose gradient, in 
which 130 µg of concentrated tandibody (either τ-gp120 or τ-GFP as a control) was mixed with 
8 µg of commercially obtained recombinant gp120 (CFAR, NIBSC). This mixture was then run 
on a continuous sucrose gradient, and the fractions were analysed by duplicate western blots 
probed with either anti-gp120 or anti-HBcAg antibodies (Fig. 6.4). Because the recombinant 
gp120 is produced in a baculovirus expression system, it runs at about 90 kDa instead of the 
native 120. For both co-infiltrations, signal corresponding to gp120 was seen to be present in 
low- to mid-concentration sucrose fractions, with signal corresponding to the tandibodies 
being present in mid-concentration sucrose fractions. The results were largely inconclusive 
because gp120 was found to migrate into the sucrose and partially co-localise with both 
tandibodies. However, the co-localisation was not complete, as would have been expected if τ-
gp120 bound strongly to gp120. So this result suggests that if there is interaction between τ-
gp120 and gp120, it is probably very weak. 
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Figure 6.4 Sucrose gradient pull-down of gp120 by tandibodies. Commercially-obtained gp120 was mixed with 
partially purified plant-produced τ-GFP (left) and τ-gp120 (right) before being loaded onto sucrose cushions. After 
ultracentrifugation, the gradients were fractionated and the fractions were analysed by duplicate western blots 
probed with anti-gp120 (top) or anti-HBcAg (bottom) antibodies. The gp120 is heavy enough to penetrate the 
sucrose, and it col-localises with both tandibodies, so no conclusions can be drawn about gp120 binding to τ-gp120. 
 
The next method used to investigate binding of τ-gp120 to gp120 was an ELISA. The protocol 
used was very similar to that used to determine binding of τ-GFP to GFP (see figure 5.8), except 
that the positive control was commercially obtained gp120 coating the wells directly, as 
opposed to a sandwich ELISA. The wells were coated with 200 ng of sucrose cushion – purified 
tandibody or commercially obtained anti-gp120 polyclonal antibody; and the amount of gp120 
added per well ranged from 1.56- 12.5 ng. The goal was to have an excess of 
tandibody/antibody compared to gp120. Average signals for each treatment was subtracted 
from the background signal as determined by control wells where no gp120 was added. 
Neither τ-gp120 nor the τ-GFP control showed signal above background, whereas the positive 
control showed signal which decreased in proportion to the decreasing gp120 concentration, 
although this signal was quite low in general (Fig. 6.5). The result of this experiment indicated 
that τ-gp120 does not interact with gp120.  
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Figure 6.5 τ-gp120 CLPs do not bind to gp120 in an ELISA. Partially-purified τ-GFP and τ-gp120 CLPs were used to 
coat the wells of a 96-well plate in order to act like anti-gp120 antibodies in a sandwich ELISA. Pure gp120 (obtained 
commercially) was added at a range of concentrations to the wells and the gp120 was detected with a polyclonal 
anti-gp120 IgG conjugated to HRP. As a positive control, gp120 was used to coat the wells directly. Absorbance 
measurements indicated the amount of gp120 present in each well. Treatments were carried out in quadruplicates 
and average readings were subtracted from background to give net signal. While wells coated with gp120 gave 
signal in proportion to the amount of gp120 used, those coated with tandibodies did not. Error bars represent 
standard error. 
 
This negative result suggested that the anti-gp120 nanobody on the τ-gp120 is not functional. 
There are two reasons why this might be the case: either the plant expression system is not 
conducive to proper folding of this nanobody, or the fusion of this nanobody to the tandem 
HBcAg affects its ability to bind its cognate antigen in some way. This could be through 
improper folding, or because it the presence of the CLP does not allow the nanobody to dock 
properly with its binding site on gp120, which is predicted to be the inside of the cavity under 
the bridging sheets of gp120 (Strokappe et al., 2012). To investigate this, the anti-gp120 A12 
nanobody sequence was cloned into pEAQ-HT using the AgeI and SmaI restriction sites in order 
to produce a 6XHis-tagged version of the A12 nanobody. The resulting pEAQ-HT-A12-His vector 
was expressed in plants. A small scale-extraction followed by His-tag affinity chromatography 
was carried out, and the fractions from the chromatography were analysed on a western blot 
probed with an anti-His antibody (Fig. 6.6). This revealed bands of the expected size (15 kDa) 
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for the nanobody in the total soluble protein extract, as well as in the two elution fractions. 
Very little signal was seen in the flow-through or the wash fractions, indicating that most of 
the A12-His protein binds to the nickel column, indicating that the His-tag is exposed. A faint 
band at about 30 kDa was seen in the first elution fraction, indicating possible dimerisation of 
the A12-His protein.  
 
Figure 6.6 The His-tagged A12 nanobody is expressed in plants. The A12 nanobody was produced in plants using 
the pEAQ-HT vector with a C-terminal His-tag. The total soluble protein (TSP) containing recombinant A12-His was 
used for nickel column affinity purification. The different fractions were analysed by anti-His western blot, which 
revealed that the A12-His protein can be purified in this manner, indicating that the His-tag is exposed. 
 
As an initial test to check binding of plant-produced A12-His to gp120, cobalt-coated magnetic 
beads (Dynabeads, Life Technologies) were used in a pull-down assay. The His-tagged A12 
nanobody was fixed onto the beads, and these beads were used to pull down 10 µg of 
commercially obtained gp120 (NIBSC). As a control, unbound beads were mixed with the same 
amount (10 µg) of gp120, to make sure that any apparent binding of gp120 was to the 
nanobody, and not directly to the bead (Fig. 6.7). The different fractions were analysed by 
duplicate anti-gp120 and anti-His western blots. This revealed that gp120 (90 kDa) could be 
Chapter 6: Adapting tandibody technology to display antigens of medical relevance 
 
118 
 
pulled down by the beads coated with the nanobody, but not by the uncoated beads. This 
indicates that plant-produced A12-His does indeed bind gp120. 
 
 
Figure 6.7 The plant-produced A12-His nanobody binds gp120 in a Dynabead pull-down assay. Cobalt-coated 
magnetic beads (Dynabeads) were coated with A12-His and used to pull down gp120. The gp120 co-localised with 
the A12-His nanobody in the elution fraction (elute), and on the beads after elution (beads). As a negative control, 
unbound beads were used, and these did not bind significantly to gp120 (unbound fraction). Fractions were 
analysed by duplicate western blots probed with anti-gp120 (top) and anti-His (bottom) antibodies. 
 
To investigate this binding in more detail, an ELISA was set up to compare binding of A12-His 
and τ-gp120 to gp120, using a standard sandwich ELISA with commercially obtained polyclonal 
antibodies as a control. This experiment differs from that shown in figure 6.4 in three ways. 
Firstly, the positive control in this experiment was a sandwich ELISA in which gp120 was added 
to wells already coated with commercially obtained anti-gp120 polyclonal antibodies (as was 
done in figure 5.8). Secondly, much more protein was used to coat the wells of the plate: 500 
ng per well of τ-gp120, A12-His, or anti-gp120 polyclonal antibody instead of 200 ng. Thirdly, 
much more gp120 was added to the wells after blocking: 50- 400 ng instead of 1.56- 12.5 ng. 
The results revealed net signal that decreases concomitantly with the decrease in gp120 
Chapter 6: Adapting tandibody technology to display antigens of medical relevance 
 
119 
 
concentration (Fig. 6.8). All net signals are relatively low, and the signal from wells coated with 
τ-gp120 is lower than the signal from wells coated with A12-His, which is itself lower than the 
signal corresponding to the commercially obtained anti-gp120 antibody. This is consistent with 
some low-level binding of both A12-His and τ-gp120, although A12-His seemed to bind more 
strongly than τ-gp120 at higher concentrations of gp120. It should be noted however that the 
amounts of protein used to detect this low-level binding are logs higher than what one might 
normally expect to use in an ELISA (see figure 5.8). This made obtaining the appropriate 
amount of material difficult given the low yields typically obtained for τ-gp120. 
 
 
Figure 6.8 gp120 binds to A12-His more strongly than to τ-gp120 CLPs, but not as strongly as to a commercially 
available anti-gp120 antibody. Partially-purified τ-gp120 CLPs (orange) and A12-His nanobodies (red) were used to 
coat the wells of a 96-well plate in order to act like anti-gp120 antibodies in a sandwich ELISA. As a positive control, 
a polyclonal anti-gp120 IgG was used. Pure gp120 (obtained commercially) was added at a range of concentrations 
to the wells and the gp120 was detected with a polyclonal anti-gp120 IgG conjugated to HRP different to that used 
to coat the positive control wells. Absorbance measurements indicated the amount of gp120 present in each well. 
Treatments were carried out in quadruplicates and average readings were subtracted from background to give net 
signal. All net signal was low, despite using large quantities of protein. A12-His showed stronger binding to gp120 
than τ-gp120 did, but this was weaker than gp120 binding to the anti-gp120 IgG. Error bars represent standard 
error. 
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IV - Expression and characterisation of τ-p24 and p24 
 
A small-scale extraction was carried out on plant leaves separately expressing either pEAQ-HT-
τ-p24 or pEAQ-HT-p24. The soluble protein fractions were then analysed on western blots 
using anti-HBcAg or anti-p24 antibodies (Fig. 6.9a). This analysis revealed that both proteins 
were expressed: a band corresponding to τ-p24 (55.7 kDa) was seen alongside a non-specific 
band that was also present in the empty vector control – infiltrated leaf tissue. A band 
corresponding to p24 (24 kDa) was seen in plant tissue expressing this protein, along with 
another band (about 48 kDa), which was considered to be a sign of dimerisation. Because co-
expression of τ-GFP and GFP had resulted in increased yield and solubility of τ-GFP, τ-p24 was 
co-expressed with p24 alongside τ-GFP and GFP, and τ-gp120 and gp120. Small-sale extractions 
followed by western blot analysis of the supernatant (soluble) and resuspended pellet 
(insoluble) fractions were carried out (Fig. 6.9b - this is in fact the same western blot as shown 
in figures 5.3 and 6.2d). This revealed a band corresponding to τ-p24 (55.7 kDa) present in the 
insoluble fraction but not visible in the soluble fraction, similar to the situation found with τ-
gp120. Moreover, the co-expression of τ-p24 with p24 (last lane on both blots) did not visibly 
increase the solubility of τ-p24. Furthermore, it is clear that expression levels of τ-p24 are not 
as high as τ-GFP. Further experiments revealed that τ-p24 yield is similar to that of τ-gp120: 2-5 
µg/g FWT. 
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Figure 6.9 τ-p24 and p24 can be expressed in plants  a) Anti-HBcAg western blot of plant extract soluble fractions 
expressing τ-p24, p24, or the empty vector control (EV). b) Western blots of supernatant (left) and resuspended 
pellet (right) fractions of plant extract expressing τ-GFP, τ-gp120, or τ-p24 alone or co-expressed with its cognate 
antigen. This is the same blot as shown in figures 5.3 and 6.2d. 
 
 
To demonstrate that τ-p24 forms CLPs, τ-p24 with and without co-expressed p24 was partially 
purified on a sucrose cushion with layers of 25% and 70% sucrose. The interface between 
these two regions was collected and inspected by electron microscopy (Fig. 6.10). This 
revealed that τ-p24 does indeed form particles in plants, and that these particles can be 
produced, partially purified, and detected by using the same protocol as τ-GFP and τ-gp120. 
Moreover, τ-p24 CLPs are indistinguishable from τ-GFP or τ-gp120 CLPs under standard TEM 
conditions, including a similar preference for T=4 conformation over T=3 (arrows). There may 
be some evidence of a difference between τ-p24 CLPs produced alone or co-expressed with 
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p24: it seems that the CLPs produced from co-expression have a more pronounced knobbly 
morphology with less clearly defined spikes and apparent material projecting from the surface 
of the CLPs, as compared to τ-p24 CLPs produced alone (see figures 5.4 and 6.3). This could be 
an indication of p24 binding to the surface of τ-p24 CLPs, but it is by no means conclusive. 
 
 
Figure 6.10 Plant-produced τ-p24 forms particles in plants when expressed alone or with p24. Left: τ-p24 CLPs 
produced alone in plants. Right: τ-p24 CLPs obtained from co-expression with p24. Arrow indicates T=3 particles, 
scale bars are 100 nm. 
 
Once particle formation had been established, the functionality of the anti-p24 nanobody 
moiety of τ-p24 was studied. A sucrose cushion experiment similar to that described in chapter 
5 was carried out. Briefly, plant leaf extracts from co-infiltrations of τ-p24 (or τ-GFP as a 
control) and p24 were run on sucrose cushions, and after ultracentrifugation, four fractions 
were collected: the supernatant (s), the top of the 25% sucrose layer (T), the interface 
between the 25% and 70% layers (M), and the bottom of the 70% sucrose layer (B). These 
fractions were analysed by duplicate western blots with either an anti-HBcAg antibody or an 
anti-p24 antibody used for detection (Fig. 6.11). The results revealed that p24 (24 kDa 
monomer band or 48 kDa dimer band) on its own or in the presence of τ-GFP particles (a 
negative control in this case) separates into two distinct species: a “light” species which 
remains in the supernatant or at the top of the 25% sucrose layer, and a “heavy” species which 
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migrates to the bottom of the gradient. Very little p24 was detected in the interface fraction. 
This suggests that the p24 forms two discrete species, as opposed to a continuum of forms of 
increasing size. The p24 capsid protein is known to be capable of oligomerisation under the 
right conditions (Momany et al., 1996; Berthet-Colominas et al., 1999), and the presence of 48 
kDa dimer bands in all fractions indicates that the sizes are due to more than dimerisation. In 
any case, when τ-p24 is present in the plant extract, the amount of the light species of p24 is 
substantially reduced, and the p24 co-localises with τ-p24, mostly at the bottom of the 
cushion. This strongly suggests that τ-p24 interacts with at least the light form of p24, 
presumably by binding to it and causing it to sediment at the bottom of the sucrose cushion. 
 
 
Figure 6.11 Plant-produced τ-p24 affects p24 in a sucrose gradient pull-down. Leaves producing p24 alone, τ-GFP 
and p24, τ-p24 alone, or τ-p24 and p24 were prepared. Extracts were subjected to sucrose cushions, and duplicate 
anti-HBcAg (top) and anti-p24 (bottom) western blots of the different fractions were prepared. When p24 is 
produced alone or with τ-GFP, there are two distinct species of p24 (24 kDa), which localise in the supernatant (S), 
and at the bottom (B) of the cushion, respectively. When p24 is produced with τ-p24, the light species in the 
supernatant almost completely disappears, suggesting that τ-p24 CLPs have caused it to sediment at the bottom of 
the cushion. S: supernatant, T: top of the sucrose cushion, M: interface between the 25% and 70% sucrose fractions, 
B: bottom of the sucrose cushion. 
 
To further study the binding of τ-p24 to p24, a sandwich ELISA, similar to that described in 
figure 5.8, was performed. The wells were coated with 125 ng of tandibody (τ-p24 or τ-GFP as 
a control) or commercially obtained anti-p24 polyclonal antibody, and the amount of p24 
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added per well ranged from 1.5- 10 ng, the goal being to have excess of tandibody/antibody 
compared to p24. The presence of p24 was then detected using an anti-p24 antibody 
conjugated to HRP (different to that used to coat the surface of the positive control wells). 
Average signals for each treatment was subtracted from background signal as determined by 
control wells where no p24 was added. The results show that there is stronger net signal 
present in wells coated with τ-p24 than in wells coated with τ-GFP, although this signal is lower 
than that obtained from wells coated with the commercially obtained anti-p24 antibody (Fig. 
6.12). This suggests that τ-p24 binds to p24, although the overall net signal was relatively 
weak, and background was relatively strong compared to the experiment carried out with τ-
GFP and GFP (see figure 5.8).  
 
 
Figure 6.12 τ-p24 CLPs bind to p24 in an ELISA. Partially-purified τ-GFP and τ-p24 CLPs were used to coat the wells 
of a 96-well plate in order to act like anti-p24 antibodies in a sandwich ELISA. Pure p24 (commercially obtained) was 
added at a range of concentrations to the wells and this was detected with a polyclonal anti-p24 IgG conjugated to 
HRP. As a positive control, a commercially obtained polyclonal anti-p24 IgG different to that used for detection was 
used as part of a standard sandwich ELISA. Absorbance measurements indicated the amount of GFP present in each 
well. Treatments were carried out in quadruplicates and average readings were subtracted from background to give 
net signal. While the τ-GFP CLPs did not bind p24, τ-p24 CLPs bound did, although not as clearly as the anti-GFP IgG. 
Error bars represent standard error. 
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To further investigate binding, Surface Plasmon Resonance was used. In order to do this, a C-
terminal His-tagged p24 construct was prepared in the pEAQ-HT vector. The pEAQ-HT-p24His 
plasmid was expressed in N. benthamiana, and a large-scale extraction followed by His-tag 
affinity chromatography was used to determine whether the protein was expressed and 
whether its C-terminal His-tag was exposed. The different fractions were analysed by a 
western blot probed with an anti-p24 antibody (Fig. 6.13). A band of the correct size (24 kDa) 
was seen in the soluble fraction of the crude extract, along with a 48 kDa dimer band, as was 
seen with non His-tagged p24. Moreover, p24His was detected in the flow-through from the 
affinity chromatography as well as the wash fraction, but the strongest signal was seen in the 
elution fraction. This indicates that p24His is expressed and the His-tag is exposed, and the 
protein can be purified by affinity chromatography.  
 
 
Figure 6.13 Plant-produced C-terminally His-tagged p24 is expressed in plants. The pEAQ-HT vector was used to 
produce p24 with a C-terminal His-tag. Soluble protein extract from leaves expressing this construct were subjected 
to affinity chromatography, and the fractions were analysed on a western blot probed with an anti-p24 antibody. 
While some of the p24 did not bind to the column (FT, flow-through), and some bound but was washed off during 
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the washing step (wash), most of the p24 bound tightly and was recovered during elution. This indicates that the 
His-tag is exposed. 
 
This His-tagged p24 could be used for SPR by using a Ni-NTA Biacore chip, the same as was 
used for studying binding of τ-GFP to GFP (see figure 5.9). As with the SPR carried out with τ-
GFP, Dr. Clare Stevenson (John Innes Centre) provided expert guidance and help with the data 
collection and analysis. The His-tagged p24 (at a concentration of 3 µM) was bound to the chip 
and then either τ-p24 or τ-GFP (negative control) at concentrations of 4 nM were flowed over 
the chip at 2, 5, or 10 µl/min, with a contact time on the chip of either 60, 120, or 180 seconds. 
The resulting sensograms were zeroed at injection of the tandibody, and these adjusted 
sensograms are shown in figure 6.14. These show a response that is consistently higher for τ-
p24 (orange lines) than τ-GFP (green lines), regardless of flow rate or contact time. However, 
this response is only present during the injection of the tandibody: if tandibodies are binding 
p24, the binding is only transient. It should be noted that all responses appear to decrease 
over time, even during injection. This reflects p24-His washing off the chip spontaneously, 
even as the tandibodies are being flowed over the chip. A similar phenomenon was seen with 
GFP (see figure 5.9). In any case, the binding of the tandibody to its cognate antigen in this 
case contrasts markedly with τ-GFP binding to GFP (see figure 5.9). In the current case, binding 
is at best weak and transient, whereas τ-GFP clearly bound GFP very tightly. In fact, the only 
reason that τ-p24 can be said to bind to p24 from this experiment is that there is a very 
consistent difference between signal from τ-p24 and signal from the τ-GFP control. It is, 
however, possible that there were slight differences in the concentrations of the tandibody 
solutions, or their respective purity, and the difference in response could in fact be bulk non-
specific signal. Overall, this experiment was largely inconclusive, and it suggests that if τ-p24 
does bind p24, this binding is weak and transient. 
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Figure 6.14 τ-p24 CLPs do not bind to p24 during surface plasmon resonance. Plant-produced His-tagged p24 was 
bound to the surface of a Ni-NTA SPR chip, and partially purified τ-GFP (green) or τ-p24 (orange) CLPs were flowed 
at varying flow rates (2, 5, and 10 µl/min) over the p24. Binding resulted in detection of Response Units. At three 
different contact times (corresponding to the amount of time given to the tandibodies to flow over the p24) of 60 s 
(top), 120 s (middle), and 180 s (bottom); τ-p24 response was very low, albeit consistently higher than τ-GFP 
response. Any weak and transient binding occurring during tandibody injection ended immediately after injection.  
 
The results taken together show that τ-p24 does not bind to p24 as readily as τ-GFP binds to 
GFP (see chapter 5), and τ-gp120 does not bind to gp120. However, because the overall goal of 
the project is to develop a system for candidate vaccine production, it seemed worthwhile to 
make extra effort to display an antigen of medical relevance on the surface of a tandibody 
particle. To this end, the binding properties of τ-GFP and the medical relevance of p24 were 
combined: a fusion protein was created whereby solubility-enhanced GFP (sGFP, see Chapter 
3) was fused to the N-terminus of p24 via a flexible 8 amino acid - long glycine rich linker 
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(GGSVDGGS). This fusion construct was cloned into pEAQ-HT via the AgeI and SmaI restriction 
sites to add a 6XHis tag added at the C-terminus of p24.  
Co-infiltrations were set up in which the fusion protein, sGFP-p24His, was agroinfiltrated with 
τ-GFP, τ-gp120, or τ-p24. As controls, sGFP-p24His was also infiltrated on its own, and τ-GFP 
was co-infiltrated with GFP as in figure 5.6. At 6 dpi, large-scale extractions were carried out 
and the clarified extracts were loaded onto sucrose cushions and ultracentrifuged as described 
in chapter 5. The tubes were then visualised under UV light (Fig. 6.15a). This revealed that the 
fluorescence associated with sGFP-p24His infiltrated on its own or co-infiltrated with τ-gp120 
is visible only in the supernatant (clarified extract). But when it is co-infiltrated with τ-GFP or τ-
p24, the fluorescence is visible at the bottom of the sucrose cushions. This result is entirely 
compatible with the hypothesis that both τ-GFP and τ-p24 can bind to sGFP-p24His, but that τ-
gp120 cannot. Duplicate western blots of the various fractions (bottom, middle, and top of the 
sucrose layers along with supernatant) were carried out with anti-HBcAg and anti-p24 
antibodies (Fig. 6.15b). This showed that signal associated with sGFP-p24His (with an expected 
size of 52.4 ka) is present in all extracts in which it was expressed, and that it is subject to a 
certain amount of degradation. Moreover, the majority of the signal associated with sGFP-
p24His is found in the supernatant when it is expressed on its own or co-expressed with τ-
gp120. However, when sGFP-p24His is co-expressed with τ-GFP or τ-p24, the majority of the 
signal associated with the fusion protein is found in the bottom fraction (70 % sucrose), co-
localising with the tandibody. The data from the UV fluorescence and from the western blot 
are concordant: the fluorescence is associated with sGFP-p24His, and this fusion protein co-
migrates with τ-GFP and τ-p24, but not with τ-gp120 when the fusion protein and the 
tandibodies are co-expressed. 
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Figure 6.15 Both τ-GFP and τ-p24 bind the fusion protein sGFP-p24His. a) Leaves were co-infiltrated with different 
constructs as indicated above each tube, and the extracts were subjected to ultracentrifugation over sucrose 
cushions. These tubes were then photographed under UV light. This revealed that sGFP-p24His fluorescence is 
located in the supernatant (clarified extracts) when it this protein is produced alone or with τ-gp120. But when the 
fusion protein is co-expressed with τ-GFP or τ-p24, fluorescence sediments to the bottom of the sucrose cushion. b) 
The different fractions from the sucrose cushions above were analysed by duplicate western blots probed with anti-
HBcAg (top) or anti-p24 (bottom) antibodies. This confirmed that sGFP-p24His co-localises with τ-GFP and τ-p24, but 
not with τ-gp120. 
 
These results show that a fusion of sGFP and p24 can interact with both τ-GFP and τ-p24, 
which is strong evidence that it binds to both types of tandibodies. By contrast, τ-gp120, 
conforming to expectations, does not interact with the fusion protein. This confirms the 
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conclusions drawn from the pull-down experiment shown in figure 6.11, which suggested that 
τ-p24 binds to p24; but it conflicts with the results from SPR shown in figure 6.14, which 
suggested that any interaction between τ-p24 and C-terminally his-tagged p24 is, at best, weak 
and transient. Moreover figure 6.15b shows that co-infiltration of sGFP-p24His is associated 
with an increase in soluble amounts of τ-p24, to the extent that there is more τ-p24 than τ-GFP 
in the clarified extracts after co-infiltration. This is noteworthy because, as figure 6.9b shows, 
greater yields of soluble τ-GFP are typically obtained compared to soluble τ-p24, even when 
both are co-infiltrated with their cognate antigen. One possible explanation for this is that τ-
p24 has higher affinity for sGFP-p24His than τ-GFP does. If the increase in solubility in all 
experiments is caused by GFP or sGFP, then it is possible that in the experiment shown in 
figure 6.15, τ-p24 benefits from this more than τ-GFP because τ-p24 has higher affinity for 
sGFP-p24His.  
The bottom fractions of the co-infiltrations with τ-GFP and τ-p24 (labelled B on the western 
blots in figure 6.15b) were dialysed against PBS and visualised by TEM (Fig. 6.16). A high 
concentration of particles was seen in both samples, particularly with τ-p24, and the particles 
show the atypical knobbly surface morphology seen with τ-GFP particles bound to GFP (see 
chapter 5), with the surface spikes being far less clearly defined than those on HBcAg CLPs with 
no protein insert in the e1 loop. As expected, T=4 conformation dominates, with a small 
minority of T=3 CLPs (arrows). This is completely coherent with the results shown in figure 
6.10, and with the conclusion that these particles are bound to sGFP-p24His. 
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Figure 6.16 τ-GFP and τ-p24 CLPs co-expressed with sGFP-p24His exhibit “knobbly” morphology. The τ-GFP (left) 
and τ-p24 (right) particles obtained from the bottom fractions of the sucrose cushions shown in figure 6.15 were 
visualised by TEM. These are bound to the sGFP-p24His fusion protein and exhibit the knobbly morphology seen 
with tandibody particles, particularly when they are bound to an antigen. Arrows indicate T=3 particles, and scale 
bars are 100 nm. 
 
V - Discussion 
 
As well as the production of a further two tandibodies, the results presented in this chapter 
showed that HIV-1 gp120, p24, and a camelid nanobody (A12His) on its own, can be transiently 
expressed in plants using the pEAQ vector system. This is not the first time that that these 
proteins have been expressed in plant tissue. The gp140 protein, which is a synthetic construct 
containing gp120 along with the gp41 fusion peptide and heptad repeats, has been produced 
in plants (Rosenberg et al., 2013). Similarly, HIV-1 p24 has been produced transiently in 
tobacco (Pérez-Filgueira et al., 2004), and purified functional nanobodies have been obtained 
from plants as well (Ismaili et al., 2007; Winichayakul et al., 2009; Teh and Kavanagh, 2010). 
The results presented in this chapter have interesting similarities and differences compared to 
those presented in chapter 5. The main similarity is that τ-gp120 and τ-p24 were found to form 
CLPs when expressed in plants, indicating that tandem HBcAg seems to be a reliable scaffold 
for nanobodies. However, the anti-gp120 nanobody did not appear to be fully functional when 
displayed on the surface of the tandem core particles. This nanobody, when expressed on its 
own, unconstrained by the HBcAg particle, was shown to bind gp120, although not as well or 
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as reliably as might have been expected given its published KD of 0.1 nM. Indeed, it took 
extremely high concentrations of tandibody/nanobody and gp120 to detect any binding, which 
indicates that this binding was perhaps somewhat forced. But this raises the issue of 
comparison between the tandibody, the nanobody, and the commercially obtained polyclonal 
antibody used in the ELISA experiments. All have different sizes, spatial conformations, and 
valencies, making comparisons by mass or molar amounts somewhat difficult. In order to 
minimise the impact of these differences as much as possible, a conscious effort was made to 
coat the wells with excess of tandibody/nanobody/antibody compared to the amount of gp120 
added subsequently. A similar effort was made in the sucrose gradient experiment, in which 
there was an excess of fused nanobody compared to gp120.  
Because the commercially obtained gp120 used for these experiments came from the same 
source as the gp120 which was first used to identify the A12 nanobody, differences in gp120 
sequence or glycosylation pattern are not likely to be a factor in the loss of function of the A12 
nanobody. This suggests that this loss of function shown in these experiments is most likely 
due to both the plant expression system, and its fusion onto the tandem HBcAg particle. One 
potential factor to explain this is that the A12 produced in these experiments (both alone and 
as a fusion to HBcAg) has not been trafficked through the cell secretory pathway. This could 
affect the folding of the nanobody, since the ER and Golgi body environments are different to 
the cytosolic environment. That having been said, A12 was functional when expressed in E. coli 
(Strokappe et al., 2012), though while bacteria do not have ER and Golgi body, the bacterial 
environment is again different from that of the plant cytosol.  
Another potential factor is the flexibility of the nanobody when fused to the HBcAg scaffold, 
allowing it to bind an inner pocket of gp120. However, in this case it is expected that the 
nanobody fused to the surface of the HBcAg particles via long flexible linkers would have more 
freedom of movement than the nanobody on its own in an ELISA, since the latter would be 
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adsorbed onto the surface of the wells and be essentially prevented from moving. Moreover, 
the A12 nanobody was shown to be functional when displayed on the surface of 
bacteriophage as part of a phage display library (Forsman et al., 2008), and when coated onto 
the well of a microtiter plate for ELISA (Strokappe et al., 2012). The evidence therefore 
suggests that the lack of function of A12 here is mainly due to its expression in a plant system, 
with fusion to the tandem core scaffold also playing a role. These problems were not 
encountered with the anti-GFP Enhancer nanobody described in the previous chapter. In any 
case, the conclusion to be drawn from this set of experiments is that τ-gp120 can indeed form 
particles in plants (albeit at lower levels than τ-GFP), but that they do not interact strongly, if at 
all, with gp120.  
The situation with τ-pgp120 contrasts with that found with τ-p24, which in several tests was 
found to bind p24, albeit not as clearly as τ-GFP was shown to bind GFP. However, the results 
relating to τ-p24 binding to p24 were somewhat contradictory. While the sucrose cushion pull-
down experiments indicated binding, the ELISA painted a slightly less convincing picture, and 
the SPR data are underwhelming when compared to the SPR data in figure 5.9. In this sense it 
seems that as the sophistication of the analytical technique used increases, the apparent 
binding ability of τ-p24 decreases. However, there are a few practical considerations to bear in 
mind. In the SPR experiment (Fig. 6.14), τ-p24 was expected to bind to His-tagged p24 bound 
on the surface of the chip via this His-tag. However, the His-tag is on the C-terminus, and it is 
known that the anti-p24 nanobody binds to p24 at the C-terminus. Thus, it is possible that the 
physical conformation of the p24 during the SPR experiment could have had a negative impact 
on presentation of the antigen. The fusion protein sucrose cushion experiment shows that τ-
p24 can bind to C-terminally His-tagged p24 in solution, so failure to bind during SPR would 
likely be due to the C-terminus of p24 facing the wrong way rather than occlusion by the His-
tag. That having been said, all of the experiments done with plant-produced p24 (including the 
sucrose cushion pull-downs and the SPR) showed that oligomerisation occurs, and there is 
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literature which suggests that p24 dimerises in different conformations, including head-to-tail 
N- to C- dimerisation (Berthet-Colominas et al., 1999). This means that we should not treat p24 
used in the SPR experiment as a homogeneous solution of monomers, and it is possible that 
the p24 is being presented in a variety of conformational states in both liquid and solid phases. 
Moreover, due to lack of availability of material, the concentration of tandibody used in this 
SPR experiment was 4 nM, which is much lower than the 20 nM used to test for τ-GFP binding 
to GFP. A low concentration of tandibody would be expected to result in low signal, but it 
should still allow a difference to be seen between the test tandibody and the control, and it 
should still allow the characteristics of the interaction between tandibody and antigen to be 
visualised. If binding of τ-p24 to p24 was tight, the response curve would not be expected to 
drop completely after the end of tandibody injection, regardless of concentration. This adds to 
the overall conclusion to be drawn from the SPR experiment, which is that in that particular 
case, binding of τ-p24 to p24, if there was any at all, was weak and transient. 
In contrast to the SPR results, other assays present a far more optimistic picture of interaction 
between τ-p24 and p24. In the first sucrose cushion experiment (Fig. 6.11), the distribution of 
p24 throughout the different fractions after ultracentrifugation is clearly different when τ-p24 
is present compared to when it is not. In the second sucrose cushion experiment, with the 
sGFP-p24His fusion protein (Fig. 6.15b), the interaction is even clearer. The most parsimonious 
explanation for this is that τ-p24 binds to p24 and causes it to sediment to the bottom of the 
sucrose cushion. In the ELISA experiment (Fig. 6.12), the signal seen is as would be expected 
for a tandibody that binds relatively weakly: consistent net signal which is higher than that 
seen in the negative control, and which decreases with the decreasing concentration of p24. 
However, the caveat with the ELISA experiment is in the strength of the net signal: the 
background noise was high, leading to very low net signal after subtraction of background for 
each treatment. While the end result should still be reliable, the data is not of the same quality 
as the ELISA described in figure 5.8.  
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The apparent difference between the results of the different binding assays could reflect the 
differences in how the p24 is presented to the tandibody. In the sucrose cushion experiments, 
the two moieties are present together in the leaf tissue after co-infiltration, and in the leaf 
extract after harvest. This means that p24 is effectively in contact with τ-p24 in a liquid phase 
in vivo for days at 25°C pre-harvest and hours post-harvest at a range of temperatures (mostly 
at 4-8°C from grinding of the leaves to ultracentrifugation). In addition, there is no steric 
constraint on how p24 can interact with τ-p24, although it also means that all of the p24 may 
not be presented in the optimal conformation (whatever that may be) to τ-p24. In the ELISA, 
commercially-obtained, p24 is presented to the tandibodies in solution, with complete 
flexibility in terms of how it can bind to the nanobodies. The tandibody is then in contact with 
p24 for two hours at 37 °C. In the SPR experiment, the p24 had a C-terminal His-tag, was fixed 
onto a solid phase (the chip surface), and was not necessarily in a single conformation due to 
oligomerisation. Moreover the tandibody had, at most, 3 minutes of contact time at 25°C with 
p24. These differences in the way that τ-p24 is made to interact with p24 in these different 
experiments may explain the variability of the results. It is still possible, however, to conclude 
that τ-p24 does interact with p24, but this interaction is not as strong as the interaction 
between GFP and τ-GFP. Moreover, the data shown in figure 6.15 provide proof of concept for 
presenting a protein on the surface of a tandibody via a fusion partner which acts like a tag to 
link the protein of interest to a tandibody which displays a nanobody that does not recognise 
the protein of interest. This could be of crucial importance for displaying a protein for which 
there is no strongly-binding nanobodies available. 
Ultimately the data presented here show that tandibody technology is generic in the sense 
that any nanobody is likely to allow particle formation when fused in the C-terminal loop of a 
tandem core construct. However, the yield of recovered tandibody particles will not always be 
identical from one tandibody to another: figure 6.9b clearly shows that more τ-GFP 
accumulates in plant leaves at 7 dpi than τ-gp120 or τ-p24, although figure 6.15b suggests that 
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this may depend on what proteins are bound to the tandibodies. Moreover, the capacity for 
the tandibody to bind to its cognate antigen is not a given, but this may be overcome by using 
a common peptide tag which could be added to antigens of interest, and against which a 
functional nanobody could be used. 
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Chapter 7 : And now for something completely different. 
Producing a human enzyme in stable transgenic plants 
 
I - Introduction 
 
This chapter will describe the use of a derivative of the pEAQ-HT vector system to produce 
stable transgenic N. benthamiana which constitutively produce a human enzyme of medical 
relevance: human gastric lipase (hGL). Because of the difference between the work presented 
here and the work on HBcAg presented in previous chapters, and in the interest of clarity, this 
chapter will contain its own section on materials and methods.  
Human gastric lipase is a human stomach enzyme which catabolises lipids in food by 
hydrolysing triglycerides (Ville et al., 2002). There is potential for this enzyme to find uses in 
biotechnology, for in vitro digestion studies, as well as in medicine, such as for enzyme 
replacement therapy in patients suffering from pancreatic insufficiency. Indeed, patients 
suffering from this condition (which is often part of a broader condition such as cystic fibrosis 
or pancreatitis) have a more acidic smaller intestine, which decreases the efficiency of 
pancreatic lipase. Gastric lipase, with a pH optimum of 4, is still functional under these 
conditions, and can partially compensate for loss of pancreatic lipase activity (Abrams et al., 
1987; Carriere et al., 2005). This enzyme has previously been transiently expressed to high 
levels in N. benthamiana using the pEAQ vector system (Vardakou et al., 2012). The objective 
of the work presented here was to develop two stable transgenic lines of N. benthamiana, one 
of which was to express hGL-wt (unmodified hGL), while the other was to express hGL-C-His 
(hGL with a C-terminal 6XHis tag as an aid to purification).  The ultimate goal was to produce 
transgenic lines that can be easily propagated and used as a steady supply of recombinant hGL 
for research purposes. The original plasmids that had been used for transient expression were 
unsuitable for the production of such stable transgenic lines because they contain the wild-
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type P19 suppressor of gene silencing, which is developmentally toxic to plants (Chu et al., 
2000). The approach adopted was the use of the pEAQ vectors containing a modified version 
of the P19 (mP19) suppressor of silencing (Saxena et al., 2011), which retains the ability to 
suppress silencing but is not developmentally toxic. Genetically stable, true-breeding 
transgenic lines were obtained for both constructs, and these transgenic lines were shown to 
produce active hGL. 
 
II - Materials and Methods 
 
A) Cloning 
The plasmids encoding mP19 and either native or C-terminally His-tagged hGL (pEAQ-HTm-
hGL-wt and pEAQ-HTm-hGL-C-His, respectively) were derived from pre-existing pEAQ-HT-hGL-
wt and pEAQ-HT-hGL-C-His plasmids (Vardakou et al., 2012). The modification required only a 
single-nucleotide change in the P19 suppressor of silencing gene: to change arginine 43 to 
tryptophan to create mP19. This eliminates the developmental toxicity, albeit at the cost of 
reduced yield of recombinant protein (Saxena et al., 2011). This mutagenesis was carried out 
with the XL-Site-Directed Mutagenesis kit (Stratagene) for both plasmids. The introduction of 
the correct mutation was confirmed by sequence analysis. 
B) Making transgenic plants 
Plasmids pEAQ- HTm-hGL-wt and pEAQ-HTm-hGL-C-His were transformed into A. tumefaciens 
LBA4404 and tested in an agroinfiltration transient expression assay to confirm that they 
retained the ability to direct the expression of hGL-wt and hGL-C-His. Small-scale extractions 
were carried out on agroinfiltrated leaves and the soluble protein extracts were analysed by 
SDS-PAGE. Once the constructs were confirmed to be functional, N. benthamiana leaf-discs 
were transformed using the method described in Horsch and Klee (1986) in order to create 
stable transgenic lines. Briefly, N. benthamiana leaves were washed in 5 % (v/v) bleach 
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followed by 70 % (v/v) ethanol before leaf discs were cut out using a cork borer (size number 
7). These were then incubated for 24 h in constant light at 25 °C on pre-callusing agar plates. 
These were composed of Murashige and Skoog (MS) agar (0.8% w/v agar, MS salts, 3% sucrose 
in 3 mM MES buffer, pH 5.7) supplemented with 1 µg/ml BAP (benzyl aminopurine); 0.1 µg/ml 
NAA (naphthalene acetic acid) and organic supplements (0.5 µg/ml nicotinic acid, 0.5 µg/ml 
pyridoxine, 0.5 µg/ml thiamine, 0.5 µg/ml glycine). The leaf discs were then dipped in a liquid 
culture of A. tumefaciens freshly grown without antibiotics but containing the appropriate 
plasmid. The leaf discs were then placed on fresh pre-callusing plates. After 48 h, the leaf discs 
were transferred to fresh pre-callusing plates which contained 500 µg/ml carbenicillin (to 
avoid contamination of the plates and to eliminate the agrobacteria) and 100 µg/ml kanamycin 
(for selection of transformed tissue). After 3-5 weeks, shoots began to appear on the growing 
calli. These were excised and transferred to sterile plastic rooting pots containing pre-callusing 
medium with only 0.6 % (w/v) agar and lacking the BAP and NAA hormones. Photographs of 
the different stages of transformation are shown in figure 7.1. All material on pre-callusing 
medium or in rooting pots was grown in a controlled-environment cabinet with 24 h light at 25 
°C. Once roots had developed, the plantlets were transferred to soil and grown in the 
glasshouse (see chapter 2). 
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Figure 7.1 The different stages of transformation. N. benthamiana leaves (top left) were used to obtain leaf discs, 
which were incubated on pre-callusing medium. These developed into calli, until small shoots appeared (bottom 
right plate). These shoots were excised and transferred to a rooting pot (bottom left), where roots developed and 
the plantlet grew until it was large enough to be transferred to soil. 
 
C) Obtaining homozygous lines from primary transformants 
In order to obtain homozygous lines and to regenerate these for analysis, all transgenic plants 
were self-fertilised. Flowers were taped shut before they opened and only seed from taped 
flowers was used to grow the next generation (Fig. 7.2a). Transgenic seeds were grown in the 
controlled-environment cabinet on MS agar with 100 µg/ml kanamycin for selection of 
transgenic seeds (Fig. 7.2b). After 3-4 weeks, these were transferred to soil in the glasshouse. 
Homozygous lines were identified by analysing the kanamycin resistance of progeny seedlings: 
kanamycin is toxic to seedlings, and causes the cotyledons to bleach. The pEAQ vector used to 
transform the plants contained a kanamycin resistance gene in the T-DNA, so transformed 
plants are resistant to kanamycin. Simple Mendelian genetics therefore allows identification of 
homozygous T1 plants by analysing the percentage of bleached T2 seedlings obtained from 
self-fertilisation of a T1 plant.  
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Figure 7.2 Using antibiotic selection to determine seedling zygosity. a) Developing flowers of transgenic plants are 
taped shut before they open to ensure self-fertilisation. b) The seeds obtained from self-fertilised flowers are sown 
on agar plates containing kanamycin. Transgenic seedlings carry the kanamycin resistance selection marker and 
develop normally, whereas non-transgenic seedlings undergo bleaching and die. T2 seedlings from a homozygous 
T1 parent plant will all carry the kanamycin resistance gene, so 100 % of the seedlings will survive. However, only 75 
% of T2 seedlings from a heterozygous T1 parent plant will carry the resistance, so the remaining 25 % will bleach. 
 
D) Verifying hGL expression and activity 
In order to test the different lines for hGL expression, apoplastic washes were carried out (see 
chapter 2) using hGL extraction buffer: 90 % buffer A (50 mM NaOAc pH 4; 200 mM NaCl; 1 % 
(v/v) Triton X-100) and 10 % (v/v) isopropanol. The apoplastic fluid was then heat-shocked at 
40°C for 10 minutes in order to denature plant proteins present in the apoplast, centrifuged to 
pellet insoluble material, and the supernatant was then used to analyse protein content by 
SDS-PAGE analysis (see chapter 2), or by a simple lipase activity assay, by measuring 
fluorescence released by hGL digestion of the reporter substrate methylumbeliferyl-oleate 
substrate (MUF-oleate, see Vardakou et al., 2012). The activity of two hGL-wt lines was tested 
quantitatively by grinding transgenic leaves in hGL extraction buffer (described above), filtering 
through muslin cloth, clarifying the extract by centrifugation at 9,000 x g for 10 min, then 
analysing the extract on a pH-stat Titrino (718 STAT, Metrohm, UK) using the short chain 
triacylglycerol substrate tributyrin as described in Vardakou et al. (2012). 
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III - Results 
 
It has previously been shown that hGL can be produced in N. benthamiana through transient 
expression using the pEAQ vector system (Vardakou et al., 2012). This previous work had 
involved the creation of pEAQ-HT-hGL-wt, which does not encode a His-tag, and pEAQ-HT-hGL-
C-His, which includes a C-terminal His-tag. Vectors for stable transgenics could therefore be 
easily produced by simply mutating the P19 suppressor of silencing on these extant plasmids 
(Saxena et al., 2011). Site-directed mutagenesis was carried out on both hGL-bearing plasmids 
and sequencing of the mutated region of the P19 gene confirmed that they contained mP19. 
The ability of pEAQ-HTm-hGL-wt and pEAQ-HTm-hGL-C-His to direct the synthesis of hGL was 
tested alongside their parent vectors (pEAQ-HT-hGL-wt and pEAQ-HT-hGL-C-His, respectively) 
by transient expression. After 7 dpi, soluble fractions obtained from small-scale extractions 
were analysed by SDS-PAGE (Fig. 7.3). While the polypeptide chain of hGL is expected to have 
a size of 45.2 kDa, the protein is secreted and glycosylated, making it appear closer to 55 kDa 
on an SDS-PAGE gel. The extracts from leaves infiltrated with the mP19 forms of the plasmids 
showed expression of a protein of the expected size which was not present in the empty 
vector control plant extract. The amounts of hGL were lower than those seen in plant extract 
from leaves infiltrated with forms of the plasmids containing wild-type P19. This is consistent 
with the expected decrease in yield of recombinant protein which is known to occur when 
switching from wild-type P19 to mP19 (Saxena et al., 2011).  
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Figure 7.3 hGL can be transiently expressed in plants with both wild-type and mutant P19. Small-scale extractions 
were carried out on leaves that were agroinfiltrated with pEAQ vectors containing hGL-wt and hGL-C-His constructs 
with either mutant (HTm) or wild-type (HT) P19 suppressor of silencing. The soluble fractions were analysed by SDS-
PAGE alongside purified plant-produced hGL (1 and 0.2 µg, kindly provided by Dr. Maria Vardakou) and extract from 
plants infiltrated with the empty-vector control. A band of the appropriate size (about 55 kDa) was seen in extracts 
from plants expressing hGL, but not in extracts from plants expressing the empty vector control. Clearly, yields of 
hGL are higher in plants infiltrated with a plasmid bearing wild-type P19 than in plants infiltrated with a plasmid 
bearing mutant P19.  
 
Once the plasmids were shown to be functional, leaf discs (32 for each construct) were 
transformed with either pEAQ-HTm-hGL-wt or pEAQ-HTm-hGL-C-His. Because hGL is expected 
to be secreted and stable in the apoplast, apoplastic washes were carried out on leaves of 
regenerated plants in order to test for expression of hGL. These washes were analysed by SDS-
PAGE (Fig. 7.4). This revealed that a protein of the expected size was visible in the apoplasts of 
all of the T0 lines tested (with the possible exception of hGL-wt line 9), with no protein of a 
similar size detected in the apoplast of a non-transgenic control plant. The results also indicate 
that relatively pure hGL can be obtained from apoplastic washes, as compared to soluble 
protein extracts shown in figure 7.3. 
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Figure 7.4 Apoplastic washes reveal hGL expression in T0 transformants. Apoplastic washes were carried out on 
leaves from 6 hGL-wt primary transformants and 4 hGL-C-His primary transformants, along with a non-transgenic 
negative control plant. These washes were analysed by SDS-PAGE, and hGL was detected in all lines except hGL-wt 
line 9. It should be noted that the plants (and the sampled leaves) were not all the same age when sampled. 
 
Apoplastic washes from the hGL-wt T0 plants were then used for a non-quantitative lipase 
activity assay based on a synthetic fluorescent lipid analog (MUF-oleate). The positive control 
was an apoplastic wash from a leaf transiently expressing hGL-wt, and the negative control 
was an apoplastic wash from a non-transgenic leaf. This revealed that all lines tested produced 
active lipase, including line 9, for which the actual amount of hGL produced had been 
undetectable by SDS-PAGE analysis above (Fig. 7.5). 
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Figure 7.5 MUF-oleate digestion assay reveals that apoplastic washes from all hGL-wt T0 plants contain active 
lipase. Apoplastic washes from primary transformants expressing hGL-wt were used in a fluorescence-based lipase 
activity assay which relies on digestion of the synthetic lipid analog MUF-oleate. Because the MUF-oleate could not 
be added to all apoplastic washes at the same time, and because fluorescence could not be measured immediately 
after injection, the evolution of fluorescence through time is not comparable between lines. Numbers indicate the 
number of the transgenic plant, +ve ctrl is apoplastic wash from a transiently-transformed leaf, and –ve ctrl is 
apoplastic wash from a non-transformed leaf. 
 
The hGL-wt and hGL-His T0 lines were self-fertilised and plants from the T1 generation were 
also self-fertilised so that the seeds could be used to determine which of the T1 plants were 
homozygous: the segregation pattern of T2 seedlings is visible on kanamycin-containing agar 
plates, where non-transgenic plantlets die rapidly after germination (see figure 7.2b). For hGL-
wt T0, lines 2, 4, 6, and 10 were tested for homozygous T1 offspring in this way, and 
homozygous offspring from both plants 2 and 10 were identified. Homozygous T1 plants 2.06 
and 10.03 were selected for transgenerational gene stability studies. For hGL-His, T0 lines 6, 
11, and 14 were tested for homozygous T1 offspring, and homozygous offspring were 
identified from plants 11 and 14. Homozygous T1 plants 2.06 and 10.03 (for hGL-wt), along 
with 11.08 and 14.03 (for hGL-C-His) were selected for transgenerational gene stability studies. 
These consisted of self-fertilising the plants and analysing the offspring for presence of hGL by 
SDS-PAGE analysis of the apoplastic fluid. The two hGL-wt lines were propagated for a total of 
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six generations (seed from the T6 generation was collected and stored), and the two hGL-His 
lines were propagated for a total of three generations (seed from the T3 generation was 
collected and stored). At each generation, an apoplastic wash of one leaf from each plant was 
tested for the presence of hGL by SDS-PAGE analysis, and all plants were determined to be 
expressing the recombinant protein. Figure 7.6 shows a representative gel of these apoplastic 
washes. This specific gel shows apoplastic washes from 5 individual plants from the T4 
generation for each homozygous hGL-wt line 2 and 10. All plants clearly produce a protein of 
the appropriate size which is not present in the apoplast of a non-transgenic control plant. 
 
 
Figure 7.6 Representative analysis of homozygous line hGL expression assay. At each generation, transgenic plants 
were tested for hGL expression by SDS-PAGE analysis of apoplastic washes. In this specific instance, five T4 
generation plants from each of homozygous hGL-wt lines 2 and 10 were tested. All plants expressed hGL.  
 
The homozygous hGL-wt T1 plants 2.06 and 10.03 (the same as used for subsequent gene 
stability studies) were used in a quantitative lipase activity assay. Leaves were blended in hGL 
extraction buffer and the soluble protein extracts were tested using a pH-Stat Titrino as 
described in Vardakou et al. (2012). This method allows the lipase activity of the extract to be 
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measured in enzyme units (U) per gram of fresh weight leaf tissue (FWT). The result, shown in 
figure 7.7, reveals that both lines produce between 25 and 30 U/g FWT. 
 
 
Figure 7.7 Lipase activity of soluble protein extracts from hGL-wt lines 2 and 10. Homozygous T1 plants hGL-wt 
lines 2 and 10 were used to quantify lipase activity in transgenic plants. Large-scale extractions were carried out and 
soluble protein extracts were analysed by the pH Stat Titrino method. Both lines produced between 25 and 30 units 
of lipase activity per gram of fresh-weight leaf tissue. 
 
During propagation of the transgenic plants, it was noted that taped flowers often yielded 
small, atrophied seed pods, or no seed pods at all. In an attempt to examine this phenomenon, 
the percentage of taped flowers which yielded usable seed pods was noted, and the results are 
summarised in figure 7.8. For hGL-wt lines, fertility decreased until generation T4, and then 
increased slightly in generation T6 (no data was collected for generation T5). For hGL-His lines, 
fertility decreased between generations T2 and T3. 
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Figure 7.8 Fertility of transgenic lines varies from one generation to the next. The number of flowers taped on 
homozygous lines, along with the number of fertile seed pods obtained from these lines, was recorded. The 
percentage of taped flowers which yielded seed pods was calculated for each generation of each transgenic line. 
This revealed that fertility decreases in the early generations of hGL transgenics. 
 
IV - Discussion 
 
The results presented here demonstrate that the pEAQ-HT plasmid can be used to generate 
stable transgenic lines which constitutively produce an active enzyme. The only modification 
that needs to be carried out is the R43W mutation in the P19 suppressor of silencing gene; this 
mutation abolishes developmental toxicity, as demonstrated by Saxena et al. (2011). However, 
this study reported only the generation of GFP- producing stable transgenic lines. Attempts to 
create anti-HIV IgG – producing lines resulted in the creation of sterile transgenic plants 
(Saxena, 2012), suggesting that the ability to produce fertile lines may depend on the protein 
that is being expressed. The data presented here demonstrate that an active enzyme of human 
origin, hGL, can be produced constitutively in transgenic plants, and that the resulting plants 
are fertile. Preliminary enzyme activity data suggested that the lipase activity is too low for 
routine use of the transgenic plant extracts in in vitro models of digestion such as the Dynamic 
Chapter 7: Producing a human enzyme in stable transgenic plants 
 
149 
 
Gastric Model (DGM) in use at the Institute of Food Research (IFR, Norwich, UK). That said, the 
hGL-His lines were never tested for lipase activity, and it could be that they produce greater 
lipase activity than the hGL-wt lines. Moreover, it would probably be worth testing apoplastic 
washes (as opposed to blended leaf extracts) from leaves of different ages, and possibly 
purified lipase from the different lines, before deciding that the lipase activity is insufficient in 
all lines. It is likely that crude extracts such as those used here contain lipids which might 
compete for hGL activity during the lipase activity assay. Due to time constraints, testing the 
activity of hGL from apoplastic washes or after purification could not be carried out. 
Whatever the lipase activity of the transgenic plants, this has still been informative in terms of 
the production of transgenic plants using pEAQ-HT. Indeed, it was found that numerous fertile 
T0 plantlets could readily be obtained from only a few transformed leaf discs, and these T0 
plants could produce homozygous offspring. These homozygous offspring were found to be 
fertile and their transgene was found to be stable from one generation to the next; although 
an interesting decrease in fertility was observed in all lines from one generation to the next, 
until T6 (for hGL-wt lines). This phenomenon was characterised by self-fertilised flowers which 
did not yield fully-developed seed pods. Often, a seed pod was observed to be forming, but it 
would become abortive and necrotic before reaching maturity. The seed pods that did form 
tended to be small and contained few seeds, although these few seeds were typically capable 
of germinating and producing the next generation of plants. The overall impression was that all 
of the self-fertilised flowers gave rise to abortive seed pods in the observed generations, but 
this seed pod abortion was a long process rather than a sudden event, and some pods 
managed to set seed before development aborted, and thus yielded some seeds. This 
occurrence therefore seemed to be more complex than simple low fertility: it appeared to be a 
sort of transgenerational seed pod degeneracy phenomenon. There does not seem to be any 
obvious reason why such a process might occur. It is unlikely to be a consequence of 
inbreeding since N. benthamiana is known to be self-compatible (Busot et al., 2008). The cause 
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is therefore likely to be either environmental or epigenetic. It is interesting to note that while 
this effect seemed to get worse from one generation to the next, the last generation tested (T6 
for hGL-wt lines) showed an improvement over the previous tested generation (T4), 
particularly with line hGL-wt-10. This is encouraging, since persistence in such a syndrome 
would ultimately lead to plants that are incapable of self-fertilising, thus preventing the inbred 
lines from being propagated. It would be interesting to continue propagating the plants in 
order to study the phenomenon further. It would also be of interest to cross the lines with one 
another, or with non-transgenic plants, in order to see if this effect takes place in the offspring 
of such hybrids.   
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Chapter 8 : General Conclusion 
 
The primary aim of this thesis was to develop plant-produced HBcAg CLPs as generic carriers 
for antigens of interest using a variety of approaches. For the first time, the SplitCore system 
(Walker et al., 2011) was compared to tandem core technology, and the latter was found to be 
a more suitable for use in a plant expression system (see chapter 3). An attempt to display an 
anti-phOx scFv revealed a limitation of tandem core technology: it is difficult to display 
proteins with more than one domain (see chapter 4). While it may be worth trying to present 
different scFvs on tandem cores, the data presented in chapter 4 suggest that scFv-display may 
well be impossible, or at least prohibitively impractical, with the tandem core system.  
Tandem core technology was successfully developed for antigen presentation using two 
different approaches: with t-KD particles allowing the chemical conjugation of antigens of 
interest (see chapter 4) and through the development of tandibody particles displaying 
nanobodies capable of binding antigens of interest (see chapters 5 and 6). Both of these 
methods are potentially generic and thus could make an important contribution to the field of 
VLP-based vaccines.  
The hypothesis on which tandibody technology was originally based is that once proof of 
concept had been established with one nanobody-antigen pair, it would be straightforward to 
switch to a different nanobody-antigen pair, with similar results. This hypothesis proved to be 
correct insofar as nanobodies against GFP, HIV gp120, and HIV p24 (originally from camel, 
llama, and alpaca, respectively) were shown to allow CLP formation when fused to the C-
terminal e1 loop of a tandem core construct. The three different tandibody particles could be 
produced, extracted and purified in the same way. However, there was a difference in total 
yield between the three different tandibodies, with τ-GFP accumulating to higher levels than τ-
gp120 or τ-p24. Moreover, the solubility and final yield of the tandibody particles was shown 
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to be affected by binding to the cognate antigen. Finally, only two of the tandibodies could be 
shown to bind to their cognate antigen, with the third (τ-gp120) apparently being rendered 
non-functional by fusion to a tandem core (and possibly to some extent by the plant 
expression system). Taken together, these results suggest that the tandibody system is generic 
in the sense of allowing the production of CLPs presenting any nanobody, but not necessarily 
in the sense of allowing these nanobodies to retain their ability to bind to the cognate antigen. 
The problem of variation in binding ability of the presented nanobody can potentially be 
circumvented by presenting a nanobody specific for an antigenic tag. In this way, any protein 
fused to the tag could be displayed on the surface of a tandibody particle presenting the tag-
specific nanobody. This was demonstrated with the fusion protein sGFP-p24His (see chapter 
6), but it opens the possibility of using a more convenient small peptide tag instead of a whole 
protein as the fusion partner for the antigen of interest, provided a compatible tag-specific 
nanobody can be obtained. An attractive candidate for this approach would be the creation of 
a tandibody displaying the anti-EPEA nanobody (GenBank accession number 2X6M_A), a VHH 
of camel origin which recognises the amino acid sequence EPEA at the C-terminus of a protein 
(De Genst et al., 2010; Djender et al., 2014). Testing tandibody technology with this nanobody 
will undoubtedly form a major part of future work on this technology.  
If a tandibody particle with this nanobody (or another which binds a different small peptide tag 
sequence) is found to function as well as τ-GFP in plants, then a truly generic system will have 
been created whereby any protein can be non-covalently attached to the surface of the same 
“universal” tandibody CLP so long as the antigen contains the peptide tag. While the same 
effect could be achieved by using a whole protein tag (as was done with sGFP-p24His), this 
would almost certainly be unsuitable for use in vaccines, due to regulatory distrust with 
regards to non-native proteins. That having been said, it is also possible that a small peptide 
tag such as EPEA would also be unsuitable in the eyes of regulators, as it would also, in effect, 
Chapter 8: General Conclusion 
 
153 
 
render the antigen non-native. However, if a universal tandibody were to be deemed 
unsuitable for the design of human vaccines, it might still be authorised for veterinary 
vaccines. 
Even if a universal tandibody were deemed unsuitable for vaccine design, specific nanobodies 
could be developed for use in the tandibody system. The work carried out in this thesis has 
focused on previously-characterised nanobodies with publicly available sequences, but nothing 
precludes future work from developing new nanobodies. In fact, nanobody phage display 
technology (Maass et al., 2007) could be used to identify nanobodies that bind an antigen of 
interest with high affinity, and also function well in the tandibody system.  
It may also be possible to optimise existing nanobodies for use in the tandibody system. The 
complementarity determining regions (CDRs) of a nanobody are the sequences which interact 
directly with the cognate antigen (Muyldermans, 2001; Vanlandschoot et al., 2011). These 
three regions are usually easily identifiable in all antibody sequences due to their conserved 
location and hypervariable nature (Sela-Culang et al., 2013). It is therefore conceivable that 
the CDRs of a nanobody which is not functional in the tandibody system could be transferred 
to the sequence of a nanobody which is. For example, the CDRs of the anti-gp120 nanobody 
could be used to replace the CDRs of the anti-GFP nanobody used in this thesis. In this way, it 
might be possible to rescue functionality of recalcitrant nanobodies. Moreover, this could 
potentially be an interesting tool to study the effect of each CDR: it is suspected that CDR3 is 
the CDR that contributes most to affinity in nanobodies (Muyldermans, 2001). Comparing a 
nanobody that has been modified at all three CDRs to one that has only had CDR3 modified 
could test this commonly-held belief. Such CDR grafting has been done before, though it is 
sometimes called “framework shuffling”, with “framework” referring to the parts of an 
antibody variable region sequence that are not CDRs. Indeed, this has been done to switch 
CDRs between murine antibody fragments (Calcutt et al., 1996), and to “humanise” mouse 
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antibodies by replacing human CDRs with those from a mouse antibody (Dall'Acqua et al., 
2005). It has also been done with nanobodies: (Vincke et al., 2009) grafted CDRs from a llama 
nanobody onto a “humanised” camel nanobody scaffold. This “humanisation” corresponds to 
a series of point mutations in the framework regions of the nanobody to better mimic a 
consensus human sequence. It is described as a necessary step for the deployment of 
nanobodies as human therapeutics, for regulatory reasons. Humanisation could also be 
attempted in the context of tandibody technology. 
The work carried out with hGL-producing stable transgenic lines demonstrates that proteins of 
pharmaceutical interest can be readily produced in stable transgenic lines once the constructs 
have been validated using the transient approach. This opens up the possibility of creating 
stable transgenic lines which constitutively produce tandibodies. This would be useful if a long-
term, consistent supply of a particular tandibody is required, as the time-consuming 
agroinfiltration step would be removed once stable transgenic lines are obtained. This would 
be of particular relevance if a universal tandibody, as described above, were to be developed. 
Because stable transgenic plants yield lower quantities of recombinant protein than 
transiently-expressed plants, future work may focus on further optimising the pEAQ vector 
system for the production of stable transgenic plants – perhaps by placing the wild-type P19 
suppressor of silencing under the control of an inducible promoter. 
The work presented in this thesis has made significant contribution to the development of 
genetically engineered HBcAg as a tool for vaccine design. This is of particular significance to 
the field of VLP-based vaccines, which is likely to be the key contributor to the next generation 
of prophylactic and therapeutic vaccines. Future work will make the leap from the synthetic 
biology presented in this thesis to the immunology that will determine how well these new 
tools perform in vivo. Light will be thrown on the usefulness of tandem core particles and their 
efficacy as antigen carriers.  
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Appendix 1: Table of primers 
 
The following table lists the DNA oligonucleotides used for cloning, sequencing, or colony PCR. Restriction sites are shown in red; stop or start codons in 
bold, italics and underlined; Kozak consensus sequence in bold and underlined; glycine-rich linker sequences in bold. 
name sequence 5'-3' 
Tm 
(°C) 
purpose 
C1 AACGTTGTCAGATCGTGCTTCGGCACC 63 colony PCR 
C3 CTGAAGGGACGACCTGCTAAACAGGAG 63 colony PCR 
pMA-tHB5' GTAATACGACTCACTATAGGGCGAATTGGCG 73 amplify t-EL from 5' end of pMA plasmid from GeneArt 
pMA-tHB3' GTTAATGCAGCTGGCACGACAGGTTTCCCG 80 amplify t-EL from 3' end of pMA plasmid from GeneArt 
pMA-
wtHB5' 
GGTGGTAGTGGTGGGACCGGTACAATGGATATC 78 amplify 5' end of m-EL from t-EL & mutagenise AgeI-like site 
pMA-
CoreN5' 
GTAATACGACTCACTATAGGGCGAATTGGC 71 amplify CoreN from 5' end of pMA plasmid from GeneArt 
pMA-
CoreN3' 
CCCATGAGGCCAGTCTTGTGCTCCAGGTAC 79 amplify CoreN from 3' end of pMA plasmid from GeneArt 
pMA-
CoreC5' 
GTAATACGACTCACTATAGGGCGAATTGGCGG 75 amplify CoreC from 5' end of pMA plasmid from GeneArt 
pMA-
coreC3' 
CAGCTGGCACGACAGGTTTCCCGACTG 80 amplify CoreC from 3' end of pMA plasmid from GeneArt 
5'UTRinsert GTTTTCCCGTGGTTTTCGAACTTG 70 sequence ORF from 5'UTR of CPMV RNA-2 
5'HBcAg-
ce/1 
GAACTGATGACCCTGGCAACCTG 71 sequence insert in ce/1 loop of HBcAg construct from 5' end 
5'anti-phOx GTTATGCACAGAACTTCCAGGGC 68 sequence anti-phOx scFv 
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3'anti-phOx GTTGAACGTACCAGGAGACATAATTATTTCC 68 sequence anti-phOx scFv 
3'HBcAg-
ce/1 
GGTGTTCACGTAATTAACAACCAGATCAC 68 sequence insert in ce/1 loop of HBcAg construct from 3' end 
3'UTRinsert GCACACCGAATAACAGTAAATTCAAACTAAAG 68 sequence ORF from 3'UTR of CPMV RNA-2 
5'CoreN GGATATCGACCCATATAAAGAATTTG 64 sequence HBcAg from 5' end 
3'CoreNR CTTCGCCAATTGCCAGTGACAAG 72 sequence in 3' direction from 3' end of CoreN 
3'CoreNF CTTGTCACTGGCAATTGGCGAAG 72 sequence in 5' direction from 3' end of CoreN 
5'CoreCF GTAGTCGACGTTACGATACTTCGCAAC 68 sequence in 5' direction from 5' end of CoreC 
5'CoreCR GTTGCGAAGTATCGTAACGTCGACTAC 68 sequence in 3' direction from 5' end of CoreC 
3'CoreC CCTAACATTGGCTTTCACG 60 sequence HBcAg from 3' end 
5'solGFPR GTGAACAGCTCCTCGCCCTTGC 73 sequence in 3' direction from 5' of sGFP1-10 
5'solGFPF GCAAGGGCGAGGAGCTGTTCAC 73 sequence in 5' direction from 5' of sGFP1-10 
solGFPF CTGGTGAACCGCATCGAGCTGAAG 75 sequence in 5' direction from middle of sGFP1-10 
solGFPR CTTCAGCTCGATGCGGTTCACCAG 75 sequence in 3' direction from middle of sGFP1-10 
3'solGFPF GATCACATGGTCCTGCACGAGTACG 72 sequence in 5' direction from 3' end of sGFP (middle of sGFP11) 
3'solGFPR CGTACTCGTGCAGGACCATGTGATC 72 sequence in 3' direction from 3' end of sGFP (middle of sGFP11) 
gp120F1 CCT GTT CCT GAT CTT CAG CCT GCT GC 63 sequence gp120 from modified N-terminal secretion signal 
gp120R1 CAC ACC CAG AGG CTC AAT CTT CAC CAC C 64 sequence gp120 from C-terminus 
gp120F2 GGCTTGCCCTAAGGTGAGCTTCGAGC 64 sequence gp120 from middle of gene 
gp120R2 GTT ACC GAT CTT ACC AAT GGT CAC GAA AGC C 63 sequence gp120 from middle of gene 
VHH2F GACCGGTAACAATGGCTGTTCAGCTTCAAG 76 clone gp120 from pMA plasmid adding AgeI site and Kozak sequence 
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VHH2R GCCCGGGAGATGAAACGGTCACC 77 clone gp120 from pMA plasmid adding XmaI site 
p24F GTCTTGTCCAGAGCTCACCGGTAAC 70 clone p24 from backbone of pMA plasmid 
p24R GTATCCCGGGAAGCACTCTAGCC 70 clone p24 from pMA plasmid, replacing stop codon and XhoI site with SmaI site 
GFP-p24_F CGTACCGGTAACAATGGTGAGCAAGGGCGAGG 82 clone sGFP from pEAQ-HT-t-sGFP, adding Kozak sequence, start codon and AgeI site 
GFP-p24_R GTATCCCGGGAAGCACTCTAGCCTTATGTCCAGGACC 80 clone p24 from pMA, replacing stop codon with SmaI site 
GFP-
p24_2R 
CACCGTCGACACTTCCTCCCTTGTACAGCTCGTCC 83 clone sGFP from pEAQ-HT-t-sGFP, adding SalI site and GGS 
GFP-
p24_2F 
GAAGTGTCGACGGTGGTTCTATGCCTAGGACTCTTAACG 79 clone p24 from pMA adding SalI site and GGS 
sGFP seqF CAACTTCAACAGCCACAACGTCTATATCACCGCC 79 sequence middle of sGFP in forward direction 
p24 seqR CCACGGTATTAAGCATGGTGTTAAGATCCTGAGGGGTAGC 80 sequence middle of p24 in reverse direction 
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Appendix 2: Publications 
 
During the course of this thesis, a review of the use of the pEAQ vectors was published, along 
with a research article introducing tandem core technology including the use of tandibodies: 
 
Peyret, H., and Lomonossoff, G.P. (2013). The pEAQ vector series: the easy and quick way to 
produce recombinant proteins in plants. Plant Mol Biol, 83(1-2): 51-8. 
 
 
Peyret, H., Gehin, A., Thuenemann, E.C., Blond, D.,  El Turabi, A.,  Beales, L., Clarke, D., 
Gilbert, R.J.C., Fry, E.E., Stuart, D.I., Holmes, K., Stonehouse, N.J., Whelan, M., Rosenberg, 
W., Lomonossoff, G.P.,  Rowlands, D.J. (2015). Tandem fusion of hepatitis B core antigen 
allows assembly of virus-like particles in bacteria and plants with enhanced capacity to 
accommodate foreign proteins. PLOS One, In Press 
 
 
